U.S. patent application number 16/183058 was filed with the patent office on 2019-03-07 for methods for top-down multiplexed mass spectral analysis of mixtures of proteins or polypeptides.
The applicant listed for this patent is Thermo Finnigan LLC. Invention is credited to James L. STEPHENSON, JR., John E. P. SYKA, Ping F. YIP.
Application Number | 20190072566 16/183058 |
Document ID | / |
Family ID | 57777529 |
Filed Date | 2019-03-07 |
View All Diagrams
United States Patent
Application |
20190072566 |
Kind Code |
A1 |
YIP; Ping F. ; et
al. |
March 7, 2019 |
Methods for Top-Down Multiplexed Mass Spectral Analysis of Mixtures
of Proteins or Polypeptides
Abstract
Applications of ion-ion reaction chemistry are disclosed in
which proton transfer reactions (PTR) and real-time data analysis
methods are used to (1) simplify complex mixture analysis of
samples introduced into a mass spectrometer, and (2) improve
resolution and sensitivity for the analysis of large proteins in
excess of 50 kDa by removing charge and reducing the collisional
cross section.
Inventors: |
YIP; Ping F.; (Salem,
MA) ; STEPHENSON, JR.; James L.; (Raleigh, NC)
; SYKA; John E. P.; (Charlottesville, VA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Thermo Finnigan LLC |
San Jose |
CA |
US |
|
|
Family ID: |
57777529 |
Appl. No.: |
16/183058 |
Filed: |
November 7, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15406626 |
Jan 13, 2017 |
10151758 |
|
|
16183058 |
|
|
|
|
62278935 |
Jan 14, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
H01J 49/0036 20130101;
G01N 33/6848 20130101; H01J 49/0031 20130101; H01J 49/0072
20130101 |
International
Class: |
G01N 33/68 20060101
G01N033/68 |
Claims
1. A method of identifying the presence or absence of a
microorganism type in a sample, comprising: (a) identifying a list
of analyte compounds whose simultaneous presence in the sample is
diagnostic of the presence of the microorganism type in the sample,
said list of analyte compounds comprising protein compounds,
polypeptide compounds or both protein and polypeptide compounds;
(b) extracting, from the sample, a liquid solution comprising a
mixture of sample-derived proteins and polypeptides; (c)
introducing at least a first portion of the liquid solution into an
ionization source of a mass spectrometer; (d) generating, from the
at least first portion of the liquid solution at the ionization
source, positively charged ions of the mixture of compounds, the
positively charged ions comprising a plurality of ion species; (e)
isolating at least a first subset of the plurality of ion species,
each isolated subset of the at least a first isolated subset
comprising a respective mass-to-charge (m/z) ratio range; (f)
generating a plurality of first-generation product ion species from
each isolated subset of ion species by causing each said isolated
subset of ion species to be reacted, for a predetermined time
duration, with reagent anions that, upon reaction, extract protons
from each of one or more ion species of said isolated subset of ion
species that comprises a protonated molecular species of a protein
or polypeptide compound; (g) generating at least one mass spectrum,
using a mass analyzer of the mass spectrometer, of either
first-generation product ion species or second-generation product
ion species generated by further reaction of the first-generation
product ion species; (h) for each respective analyte compound in
the list, performing the steps of: (h1) conducting a search of the
at least one mass spectrum of either the first-generation or the
second-generation product ion species for a set of one or more m/z
ratios that are diagnostic of the respective analyte compound; and
(h2) identifying the presence of the respective analyte compound
within the liquid solution if the set of one or more m/z ratios is
identified in the mass spectrum; and (i) identifying the presence
of the microorganism type within the sample if the presence of each
and every analyte compound of the list of analyte compounds is
identified within the liquid solution.
2. A method as recited in claim 1, wherein a performing of the
steps (h1) and (h2) is performed concurrently with the performing
of one or more of the steps (c) through (g).
3. A method as recited in claim 1, wherein the microorganism type
is defined as a particular genus of bacteria and the list of
analyte compounds includes a sufficient number of analyte compounds
that are diagnostic of the particular genus of bacteria to enable
identification of the presence or absence of the particular genus
of bacteria in the sample.
4. A method as recited in claim 1, wherein the microorganism type
is defined as a particular species of bacteria and the list of
analyte compounds includes a sufficient number of analyte compounds
that are diagnostic of the particular species of bacteria to enable
identification of the presence or absence of the particular species
of bacteria in the sample.
5. A method as recited in claim 1, wherein the microorganism type
is defined as a particular sub-species of bacteria and the list of
analyte compounds includes a sufficient number of analyte compounds
that are diagnostic of the particular sub-species of bacteria to
enable identification of the presence or absence of the particular
sub-species of bacteria in the sample.
6. A method as recited in claim 1, wherein the microorganism type
is defined as a particular strain of virus and the list of analyte
compounds includes a sufficient number of analyte compounds that
are diagnostic of the particular viral strain to enable
identification of the presence or absence of the particular viral
strain in the sample.
7. A method as recited in claim 1, wherein the microorganism type
is defined as a particular strain of virus and the list of analyte
compounds includes a sufficient number of analyte compounds that
are diagnostic of the particular viral strain to enable
identification of the presence or absence of the particular viral
strain in the sample.
8. A method for identifying the presence or absence of a protein or
polypeptide analyte compound within a sample comprising a mixture
of compounds that includes a plurality of protein compounds or a
plurality of polypeptide compounds or pluralities of both protein
and polypeptide compounds, the method comprising: (a) introducing a
portion of the liquid sample into an electrospray ionization source
of a mass spectrometer; (b) forming positively charged ions of the
mixture of compounds of the portion of the liquid sample by
electrospray ionization, the positively charged ions comprising a
plurality of first-generation ion species; (c) isolating a
plurality of subsets of the first-generation ion species comprising
respective mass-to-charge (m/z) ratio ranges, wherein each m/z
ratio range includes an m/z ratio of an ion species comprising a
respective protonation state of the analyte compound; (d)
generating a plurality of first-generation product ion species from
the isolated plurality of subsets of the first-generation ion
species by causing the isolated plurality of subsets of the
first-generation ion species to be reacted, for a predetermined
time duration, with reagent anions that, upon reaction, extract
protons from each ion species that comprises a respective
protonation state of the analyte compound; (e) generating a mass
spectrum of the first-generation product ion species; and (f)
identifying either the presence of the analyte compound within the
sample if the mass spectrum comprises one or more lines at
respective predetermined ink ratios that comprise respective
intensities above a predetermined threshold or the absence of the
analyte compound within the sample otherwise.
9. A method as recited in claim 8, further comprising repeatedly
performing steps (a) through (f) a plurality of times, wherein each
repetition of step (a) comprises introducing, into the electrospray
ionization source, an eluate from a chromatographic column
corresponding to a respective retention time.
10. A method as recited in claim 8, wherein the step (f) further
comprises determining, if the mass spectrum comprises one or more
lines at respective predetermined ink ratios that comprise
respective intensities above a predetermined threshold, a quantity
or concentration of the analyte compound within the sample based on
the one or more intensities.
11. A method as recited in claim 8, further comprising, after the
step (b) of forming positively charged ions and prior to the step
(c) of isolating a plurality of subsets of the first-generation ion
species, the steps of: (b1) isolating a subset of the
first-generation ion species comprising a randomly-selected
mass-to-charge (m/z) ratio range; (b2) generating a plurality of
product ion species from the isolated subsets of the
first-generation ion species by causing the isolated subset of the
first-generation ion species to be reacted with reagent anions
that, upon reaction, extract protons from each ion species that
comprises a respective protonation state of the analyte compound or
a respective protonation state of another protein or polypeptide
compound; (b3) generating a mass spectrum of the product ion
species; and (b4) automatically determining the m/z ratio ranges to
be used in the subsequent step (c), based on the mass spectrum of
the product ions.
12. A method as recited in claim 11, wherein the step (b4)
comprises automatically determining, from the mass spectrum, a set
of m/z ratios corresponding to multiply-protonated ion species of
the other protein or polypeptide compound.
13. A method of identifying the presence or absence of a
microorganism type in a sample, comprising: (a) identifying a list
of analyte compounds whose simultaneous presence in the sample is
diagnostic of the presence of the microorganism type in the sample,
said list of analyte compounds comprising protein compounds,
polypeptide compounds or both protein and polypeptide compounds;
(b) extracting, from the sample, a liquid solution comprising a
mixture of sample-derived proteins and polypeptides; (c) for each
respective analyte compound in the list, performing the steps of:
(c1) introducing a portion of the liquid solution into an
electrospray ionization source of a mass spectrometer; (c2) forming
positively charged ions of the mixture of compounds of the portion
of the liquid solution by electrospray ionization, the positively
charged ions comprising a plurality of ion species; (c3) isolating
a first subset of the ion species comprising a first mass-to-charge
(m/z) ratio range that includes an m/z ratio of a particular
predetermined multiply-protonated molecular species of the
respective analyte compound; (c4) generating a plurality of
first-generation product ion species from the isolated first subset
of ion species by causing the isolated first subset of ion species
to be reacted, for a predetermined time duration, with reagent
anions that, upon reaction, extract protons from each of one or
more ion species that comprises a protonated molecular species of a
protein or polypeptide compound; (c5) generating a mass spectrum,
using a mass analyzer, of either the first-generation product ion
species or of second-generation product ion species generated from
the first-generation product ion species; (c6) conducting a search
of the mass spectrum of either the first-generation or the
second-generation product ion species for a set of one or more m/z
ratios that are diagnostic of the respective analyte compound; and
(c7) identifying the presence of the respective analyte compound
within the liquid solution if the set of one or more m/z ratios is
identified in the mass spectrum; and (d) identifying the presence
of the microorganism type within the sample if the presence of each
and every analyte compound of the list of analyte compounds is
identified within the liquid solution.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a Divisional of, and claims, under 35
U.S.C. .sctn. 120, the benefit of the filing date of
commonly-assigned and co-pending U.S. application Ser. No.
15/406,626, now U.S. Pat. No. ______, which was filed on Jan. 13,
2017 and which claims, under 35 U.S.C. .sctn. 119(e), priority to
and the benefit of the filing date of commonly-assigned U.S.
Provisional Application No. 62/278,935, filed on Jan. 14, 2016, the
disclosures of which are hereby incorporated by reference in their
entirety. The subject matter of this application is also related to
commonly-assigned and co-pending U.S. application Ser. No.
15/830,439, which was filed on Dec. 4, 2017 and which is titled
"Methods for Mass Spectrometry of Mixtures of Protein or
Polypeptides Using Proton Transfer Reaction" and to
commonly-assigned and co-pending U.S. application Ser. No.
15/067,727, now U.S. Pat. No. ______, which was filed on Mar. 11,
2016, the disclosures of which are hereby incorporated by reference
herein in their entirety.
TECHNICAL FIELD
[0002] The present invention relates to mass spectrometry and, more
particularly, relates to methods for mass spectrometric analysis of
complex mixtures of proteins or polypeptides by methods that
include subjecting ionized samples to proton transfer reactions to
separate ionized proteins and polypeptides from other molecules and
performing mathematical deconvolution analysis of resulting
reaction products to simultaneously characterize a plurality of
proteins and/or polypeptides in the mixture.
BACKGROUND ART
[0003] The study of proteins in living cells and in tissues
(proteomics) is an active area of clinical and basic scientific
research because metabolic control in cells and tissues is
exercised at the protein level. For example, comparison of the
levels of protein expression between healthy and diseased tissues,
or between pathogenic and nonpathogenic microbial strains, can
speed the discovery and development of new drug compounds or
agricultural products. Further, analysis of the protein expression
pattern in diseased tissues or in tissues excised from organisms
undergoing treatment can also serve as diagnostics of disease
states or the efficacy of treatment strategies, as well as provide
prognostic information regarding suitable treatment modalities and
therapeutic options for individual patients. Still further,
identification of sets of proteins in samples dervived from
microorganisms (e.g., bacteria) can provide a means to identify the
species and/or strain of microorganism as well as, with regard to
bacteria, identify possible drug resistance properties of such
species or strains.
[0004] One important aspect of proteomics is the identification of
proteins with altered expression levels. Differences in protein and
metabolite levels over time or among populations can be associated
with diseased states, drug treatments, or changes in metabolism.
Identified molecular species may serve as biological markers for
the disease or condition in question, allowing for new methods of
diagnosis and treatment to be developed. Conventionally, because of
the large number of proteins that are generally present in any
sample extracted from natural tissue or cells, the proteins must
first be separated into individual components by gel or capillary
electrophoresis or affinity techniques, before the individual
proteins levels can be assessed and compared to a database or
between samples.
[0005] Because it can provide detailed structural information, mass
spectrometry (MS) is currently considered to be a valuable
analytical tool for biochemical mixture analysis and protein
identification. Conventional methods of protein analysis therefore
often combine two-dimensional (2D) gel electrophoresis, for
separation and quantification, with mass spectrometric
identification of proteins. Also, capillary liquid chromatography
as well as various other "front-end" separation techniques have
been combined with electrospray ionization tandem mass spectrometry
for large-scale protein identification without gel electrophoresis.
Using mass spectrometry, qualitative differences between mass
spectra can be identified, and proteins corresponding to peaks
occurring in only some of the spectra serve as candidate biological
markers.
[0006] In recent years, mass spectrometry has also gained
popularity as a tool for identifying microorganisms due to its
increased accuracy and shortened time-to-result when compared to
traditional methods for identifying microorganisms. To date, the
most common mass spectrometry method used for microbial
identification is matrix-assisted laser desorption ionization
time-of-flight (MALDI-TOF) mass spectrometry. In MALDI-TOF, cells
of an unknown microorganism are mixed with a suitable ultraviolet
light absorbing matrix solution and are allowed to dry on a sample
plate. Alternatively, an extract of microbial cells is used instead
of the intact cells. After transfer to the ion source of a mass
spectrometer, a laser beam is directed to the sample for desorption
and ionization of the proteins and time-dependent mass spectral
data is collected.
[0007] The mass spectrum of a microorganism produced by MALDI-TOF
methods reveals a number of peaks from intact peptides, proteins,
protein fragments, and other molecules that constitute the
microorganism's "fingerprint". This method relies on the pattern
matching of the peak profiles in the mass spectrum of an unknown
microorganism to a reference database comprising a collection of
mass spectra for known microorganisms obtained using essentially
the same experimental conditions. The better the match between the
spectrum of the isolated microorganism and a spectrum in the
reference database, the higher the confidence level in
identification of the organism at the genus, species, or in some
cases, subspecies level. Because the method relies upon matching
the patterns of peaks in MALDI-TOF mass spectra, there is no
requirement to identify or otherwise characterize the proteins
represented in the spectrum of the unknown microorganism in order
to identify it.
[0008] Although MALDI-TOF methods are rapid and cost effective,
they have limitations that restrict the range of applications to
pathogen characterization and identification including but not
limited to virulence detection and quantitation, resistance marker
determination, strain matching, and antibiotic susceptibility
testing to name a few. The information content within a MALDI mass
spectrum reflects the most abundant and ionizable proteins which
are generally limited to ribosomal proteins at the experimental
conditions used. Because ribosomal proteins are highly conserved
among prokaryotes, differentiation of closely related
microorganisms by MALDI-TOF is limited. In this case many of the
ribosomal proteins across closely related species contain either
the same or slightly different amino acid sequences (i.e. single
amino acid substitutions) that cannot be effectively differentiated
with low resolution mass spectrometers. Moreover, determination of
strain and/or serovar type, antibiotic resistance, antibiotic
susceptibility, virulence or other important characteristics relies
upon the detection of protein markers other than ribosomal proteins
which further limits the application of MALDI-TOF for microbial
analysis. Laboratories using MALDI-TOF for identification of
microorganisms must use other methods to further characterize the
identified microbes. In addition, the MALDI-TOF method's reliance
upon matching spectral patterns requires a pure culture for high
quality results and thus is not generally suitable for direct
testing, mixed cultures, blood culture, or other complex samples
containing different microorganisms.
[0009] Several other mass spectrometry methods for detection of
microorganisms have been used. For example, mass spectrometry-based
protein sequencing methods have been described wherein liquid
chromatography is coupled to tandem mass spectrometry (LC-MS/MS)
and sequence information is obtained from enzymatic digests of
proteins derived from the microbial sample. This approach, termed
"bottom-up" proteomics, is a widely practiced method for protein
identification. The method can provide identification to the
subspecies or strain level as chromatographic separation allows the
detection of additional proteins other than just ribosomal
proteins, including those useful for characterization of antibiotic
resistance markers and virulence factors.
[0010] In contrast to "bottom-up" proteomics, "top-down" proteomics
refers to methods of analysis in which protein samples are
introduced intact into a mass spectrometer, without enzymatic,
chemical or other means of digestion. Top-down analysis enables the
study of the intact protein, allowing identification, primary
structure determination and localization of post-translational
modifications (PTMs) directly at the protein level. Top-down
proteomic analysis typically consists of introducing an intact
protein into the ionization source of a mass spectrometer,
fragmenting the protein ions and measuring the mass-to-charge
ratios and abundances of the various fragments so-generated. The
resulting fragmentation is many times more complex than a peptide
fragmentation, which may, in the absence of the methods taught
herein, necessitate the use of a mass spectrometer with very high
mass accuracy and resolution capability in order to interpret the
fragmentation pattern with acceptable certainty. The interpretation
generally includes comparing the observed fragmentation pattern to
either a protein sequence database that includes compiled
experimental fragmentation results generated from known samples or,
alternatively, to theoretically predicted fragmentation patterns.
For example, Liu et al. ("Top-Down Protein
Identification/Characterization of a Priori Unknown Proteins via
Ion Trap Collision-Induced Dissociation and Ion/Ion Reactions in a
Quadrupole/Time-of-Flight Tandem Mass Spectrometer", Anal. Chem.
2009, 81, 1433-1441) have described top-down protein identification
and characterization of both modified and unmodified unknown
proteins with masses up to .apprxeq.28 kDa.
[0011] An advantage of a top-down analysis over a bottom-up
analysis is that a protein may be identified directly, rather than
inferred as is the case with peptides in a bottom-up analysis.
Another advantage is that alternative forms of a protein, e.g.
post-translational modifications and splice variants, may be
identified. However, top-down analysis has a disadvantage when
compared to a bottom-up analysis in that many proteins can be
difficult to isolate and purify. Thus, each protein in an
incompletely separated mixture can yield, upon mass spectrometric
analysis, multiple ion species, each species corresponding to a
different respective degree of protonation and a different
respective charge state, and each such ion species can give rise to
multiple isotopic variants. A single MS spectrum measured in a
top-down analysis can easily contain hundreds to even thousands of
peaks which belong to different analytes--all interwoven over a
given m/z range in which the ion signals of very different
intensities overlap and suppress one other.
[0012] Because mass spectra of biological samples, as obtained in
top-down analyses, are generally very complex, improved methods are
required for interpreting the mass spectra. The resulting
computational challenge that such methods must overcome is to trace
each peak back to a certain analyte(s) and, once this is done for
one or several analytes, to determine the molecular weights of
analyte(s) in a process which is best described as mathematical
decomposition (also referred to, in the art, as mathematical
deconvolution). A still further challenge associated with the use
of mass spectral analyses of proteins and polypeptides in a
clinical setting is to derive such information in the shortest time
period possible, often termed as analysis in "real time".
Obviously, the computations are much more challenging in real time
during an automatic top-down data dependent analysis since this
should occur very fast, especially when chromatographic separation
is involved. To succeed, one needs to provide both: (i) an
optimized real time computational strategy as well as (ii) a mass
spectral data acquisition strategy that anticipates multiple mass
spectral lines for each ion species and that anticipates efficient
isolation of analyte compounds of interest from a potential
multitude of contaminant compounds.
[0013] The existing data dependent and dynamic exclusion workflow
techniques and corresponding algorithms were developed for small
molecules, small peptides and other analytes which acquire a
limited number of charges (for example, 1-3 charges) in the
electrospray ionization process. When applied to
higher-molecular-weight biopolymer analytes (most commonly, intact
proteins during the course of top-down proteomics studies) these
conventional methodologies significantly under-perform due to a
combination of different electrospray behavior and computational
limitations. More specifically: (1) intact high mass analytes in
general, and proteins in particular, develop many more charge
states (up to 50 charges or more per molecule, e.g., FIG. 12C) than
do small molecules during the electrospray ionization process
because of a greater number of charge acquiring sites which results
in much more complex MS spectra; (2) in complex mixtures such as
cell lysates or their fractions, there is a wide distribution of
molecular weights and copy numbers which results in a very complex
overlap of charge state distribution patterns of varying
intensities; (3) the variability in physiochemical properties of
the high-mass analytes of the same or different chemical nature
produces significant variability of chromatographic peak shapes and
analyte retention on the column; (4) if the mass spectra are
acquired on a mass spectrometer with high resolving power such as
an Orbitrap.TM. mass analyzer (a type of electrostatic trap mass
analyzer) or a time-of-flight (TOF) mass analyzer, corresponding
peaks further resolve into a number of isotopes in a series of
clusters whose quality is often far from a theoretical binomial
distribution; (5) matrix ionization effects of a variety of
different proteins can greatly influence the observed intensity of
multiply overlapping species so as to distort the true ratios of
protein intensities found in any given standard or sample.
Additional levels of complexity are introduced by oxidized species
of the same analyte or adducts, overlaps of isotope clusters and
inability of existing software tools correctly calculate charge
state for high mass species.
[0014] In practical terms, the above considerations imply that, in
the case of intact proteins and other biopolymers, existing data
dependent algorithms are being confounded and MS/MS is being
performed in a redundant fashion on a number of different charge
states from the same biopolymer. Also, when isotopic clusters do
not match the traditional binomial distribution patterns defined by
the number of carbon, hydrogen, nitrogen, oxygen, and sulfur atoms
present in a given biopolymer, or do not meet intensity threshold
or signal-to-noise requirements, redundancy occurs from fragmenting
multiple isotopes which belong to the same isotopic cluster. This
duplication of work leads to redundancy in identification of the
most abundant/ionizable proteins, while the information about other
species is lost and provides very little opportunity for triggering
an MS.sup.n analysis.
[0015] With regard to efficient instrument-associated data
acquisition strategies, it may be noted that ion-ion reactions have
found great utility in the field of biological mass spectrometry
over the last decade, primarily with the use of electron transfer
dissociation (ETD) to dissociate peptide/proteins and determine
primary sequence information and characterize post-translational
modifications. Proton transfer, another type of ion-ion reaction,
has also been used extensively in biological applications.
Experimentally, in one form of proton transfer,
multiply-positively-charged protein ions (i.e., protein cations)
from a sample are allowed to react with singly-charged reagent
anions so as to reduce the charge state of an individual protein
cation and the number of such charge states of the protein cations.
These reactions proceed with pseudo-first order reaction kinetics
when the reagent anions are present in large excess over the
protein cation population. The rate of reaction is directly
proportional to the square of charge of the protein cation (or
other multiply-charged cation) multiplied by the charge on the
reagent anion. The same relationship also holds for reactions of
the opposite polarity, defined here as reaction between
singly-charged reagent cations and a population of multiply-charged
anions derived from a protein sample. This produces a series of
pseudo-first order consecutive reaction curves as defined by the
starting multiply-charged protein cation population. Although the
reactions are highly exothermic (in excess of 100 kcal/mol), proton
transfer is an even-electron process performed in the presence of 1
mtorr of background gas (i.e. helium) and thus does not fragment
the starting multiply-charged protein cation population. The
collision gas serves to remove the excess energy on the microsecond
time scale (10.sup.8 collisions per second), thus preventing
fragmentation of the resulting product ion population.
[0016] Proton transfer reactions (PTR) have been used successfully
to identify proteins in mixtures of proteins. Particularly,
application of proton transfer reaction methods may be envisioned
as a mixture simplification process that is carried out in
real-time (a few milliseconds) in a mass spectrometer that
separates mass spectral signatures of proteins and polypeptides
from one another as well as from generally low-charge contaminant
ions. This procedure enables isolation of the analyte proteins and
polypeptide ions either as a group or as individual ion species and
has thus been employed to determine charge state and molecular
weights of high mass proteins. PTR has also been utilized for
simplifying product ion spectra derived from the
collisional-activation of multiply-charged precursor protein ions.
Although PTR reduces the overall signal derived from
multiply-charged protein ions, this is more than offset by the
significant gain in signal-to-noise ratio of the resulting PTR
product ions. The PTR process is 100% efficient leading to only
single series of reaction products, and no side reaction products
that require special interpretation and data analysis.
[0017] Various aspects of the application of PTR to the analysis of
peptides, polypeptides and proteins have been described in the
following documents: U.S. Pat. No. 7,749,769 B2 in the names of
inventors Hunt et al., U.S. Patent Pre-Grant Publication No.
2012/0156707 A1 in the names of inventors Hartmer et al., U.S.
Pre-Grant Publication No. 2012/0205531 A1 in the name of inventor
Zabrouskov; McLuckey et al., "Ion/Ion Proton-Transfer Kinetics:
Implications for Analysis of Ions Derived from Electrospray of
Protein Mixtures", Anal. Chem. 1998, 70, 1198-1202; Stephenson et
al., "Ion-ion Proton Transfer Reactions of Bio-ions Involving
Noncovalent Interactions: Holomyoglobin", J. Am. Soc. Mass
Spectrom. 1998, 8, 637-644; Stephenson et al., "Ion/Ion Reactions
in the Gas Phase: Proton Transfer Reactions Involving
Multiply-Charged Proteins", J. Am. Chem. Soc. 1996, 118, 7390-7397;
McLuckey et al., "Ion/Molecule Reactions for Improved Effective
Mass Resolution in Electrospray Mass Spectrometry", Anal. Chem.
1995, 67, 2493-2497; Stephenson et al., "Ion/Ion Proton Transfer
Reactions for Protein Mixture Analysis", Anal. Chem. 1996, 68,
4026-4032; Stephenson et al., "Ion/Ion Reactions for Oligopeptide
Mixture Analysis: Application to Mixtures Comprised of 0.5-100 kDa
Components", J. Am. Soc. Mass Spectrom. 1998, 9, 585-596;
Stephenson et al., "Charge Manipulation for Improved Mass
Determination of High-mass Species and Mixture Components by
Electrospray Mass Spectrometry", J. Mass Spectrom. 1998, 33,
664-672; Stephenson et al., "Simplification of Product Ion Spectra
Derived from Multiply Charged Parent Ions via Ion/Ion Chemistry",
Anal. Chem., 1998, 70, 3533-3544 and Scalf et al., "Charge
Reduction Electrospray Mass Spectrometry", Anal. Chem. 2000, 72,
52-60. Various aspects of general ion/ion chemistry have been
described in McLuckey et al., "Ion/Ion Chemistry of High-Mass
Multiply Charged Ions", Mass Spectrom. Rev. 1998, 17, 369-407 and
U.S. Pat. No. 7,550,718 B2 in the names of inventors McLuckey et
al. Apparatus for performing PTR and for reducing ion charge states
in mass spectrometers have been described in U.S. Pre-Grant
Publication No. 2011/0114835 A1 in the names of inventors Chen et
al., U.S. Pre-Grant Publication No. 2011/0189788 A1 in the names of
inventors Brown et al., U.S. Pat. No. 8,283,626 B2 in the names of
inventors Brown et al. and U.S. Pat. No. 7,518,108 B2 in the names
of inventors Frey et al. Adaptation of PTR charge reduction
techniques to detection and identification of organisms has been
described by McLuckey et al. ("Electrospray/Ion Trap Mass
Spectrometry for the Detection and Identification of Organisms",
Proc. First Joint Services Workshop on Biological Mass
Spectrometry, Baltimore, Md., 28-30 Jul. 1997, 127-132).
[0018] The product ions produced by the PTR process can be
accumulated into one or into several charge states by the use of a
technique known as "ion parking". Ion parking uses supplementary AC
voltages to consolidate the PTR product ions formed from the
original variously protonated ions of any given protein molecule
into a particular charge state or states at particular
mass-to-charge (m/z) values during the reaction period. This
technique can be used to concentrate the product ion signal into a
single or limited number of charge states (and, consequently, into
a single or a few respective m/z values) for higher sensitivity
detection or further manipulation using collisional-activation,
ETD, or other ion manipulation techniques. Various aspects of ion
parking have been described in U.S. Pat. No. 7,064,317 B2 in the
name of inventor McLuckey; U.S. Pat. No. 7,355,169 B2 in the name
of inventor McLuckey; U.S. Pat. No. 8,334,503 B2 in the name of
inventor McLuckey; U.S. Pat. No. 8,440,962 B2 in the name of
inventor Le Blanc; and in the following documents: McLuckey et al.,
"Ion Parking during Ion/Ion Reactions in Electrodynamic Ion Traps",
Anal. Chem. 2002, 74, 336-346; Reid et al., "Gas-Phase
Concentration, Purification, and Identification of Whole Proteins
from Complex Mixtures", J. Am. Chem. Soc. 2002, 124, 7353-7362; He
et al., "Dissociation of Multiple Protein Ion Charge States
Following a Single Gas-Phase Purification and Concentration
Procedure", Anal. Chem. 2002, 74, 4653-4661; Xia et al., "Mutual
Storage Mode Ion/Ion Reactions in a Hybrid Linear Ion Trap", J. Am.
Soc. Mass. Spectrom. 2005, 16, 71-81; Chrisman et al., "Parallel
Ion Parking: Improving Conversion of Parents to First-Generation
Products in Electron Transfer Dissociation", Anal. Chem. 2005,
77(10), 3411-3414 and Chrisman et al., "Parallel Ion Parking of
Protein Mixtures", Anal. Chem. 2006, 78, 310-316.
[0019] As a result of the ongoing requirement in the art of mass
spectral proteome analysis for analysis of complex natural samples
in real-time or near-real-time, there is thus a need for improved
methods of mass analysis, both instrumental and computational, that
can efficiently separate analytes from contaminants, differentiate
signal from noise, correctly allocate related m/z values into
proper isotopic clusters, correctly determine charge states and
properly organize the various charge states into distribution
envelopes. Such improvements are required for success in both data
acquisition and, optionally, post-acquisition processing workflows.
Preferably, the improved instrumental methods, workflows and
algorithms should be able to work in a "real-time" environment such
that automated data-dependent decisions may be made while mass
spectra are being acquired and such that clinical interpretations
may be made shortly therafter. The present disclosure addresses
these needs.
DISCLOSURE OF INVENTION
[0020] The present disclosure teaches an application of ion-ion
reaction chemistry in which: (i) one or more stages of proton
transfer reactions, optionally supplemented by data-dependent
fragmentation, are employed to simplify the mass spectrometric
analysis of complex ion populations derived from electrospray
ionization of samples comprising mixtures of compounds extracted
from samples of tissues, biological fluids, microorganisms or other
cells; and (ii) an optimized spectral deconvolution procedure is
employed to automatically discriminate between mass spectral
signatures, in the simplified spectra, of a plurality of biopolymer
molecules in a sufficiently short time (i.e., computation time of
one second or less) such that decisions may be made in real time
regarding the course of subsequent mass spectral analysis steps of
the same respective sample.
[0021] In particular, the inventors have discovered that by
subjecting a mass-to-charge-restricted subset of such ions to PTR,
the resulting population of product ions comprises a much simpler
population of charge states of lower total charge values (where the
words "lower" or "reduced", in this context, refer to lower or
reduced in terms of absolute value) which can be readily resolved
and assigned to specific protein or peptide ions. Because the PTR
product ions represent a smaller subset of multiply-charged species
derived from a complex mixture of charge states than the original
precursor ions, mass spectral interpretation is greatly simplified
and target analysis using tandem mass spectrometry (MS/MS or
MS.sup.n) can be performed on a single protein or other
component(s) derived from a microbial extract.
[0022] The charge-reduced protein and peptide product ions
resulting from a given proton transfer reaction produce
mass-to-charge (m/z) values that are greater than those of the
original m/z values. For a mixture of protein ions that have the
same m/z value but differing mass and charge, the mixture can be
separated on the micro- or millisecond timescale. Further, these
multiply-charged protein ions of the same m/z value with differing
mass and charge can be separated from low m/z value background ions
derived from small molecules, lipids, solvents, or other
interferents based on the charge squared dependence of the
reaction. Multiply-charged ions are therefore separated in time
from the background signal thus producing a separated protein
mixture at highly increased signal-to-noise (s/n) ratio. The
inventors have discovered that, as a result of these two factors,
the spectral signatures of the protein/peptide or any other analyte
product ions may be significantly separated from those of most
interferent ions. In addition, multiple stages of PTR reactions can
be performed to separate protein mixtures on low resolution
instrumentation, such as a linear ion trap mass spectrometer, in
order to simplify and isolate these proteins and other analytes
such that target analysis can be performed via MS.sup.n analysis.
The inventors have further discovered that the advantageous
properties of simple PTR reactions may be even further amplified by
performing "ion parking" procedures in conjunction with PTR
reaction, thus enabling an analyst to at least partially select or
control the product-ion charge state distribution that results from
the PTR reaction.
[0023] PTR can also be used to improve high mass performance in
mass spectrometry. In mass spectrometry, an ion may be assigned
either an integer nominal mass or mass-to-charge ratio or an
accurate or exact mass or mass-to-charge ratio. Accurate or exact
masses or mass-to-charge ratios can be considered as comprising an
integer component or value and a decimal component or value. Atomic
and molecular masses are measured in units of daltons (Da) and m/z
ratio values are generally given in in units of daltons per
elementary charge, or Dale or thomson (Th). It is to be noted that,
in instances of described numerical values of m/z ratios in this
document, such ratios are understood to be provided in units of
daltons per elementary charge, or Th. Accurate or exact (i.e.
non-integer) masses or m/z ratios can be represented as an integer
nominal mass or mass-to-charge ratio value or component together
with a corresponding decimal component. Thus, as used in this
document, accurate mass determination or mass analysis can be
considered as comprising sub-integer accuracy, i.e. accuracy of
.+-.0.5 Da or better and, preferably, 0.1 Da or better.
[0024] Alternatively, accurate or exact masses or m/z ratios may be
defined in terms of parts-per-million (ppm) mass accuracy. For mass
spectrometric determinations of polypeptides and proteins, an
experimental mass accuracy of 50 ppm or better, more preferably 10
ppm or better and, still more preferably 1 ppm or better, is
generally required because such molecules and their ions frequently
have molecular or ionic weights of at least 10,000 Da and as much
as 100,000 Da. Thus, as used in this document, accurate mass
determination or mass analysis can alternatively be considered as
comprising an accuracy of 50 ppm or better, more preferably 10 ppm
or better and, still more preferably, 1 ppm or better.
[0025] In addition to improving the signal-to-noise ratios for this
type of analysis, the inventors have considered that the reduction
of charge on protein ions causes these large ions to refold in the
gas phase, as has been described in Zhao et al., "Effects of
Ion/Ion Proton Transfer Reactions on Conformation of Gas-Phase
Cytochrome c Ions", J. Am. Soc. Mass Spec. 2010, 21, 1208-1217. It
is believed that this results in a more compact configuration which
reduces the collisional cross section of the protein ions and,
accordingly, increases their stability against fragmentation by
collision with background gas molecules present in the mass
analyzer chamber. The inventors have discovered that this effect
can be especially beneficial with mass analyzers that employ image
current detection, such as is done in a Fourier-transform ion
cyclotron resonance (FT-ICR) mass analyzer or in an Orbitrap.TM.
mass analyzer (a type of electrostatic trap mass analyzer
commercially available from Thermo Fisher Scientific of Waltham,
Mass. USA). Another potential reason for improved high mass
performance is the large deposition of energy into a given protein
ion that results from the PTR process. The energy deposited as a
result of the PTR process exceeds 100 kcal/mol and is then
effectively dampened by the presence of collision energy. This
rapid heating process "boils off" neutral molecules that may be
attached to the protein via ion-dipole, ion-induced dipole, or
dipole-induced dipole interactions. Most importantly, the reduction
of charge state for high mass proteins may significantly improve
the transfer of these ions from the relatively high pressure of an
ion guide, ion storage or ion trapping device where the PTR process
is commonly performed, to a lower-pressure region of a mass
analyzer, such as an Orbitrap.TM. mass analyzer. The reduced charge
state means that ions are transferred at less kinetic energy thus
limiting ion scattering, direct fragmentation, or formation of
metastable species. The inventors further consider that this latter
property is especially significant in enabling high-accuracy mass
analysis of the PTR product ions in an accurate-mass
spectrometer--such as the Orbitrap.TM.-type of electrostatic trap
mass analyzer--that detects image currents produced by cyclic ionic
motion over an extended time range.
[0026] The present teachings are especially useful for the analysis
and identification of intact proteins having molecular weight in
excess of 50 kDa. The inventors have discovered the surprising
result that, taken together, the various advantageous factors noted
above can enable accurate identification of multiple intact
proteins or large peptides from even very complex mixtures derived
from natural microorganism samples. Such identifications can enable
microorganism identification to the species, subspecies or even
strain level. The target protein or polypeptide ion single species
or multiple species may be chosen so as to be indicative, based on
prior knowledge or information, either individually or in
combination, of the presence in a sample of a specific
microorganism or cell type, or a specific strain or variant of a
microorganism or cell type, or a given virulence factor or toxin,
or of the capacity of a microorganism or cell to resist an
antimicrobial compound or antibiotic drug.
[0027] The present invention, in one aspect, offers an alternative
to traditional bottom-up proteomics methods, namely top-down
analysis of intact proteins derived from microbial cells via a
method which is applicable to substantially all microorganisms
including Gram-positive bacteria, Gram-negative bacteria,
mycobacteria, mycoplasma, yeasts, protozoans, filamentous (i.e.,
microscopic) fungi. The present invention provides identification
of microorganisms at the genus, species, subspecies, strain
pathovar, and serovar level even in samples containing mixtures of
microorganisms and/or microorganisms analyzed directly from pure
and/or mixed cultures and from direct samples (e.g., surface swabs,
bodily fluids, etc.). In addition, the approaches taught herein can
be employed for targeted detection of virulence factors, antibiotic
resistance and susceptibility markers, or other characteristics.
The top-down methods of the present teachings are simple and quick
because there is no need for chemical or enzymatic digestion of a
sample and data processing is accomplished in real time.
[0028] Methods in accordance with the present teachings may
comprise at least one or more of the following steps: microbial
cell disruption, solubilization of proteins, sample clean-up (to
desalt, remove insoluble components and debris, and/or
concentrate), sample infusion or flow injection, fast partial
liquid chromatographic separation, standard chromatographic
separation, isoelectric focusing, ionization of proteins in
solution, isolation of a given m/z range of the ions, causing the
isolated range of ions to undergo PTR so as to form
first-generation PTR product ions, optional isolation of an m/z
range of the first-generation PTR product ions, optional mass
spectrometry in MS or MS/MS mode, optionally causing the isolated
range of first-generation PTR product ions to undergo a second PTR
reaction so as to form second-generation PTR product ions, mass
spectrometry in MS or MS/MS mode, and microbial identification via
molecular weight analysis and/or protein sequence analysis, or
using any statistical classification method. Preferably, but not
necessarily, the mass spectrometry steps are performed with a
high-resolution, high-accuracy mass spectrometer, such as a mass
spectrometer comprising an Orbitrap.TM. mass analyzer.
[0029] Because a common method using a limited set of chemical
reagents is performed, the methods of the present teachings are
suitable for use within a completely automated system for sample
preparation and mass spectrometry. Ideally, these methods may be
automated from sample preparation through results reporting.
Results may be automatically transferred to a hospital's electronic
medical records system where they can be directly linked to patient
treatment strategies, insurance, billing, or used in
epidemiological reporting. Such an integrated system facilitates
epidemiological tracking of an outbreak at the hospital, local,
regional, and global levels. For high throughput laboratories,
multiple systems can be interfaced to a central computer which
integrates data from the different instruments prior to reporting.
The system can import phenotypic susceptibility data where it can
be combined with identification, virulence, antibiotic resistance
and typing information generated by the invention.
[0030] Computational methods described herein enable both effective
(1) non-redundant data dependent mass spectrometry analysis
employing mass spectral workflow decision-making based on results
of the computations and, optionally, post-acquisition data
processing for individual high mass analytes and their mixtures of
different complexities. For data dependent mass spectrometry
analysis, the herein-described novel "Top P Unique Analyte-Specific
Clusters" workflow and associated computation replaces the previous
conventional state-of-the-art "Top P Most Abundant Precursors"
logic. Each such species-correlative envelope is a set of related
mass spectral lines (m/z values) which are indicated, according to
the methods of the present teachings, to all be generated from a
single unique molecule. Each species-correlative envelope groups
together various charge states and isotopic clusters that are
indicated to have been produced from a single molecular species.
The method also works with mass spectral data in which no peaks
attributable to isotopic distributions are observed (such as may be
the case for low-resolution data) or with mass spectral data having
resolved isotopic distributions but only one charge state per
molecule. However, the species-correlative envelope can exclude
adducts if desired, which are removed prior to data analysis.
[0031] Tandem mass spectrometry (or, more-generally, MS.sup.n
analysis) may be performed, based on the computational results,
only on selected representatives of a given species-correlative
charge state distribution envelope after which data acquisition is
directed to the next species-correlative charge state distribution
envelope (i.e., of a different compound) that is determined in a
preceding MS spectrum, and so on. In various embodiments, the
computations are made using data derived from one or more stages of
application of proton transfer reaction (PTR), as noted above, to
subsets of ions derived from a biological sample comprising a
complex mixture of proteins and/or polypeptides and other organic
molecules. Prior to MS.sup.n analysis, computed charge state
distribution patterns are filtered so as to exclude oxidized (or
other specified) species of the same analyte and various other
unwanted adducts. In this approach, the most possible abundant
information on the analytes in a sample is retrieved either on a
chromatographic time scale, or in experiments in which sample is
introduced into a mass spectrometer by infusion, flow injection or
by means of any other sample introduction device. In all cases,
data-acquisition redundancy is either totally eliminated or
significantly reduced.
[0032] The optimized "Top P Unique Analyte-Specific Clusters"
computational workflow may include one or more of: (1) use of
centroids for representing peak positions; (2) use of either a
binary or simplified intensity scale for representing peak heights;
(3) correct computational assignment of charge state to each peak
(centroid) in isotopic clusters found in a scan; (4) the use of
information on charge state to assign isotopic clusters (either
resolved or unresolved) to the appropriate charge-state
envelope(s); (5) optional determination of molecular weights; and
(6) the control of data-dependent acquisition in a way to allow
only one (or a selected number) of MS.sup.n event(s) per each
individual charge state envelope. The "Top P Unique Cluster" method
can be set up to recognize and work with either the most intense
charge state for a given biopolymer, the median charge state
between the highest charge state detected and the most intense
charge state observed, or any other desired charge state (i.e., not
just a maximum abundance or median charge state) or combination of
charge states. The method is therefore well-suited for use with a
variety of ion activation methods used for ion fragmentation
including but not limited to collision-induced dissociation (CID)
and electron-transfer dissociation (ETD), defined for a given
molecular weight range, or in instances in which the least abundant
proteins species are interrogated first. Similar methods may be
employed for post-acquisition data processing, in which the same
computation logic is applied to raw MS spectra for which
acquisition is completed prior to execution of the novel methods.
Either real-time or post-acquisition data processing may further
include molecular weight determination and analyte
identification.
[0033] These principles of the present teachings can be applied for
analytes of various molecular weights and chemical nature on high
resolution tandem mass spectrometry systems including but not
limited to mass spectrometer instruments that are based on or
include an Orbitrap.TM. mass analyzer. Such instruments include
Orbitrap Fusion.TM., Orbitrap Velos-Pro.TM., Q-Exactive.TM., and
Orbitrap Elite.TM. as well as quadrupole time-of-flight (QTOF) mass
spectrometers and Fourier transform ion cyclotron resonance
(FT-ICR) mass spectrometers. Further, the same computational
principles can be applied to isotopically unresolved charge state
envelopes which can be seen in mass spectra obtained on high
resolution mass spectrometry systems for comparatively very high
mass analytes, or to unit resolution mass spectra obtained on mass
analyzers such as linear ion traps or any other Paul trap
configuration. In instances, instead of making charge
determinations based on a distance between individually resolved
lines of isotopic clusters, these are instead calculated using
distances between charge states within the same charge state
envelope. Again, this clustering based strategy can be applied to
unit resolution data as well as to data generated by linear ion
traps and triple quadrupole instrumentation.
[0034] When used in conjunction with chromatographic separation,
the proposed computational workflow methods maximize information
from each individual mass spectrum obtained during the course of a
chromatographic run. The novel methods may also be employed in
conjunction with mass spectral experiments in which sample is
introduced by infusion or flow injection. In most experimental
situations, the novel methods significantly reduce total analysis
time. When applied to data already acquired, the novel "Top P
Unique Analyte-Specific Clusters" workflow methods can maximize the
information yield from MS spectra and can calculate the molecular
weights of the analytes in real time.
[0035] The novel principles, workflows and algorithms and methods
described and taught in this disclosure are applicable in all cases
when several analytes are mass spectrometrically (MS) detectable
within the same mass spectrum. For example, the novel teachings may
be employed in cases in which two or more analytes co-elute from a
chromatographic column and the co-eluting analytes are
simultaneously introduced into a mass spectrometer. As a second
example, the novel teachings may be employed in cases in which two
or more analytes are introduced into a mass spectrometer using a
flow injection methodology. In yet a third example, the novel
teachings may be employed in cases in which two or more analytes
are introduced into a mass spectrometer using syringe infusion. In
still yet other examples, the novel teachings may be employed in
cases in which analytes are introduced into a mass spectrometer
after separation by a capillary electrophoresis apparatus or a
lab-on-a-chip apparatus. The novel methods may be employed in
conjunction with mass spectrometers employing any known ionization
technique that generates multiply-charged ions, such as, without
limitation, electrospray ionization (ESI).
[0036] Accordingly, in a first aspect, there is disclosed a method
for identifying the presence or absence of a protein/polypeptide or
other biologically relevant compound within a liquid sample
comprising a mixture of compounds that includes a plurality of
protein compounds or a plurality of polypeptide compounds or
pluralities of both protein and polypeptide or other compounds,
wherein the method comprises: (a) introducing a portion or all of
the liquid sample into an electrospray ionization source of a mass
spectrometer; (b) forming positively-charged ions of the mixture of
compounds of the portion of the liquid sample by electrospray
ionization, the positively-charged ions comprising a plurality of
ion species; (c) isolating a first subset of the ion species
comprising a first mass-to-charge (m/z) ratio range that includes
an m/z ratio of a multiply-protonated molecular species of the
analyte compound; (d) generating a plurality of first-generation
product ion species from the isolated first subset of ion species
by causing the isolated first subset of ion species to be reacted,
for a predetermined time duration, with reagent anions that, upon
reaction, extract protons from each of one or more ion species that
comprises a protonated species of a protein or polypeptide
compound; (e) generating a mass spectrum, using a mass analyzer, of
either the first-generation product ion species or of
second-generation product ion species generated from the
first-generation product ion species; (f) conducting a search of
the mass spectrum of either the first-generation or the
second-generation product ion species for a set of one or more m/z
ratios that are diagnostic of the protein or polypeptide analyte
compound; and (g) making a determination of the presence or absence
of the analyte compound within the sample based on a measure of
similarity between a set of m/z ratios identified in the mass
spectrum and the set of one or more diagnostic m/z ratios. The
measure of similarity may comprise a metric that is calculated
based on a determined percentage or proportion of the one or more
diagnostic m/z ratios that are found to occur in the measured set
of identified m/z ratios. Alternatively, the presence of an analyte
compound within the sample can be determined by comparing the
measure of similarity between a set of m/z ratios identified in the
mass spectrum and those contained in a protein, DNA, or
carbohydrate based database; and (h) using the aforementioned
information as a way to positively identify any unknown
microorganism using spectral libraries, sequence based searching,
statistical classification methods including but not limited to
Bayesian, logistic regression, and decision tree classifiers. As an
alternative to forming positively-charged ions in step (b),
negatively-charged analyte ion species may be produced instead. In
such cases, the reagent anions are chosen so as to transfer protons
to the analyte ion species, thereby reducing the absolute values of
their negative charges.
[0037] In a second aspect, there is disclosed a method of
identifying the presence or absence of a microorganism type in a
sample, comprising: (i) identifying a series of molecular weights
whose simultaneous presence in the sample is diagnostic of the
presence of the microorganism type(s) in the sample (ii)
identifying a list of analyte compounds whose simultaneous presence
in the sample is diagnostic of the presence of the microorganism
type(s) in the sample, said list of analyte compounds comprising
protein compounds, polypeptide compounds or both protein and
polypeptide compounds; (iii) extracting, from the sample, a liquid
solution comprising a mixture of sample-derived proteins and
polypeptides; (iv) performing a set of analysis steps for each
respective analyte compound in the list; and (v) identifying the
presence of the microorganism(s) type within the sample if the
presence of microorganism specific analyte compounds of the list of
analyte compounds is identified within the liquid solution. The
analysis steps that are performed for each respective analyte in
the list comprise: (a) introducing a portion of the liquid solution
into an electrospray ionization source of a mass spectrometer; (b)
forming positively-charged ions of the mixture of compounds of the
portion of the liquid solution by electrospray ionization, the
positively-charged ions comprising a plurality of ion species; (c)
isolating a first subset of the ion species comprising a first
mass-to-charge (m/z) ratio range that includes an m/z ratio of
either a random or particular predetermined multiply-protonated
molecular species of the respective analyte compound; (d)
generating a plurality of first-generation product ion species from
the isolated first subset of ion species by causing the isolated
first subset of ion species to be reacted, for a predetermined time
duration, with reagent anions that spontaneously extract protons
from each of one or more ion species that comprises a protonated
species of a protein or polypeptide compound; (e) generating a mass
spectrum, using a mass analyzer, of either the first-generation
product ion species or of second-generation product ion species
generated from the first-generation product ion species; (f)
conducting a search of the mass spectrum of either the
first-generation or the second-generation product ion species for a
set of one or more m/z ratios that are diagnostic of the respective
analyte compound; and (g) identifying the presence of the
respective analyte compound within the liquid solution based on a
measure of similarity between a set of m/z ratios identified in the
mass spectrum and the set of one or more diagnostic m/z ratios. The
measure of similarity may comprise a metric that is calculated
based on a determined percentage or proportion of the one or more
diagnostic m/z ratios that are found to occur in the measured set
of identified m/z ratios. The diagnostic m/z ratios can be derived
from a spectral library or sequence database. If the m/z ratio that
is isolated in step (c) is of a random multiply-protonated
molecular species, then the search conducted in step (f) is a
sequence-based search. Otherwise, if the m/z ratio that is isolated
in step (c) is of a particular predetermined multiply-protonated
molecular species, then a spectral library search is conducted in
step (f). In addition to using the aforementioned information as a
way to positively identify an unknown microorganism using spectral
libraries or sequence based searches, statistical classification
methods including but not limited to Bayesian, logistic regression,
and decision tree classifiers can be utilized for microbial
characterization and identification. As an alternative to forming
positively-charged ions in step (b), negatively-charged analyte ion
species may be produced instead. In such cases, the reagent anions
or cations are chosen so as to transfer protons to the analyte
anion species, thereby reducing the absolute values of their
negative charges. Control of the PTR experimental processes
described herein can be performed manually or automatically in
real-time using real-time spectral deconvolution.
[0038] The term "real-time spectral deconvolution" in the above
refers to spectral deconvolution of mass spectral data that is
performed concurrently with the mass spectral experiment or
analytical run that generates (or that has generated) that mass
spectral data. For example, mass spectral data acquired by mass
analysis of analytes that elute at a first retention
chromatographic retention time during a gradient elution may be
deconvoluted, so as to identify the analytes, simultaneously with
the continued collection of additional mass spectral data of
additional analytes that elute at a second, later retention time
during the same gradient elution. Likewise, deconvolution of the
additional mass spectral data, so as to identify the additional
analytes, may be performed simultaneously with the continued
collection of mass spectral data of analytes that elute at a third
elution time during the same gradient elution. The real-time
spectral deconvolution may be facilitated by the use of a fast
computer, such as a computer that employs parallel processing or a
graphics processing unit (GPU) to perform the necessary
calculations. Alternatively or additionally, the real-time spectral
deconvolution may be facilitated by the use of a computationally
efficient or optimized algorithm, such as an algorithm that is
written at least partially in assembly language or that makes
extensive use of in-cache look-up-tables. Advantageously, and as
provided by the deconvolution computational methods in accordance
with the present teachings (described in the appendix), the
mathematical computations will not introduce any significant delays
(i.e., greater than 1.0 seconds) into the work flow, taken with
respect to the same workflow in the absence of the execution of the
deconvolution computations.
[0039] More generally, the term "real-time" may be understood as
meaning, when used in reference to an event or activity associated
with a data acquisition process, that the event or activity occurs
while some aspect or sub-process of that data acquisition process
is ongoing. The data acquisition process itself may include one of
more the following individual sub-processes: sample purification
(e.g., solid phase extraction, size-exclusion chromatography);
sample separation (e.g., chromatography); sample transfer into a
mass spectrometer (e.g., infusion or inletting of eluate from a
chromatograph); sample ionization in an ion source to as to
generate first-generation ions; selection and isolation of ions for
further manipulation; causing fragmentation of sample-derived ions
or reaction of sample-derived ions with reagent ions so as to
generate a first-generation of product ions; optional selection and
isolation of product ions; optional further fragmentation of
product ions or further reaction of product ions; transfer of ions
(first-generation ions or first-generation or subsequent-generation
product ions) to a mass analyzer, detection and measurement of ion
mass-to-charge ratios by a detector of the mass analyzer; and
transfer of data derived from the detection and measurement to a
digital processor for storage, mathematical analysis, etc. The
events or activities that may occur in "real-time", so defined, may
include, but are not necessarily limited to: determination or
identification of the presence of an analyte in a sample;
identification or determination of the presence of a microorganism
in a sample and providing a notification to a user of the
identification or determination of the presence of an analyte or
microorganism in a sample.
[0040] The above-described and various other features and
advantages of the present teachings will become more fully apparent
from the following description and appended claims, or may be
learned by the practice of the invention as set forth
hereinafter.
BRIEF DESCRIPTION OF DRAWINGS
[0041] To further clarify the above and other advantages and
features of the present disclosure, a more particular description
of the disclosure will be rendered by reference to specific
embodiments thereof, which are illustrated in the appended
drawings. It is appreciated that these drawings depict only
illustrated embodiments of the disclosure and are therefore not to
be considered limiting of its scope. The disclosure will be
described and explained with additional specificity and detail
through the use of the accompanying drawings in which:
[0042] FIG. 1 is a block diagram schematically illustrating a
system for rapid extraction and analysis of soluble proteins from
at least one microorganism for identifying the at least one
microorganism;
[0043] FIG. 2 is a schematic representation of an exemplary mass
spectrometer suitable for employment in conjunction with methods
according to the present teachings, the mass spectrometer
comprising a hybrid system comprising a quadrupole mass filter, a
dual-pressure quadrupole ion trap mass analyzer and an
electrostatic trap mass analyzer;
[0044] FIG. 3A is a flow diagram of a first method in accordance
with the present teachings;
[0045] FIG. 3B is a flow diagram of an alternative method in
accordance with the present teachings;
[0046] FIG. 3C is a flow diagram of another alternative method in
accordance with the present teachings;
[0047] FIG. 3D and FIG. 3E illustrate a flow diagram of yet another
alternative method in accordance with the present teachings;
[0048] FIG. 3F is a flow diagram of still yet another alternative
method in accordance with the present teachings;
[0049] FIG. 4A is an ESI mass spectrum via direct infusion of a
typical E. coli extract;
[0050] FIG. 4B is a PTR product-ion mass spectrum generated by
isolating ions of the E. coli extract of FIG. 4A within a 2 Th mass
window centered at m/z=750 Th and reacting the isolated ions with
PTR reagent anions;
[0051] FIG. 5A is a mass spectrum of first-generation PTR product
ions generated by isolating ions of an E. coli extract within a
mass window of width 5 Th centered at 1200 Th and reacting the
isolated ions with PTR reagent anions;
[0052] FIG. 5B is a mass spectrum of second-generation PTR product
ions generated by isolating ions of the first-generation PTR
product ions of FIG. 5A within a mass window of width 5 Th centered
at 1320 Th and reacting the isolated first-generation product ions
with PTR reagent anions a second time;
[0053] FIG. 6A is a mass spectrum of PTR product ions generated by
isolating ions of an E. coli extract within a mass window of width
5 Th centered at 640 Th and reacting the isolated ions with PTR
reagent anions;
[0054] FIG. 6B is a mass spectrum of an isolated PTR product ion
species selected from the product ion assemblage of FIG. 6A and
having an m/z ratio of 833 Th;
[0055] FIG. 6C is a mass spectrum of second-generation product ions
generated by collision-induced dissociation (CID) of the isolated
PTR product ion species of FIG. 6B;
[0056] FIG. 6D is a mass spectrum of an isolated PTR product ion
species selected from the product ion assemblage of FIG. 6A and
having an m/z ratio of 926 Th;
[0057] FIG. 6E is a mass spectrum of second-generation product ions
generated by collision-induced dissociation of the isolated PTR
product ion species of FIG. 6D;
[0058] FIG. 6F is a mass spectrum of an isolated PTR product ion
species selected from the product ion assemblage of FIG. 6A and
having an m/z ratio of 917 Th;
[0059] FIG. 6G is a mass spectrum of second-generation product ions
generated by collision-induced dissociation of the isolated PTR
product ion species of FIG. 6F;
[0060] FIG. 7A is a schematic depiction of a method, in accordance
with the present teachings, of improved-efficiency PTR conversion
of ions of a selected analyte to an assemblage of PTR product ions
by simultaneous isolation and reaction of multiple m/z ranges of
electrospray-produced first-generation precursor ions;
[0061] FIG. 7B is a schematic diagram of isolation of a first
randomly-chosen range of electrospray-produced first-generation
precursor ions for PTR reaction, as may be employed in an initial
step of a method of improved-efficiency PTR conversion of ions;
[0062] FIG. 7C is a schematic depiction of recognition of two
charge-state sequences of PTR product ions corresponding to
different analyte molecules, as may be employed as an intermediate
step of a method of improved-efficiency PTR conversion of ions;
[0063] FIG. 8 is a flow diagram of a method, in accordance with the
present teachings, of improved-efficiency PTR conversion of ions of
a selected analyte to an assemblage of PTR product ions;
[0064] FIG. 9A is a full scan mass spectrum of first-generation
ions generated from eluate at a retention time of 10 min. and 30 s.
during the course of a ten-minute gradient reverse-phase liquid
chromatography separation of an E. coli extract;
[0065] FIG. 9B is a PTR product ion spectrum generated by reacting
sulfur hexafluoride for 10 ms with an isolated population of ions
of the sample of FIG. 9A within a 10 Th wide isolation window
centered at 750 Th;
[0066] FIG. 10A is a full scan mass spectrum of first-generation
ions generated from eluate at a retention time of 42 min. and 30 s.
during the course of a sixty-minute gradient reverse-phase liquid
chromatography separation of an E. coli extract;
[0067] FIG. 10B is a PTR product ion spectrum generated by reacting
sulfur hexafluoride for 10 ms with an isolated population of ions
of the sample of FIG. 10A within a 10 Th wide isolation window
centered at 750 Th;
[0068] FIG. 11A is a full scan mass spectrum of first-generation
ions generated from eluate at a retention time of 18 min. and 9 s.
during the course of a thirty-minute gradient reverse-phase liquid
chromatography separation;
[0069] FIG. 11B is a PTR product ion spectrum generated by reaction
of PTR reagent ions with an isolated population of ions of the
sample of FIG. 11A within a 10 Th wide isolation window centered at
750 Th;
[0070] FIG. 11C is a full scan mass spectrum of first-generation
ions generated from eluate at a retention time of 22 min. and 27 s.
during the course of the same thirty-minute gradient reverse-phase
liquid chromatography separation of which the earlier elution
results are plotted in FIG. 11A;
[0071] FIG. 11D is a PTR product ion spectrum generated by reaction
of PTR reagent ions with an isolated population of ions of the
sample of FIG. 11C within a 10 Th wide isolation window centered at
750 Th;
[0072] FIG. 12A is a schematic illustration of simple
intensity-threshold-based data dependent mass spectral analysis of
two analytes exhibiting well-resolved chromatographic peaks;
[0073] FIG. 12B is a schematic illustration of a portion of a
chromatogram with highly overlapping elution peaks, both of which
are above an analytical threshold;
[0074] FIG. 12C is an illustration of multiple interleaved mass
spectral peaks of two simultaneously eluting biopolymer
analytes;
[0075] FIG. 13 is a set of chromatograms collected from a single
liquid chromatography-mass spectrometry experimental run of an E.
Coli extract, including a total ion current chromatogram (top
curve) and also illustrating various extracted ion chromatograms
(lower curves) that contribute to the total ion current, each
extracted ion chromatograph representing a respective m/z ratio
range;
[0076] FIG. 14 is a flowchart of a general set of steps employed by
various methods in accordance with the present teachings;
[0077] FIG. 15 is a flowchart of a method to convert experimentally
measured mass spectral centroids to an occupancy array, with the
indices that are related to one another by different charge states
encapsulated in a matrix, in accordance with the present
teachings;
[0078] FIG. 16 is a flowchart of a method in accordance with the
present teachings for constructing a Boolean occupancy array within
a mathematically transformed mass-to-charge space from
experimentally determined mass spectral centroid data;
[0079] FIG. 17A and continuation FIG. 17B, is a flowchart of a
method in accordance with the present teachings for assigning
tentative charge states for a plurality of experimentally
determined mass spectral centroids;
[0080] FIG. 18 is a flowchart of a method in accordance with the
present teachings for adjusting a set of previously tentatively
assigned charge states such that the resulting final assigned
charge states are self-consistent;
[0081] FIG. 19 is a flowchart of a method in accordance with the
present teachings for decomposing a set of experimentally
determined centroids having assigned charge states into
analyte-specific clusters;
[0082] FIG. 20A and continuations FIGS. 20B, 20C and 20D, is a
table showing typical molecular weights, expected number of
C.sup.13 atoms in the most abundant isotope (mode), expected
average number of C.sup.13 atoms among all isotopes and the
difference between the expected average number and the mode, as
they vary with the total number of C.sup.12 atoms in a protein;
[0083] FIGS. 21A, 21B, 21C and 21D are depictions of computer
screen user interfaces which may be employed in conjunction with
user control of and information display from computer software that
employs methods in accordance with the present teachings;
[0084] FIG. 22A is a depiction of a computer screen information
display illustrating peak cluster decomposition results, as
generated by computer software employing methods in accordance with
the present teachings, calculated from a mass spectrum of a
five-component protein mixture consisting of cytochrome-c,
lysozyme, myoglobin, trypsin inhibitor, and carbonic anhydrase;
[0085] FIG. 22B is a depiction of a computer screen information
display illustrating peak cluster decomposition results, as
generated by computer software employing methods in accordance with
the present teachings, the display illustrating an expanded portion
of the decomposition results shown in FIG. 22A;
[0086] FIG. 22C is a depiction of a computer screen information
display illustrating peak cluster decomposition results, as
generated by computer software employing methods in accordance with
the present teachings, the display illustrating an even-further
expanded portion of the decomposition results shown in FIG.
12B;
[0087] FIG. 23A is a depiction of a computer screen information
display illustrating peak cluster decomposition results, as
generated by computer software employing methods in accordance with
the present teachings, the display illustrating peak cluster
decomposition results calculated from a single-stage mass spectrum
of a crude extract from the bacterium E. coli directly infused into
a mass spectrometer;
[0088] FIG. 23B is a depiction of a computer screen information
display illustrating peak cluster decomposition results, as
generated by computer software employing methods in accordance with
the present teachings, the display illustrating an expanded portion
of the decomposition results shown in FIG. 23A;
[0089] FIG. 23C is a depiction of the mass spectral data whose peak
cluster decomposition is shown in FIGS. 23A-23B, showing peak
positions and charge-state assignments as provided by a
conventional mass spectral peak analysis computer program;
[0090] FIG. 23D is a depiction of the mass spectral data whose peak
cluster decomposition is shown in FIGS. 23A-23B, showing
charge-state assignments as provided by methods in accordance with
the present teachings;
[0091] FIG. 24A is a depiction of a mass spectrum of an intact
antibody having varying degrees of glycosylation (main plot) also
showing (inset) an expanded portion of the spectrum illustrating
the different glycoforms of the antibody;
[0092] FIG. 24B is a depiction of a computer screen information
display illustrating peak cluster decomposition results, as
generated by computer software employing methods in accordance with
the present teachings, calculated from the mass spectral data shown
in FIG. 24A, showing the calculated molecular weights of the four
decomposed glycoforms of the antibody ranging from 148378 Da to
148763 Da;
[0093] FIG. 25A is a depiction of an MS.sup.2 spectrum of the
protein carbonic anhydrase II, generated by collision-induced
dissociation of the +26 charge state of the protein occurring at
m/z=807.00 Da, showing peak assignments as determined by a
conventional mass spectral analysis method;
[0094] FIG. 25B is a depiction of a computer screen information
display illustrating peak cluster decomposition results, as
generated by computer software employing methods in accordance with
the present teachings, calculated from the MS.sup.2 mass spectral
data shown in FIG. 25A;
[0095] FIG. 25C is a depiction of a second MS.sup.2 spectrum of the
protein carbonic anhydrase II, generated by collision-induced
dissociation of the +21 charge state of the protein at m/z=1001.00
Da, showing peak assignments as determined by a conventional mass
spectral analysis method; and
[0096] FIG. 25D is a depiction of a computer screen information
display illustrating peak cluster decomposition results, as
generated by computer software employing methods in accordance with
the present teachings, calculated from the MS.sup.2 mass spectral
data shown in FIG. 25C.
MODES FOR CARRYING OUT THE INVENTION
[0097] The following description is presented to enable any person
skilled in the art to make and use the invention, and is provided
in the context of a particular application and its requirements.
Various modifications to the described embodiments will be readily
apparent to those skilled in the art and the generic principles
herein may be applied to other embodiments. Thus, the present
invention is not intended to be limited to the embodiments and
examples shown but is to be accorded the widest possible scope in
accordance with the claims. The particular features and advantages
of the invention will become more apparent with reference to the
appended FIGS. 1-11D taken in conjunction with the following
description in the main body of this document as well as FIGS.
12A-25D taken in conjunction with the description in the appendix
to this document.
[0098] Referring now to FIG. 1, a system 100 for extraction of
proteins from one or more microorganisms, detection of the
proteins, and identification of the one or more microorganisms is
schematically illustrated. The system 100 includes a sample
handling device 115, a sample 110 that is accessible by the sample
handling device 115, and sources of reagents, buffers, and the like
120, these sources being fluidly coupled to the sample handling
device 115 by various tubing or other transfer lines. The system
100 further includes a first and, optionally, a second
sample-purification device 135 (such as a solid phase extraction
cartridge) configured for cleaning up samples (e.g., desalting,
removing contaminants, concentrating proteins) and an optional
chromatography column 140 that may be configured for at least
partially purifying a sample 110 by liquid chromatography prior to
mass-spec analysis. At least one sample-purification device 135 can
comprise an in-line size exclusion chromatography column that can
be used to not only remove salts but small molecules and lipids as
well. The sample 110, the first and optional second
sample-purification devices 135, and the optional chromatography
column 140 are in fluid communication with a fluid handling pump
130, the various reagents, buffers and other fluids 120, and a mass
spectrometer 150.
[0099] The sample handling device 115 is capable of preparing a
range of sample types containing one or more microbes and
delivering a soluble protein fraction extracted from the microbes
to the mass spectrometer 150 for analysis. A sample 110 may be of
any type suspected to contain one or more microorganisms including,
without limitation, isolated colonies from a culture plate, cells
from liquid growth medium, blood, blood culture, saliva, urine,
stool, sputum, wound and body site swabs, soil, food, beverage,
water, air, and environmental surface swabs.
[0100] The sample handling device 115 may include one or more of a
cell disruption means, a robotic liquid handling means, a
centrifuge, filtration means, an incubator, mixing means, a vacuum
pump, a fluid pump, and reagents 120 that can be used for
disruption of microbes and isolation of a soluble protein fraction.
Disruption of bacterial, fungal, mycoplasma cells, viruses, and the
like may be achieved by mechanical, chemical, enzymatic and other
means as are commonly known in the art. Mechanical approaches
include bead beating, use of pressure like French press and the
like, sonication or other methods known in the art. Chemical
methods include exposure to chaotropes such as urea, thiourea, or
guanidine HCL to lyse the microbial cells and solubilize their
contents. Alternatively, organic acid/solvents mixtures may be
utilized to disrupt cells. Enzymatic methods include using
lysozyme, lysostaphin or other lytic enzymes to form "holes" in the
bacterial cell walls that allow the contents to leak out into the
surrounding solution.
[0101] As illustrated in FIG. 1, the system 100 further includes an
optional control unit 160 that can be linked to various components
of the system 100 through linkages 170a-170d. For example, the
control unit 160 can be linked to the sample 110 to control sample
application, the reagents 120 to control the application of various
reagents, the pump 130 to control fluid handling, flow rates, etc.,
to the sample handling device 115 to control sample preparation,
and to the mass spectrometer 150 to control mass spectrometry
parameters. In the illustrated embodiment, the control unit 160 can
also serve as a data processing unit to, for example, process data
from the mass spectrometer 150 or to forward the data to server(s)
for processing and storage (the server is not shown in FIG. 1).
Control unit 160 can also determine molecular weights and charge
states of any generation of PTR product ions for MS/MS, MS.sup.n,
or molecular weight determination in real time. The Control Unit
160 can also be used to automatically forward the results to health
care professionals.
[0102] In some embodiments, the system 100 is designed to be used
by a clinician or a general laboratory technician who is not
necessarily expert in all aspects of sample preparation, LC-MS
operations, LC-MS methods development, and the like. As such, the
control unit 160 can be designed to encapsulate the data system
environment by providing a user with a simplified application
interface that can be used to initiate and monitor essentially all
aspects of assaying a sample 110 without requiring the user to
interact with the overall hardware and control systems of the
system 100. The control unit 160 is therefore configured to provide
a degree of separation between the user and the underlying services
that control devices, data files and algorithms for translating
data to a user readable form. That is, the control unit 160
eliminates the need for the user to be aware of or in control of
hardware for analyzing clinical samples and provides a simplified
interface to send and receive information from the mass
spectrometer.
[0103] The control unit 160 may be configured to internally monitor
each sample analysis request and is capable of tracking the
analysis request from start to finish through the system 100. Once
data for a sample 110 is being acquired or has been acquired by the
system 100, the control unit 160 may be configured to automatically
start post processing the data based on the type of assay selected
by the user. Most importantly, the control unit 160 can be
configured to process data in real time during the acquisition
process. Here results are returned to the user in real-time that
include microbial identification, virulence and resistance
characterization, strain matching information, and data on
antibiotic susceptibility testing. Moreover, the control unit 160
can be configured to automatically select post-processing
parameters based on the type of assay selected by the user, further
reducing the need for the user to interact with the system once the
assay has been selected and started for analysis. The control unit
160 can be designed as a layer that fits between the system 100 and
the user to reduce the complexity needed to set up sample assays
for acquisition. The control system 160 can also be configured to
return only the most relevant data to the user to avoid
overwhelming the user with extraneous information.
[0104] In one embodiment, the system 100 can further include a
sample detection device (not pictured) operably coupled to or
integrated with the sample handling device 115. The sample
detection device can work with the sample handling device 115 or
independently of the sample handling device 115 perform at least
one of the following functions: i. identify samples entering the
system; ii. identify assay types for the samples entering the
system; iii. select an assay protocol based on the anticipated
assay type and/or analyte of interest; iv. direct the sample
handling device and/or the control system to initiate analysis of
the analyte of interest in the sample; v. direct the control system
to select one or more reagents based upon the assay protocol
selected for the type of assay and/or analyte of interest; vi.
direct the control system to select a liquid chromatography mobile
phase condition based upon the assay protocol selected for the type
of assay and/or analyte of interest and cause the liquid
chromatography system to perform the assay and/or purify the
analyte of interest; vii. direct the control system to select a
mass spectrometer setting based upon the assay protocol selected
for the assay type and/or analyte of interest and cause the mass
spectrometer to create mass spectral data associated with the
selected assay type and/or analyte of interest; and viii. direct
the control system to analyze the mass spectral data associated
with the selected assay type and/or analyte of interest to identify
the presence and/or concentration of the analyte of interest.
[0105] The sample, or the processed sample, may be cleaned up and
or purified prior to analysis by mass spectrometry. Such
purification, or sample clean-up, may refer to a procedure that
removes salts or lipids from the crude cell extract, or to a
procedure that enriches one or more analytes of interest relative
to one or more other components of the sample. It also may refer to
sample processing and clean-up in a separate laboratory that has
biosafety level-three facilities for handling mycobacteria or
filamentous fungi. In this embodiment samples are transferred to
the system and can be analyzed as described previously. In one
embodiment, such purification, or sample clean-up, may be
accomplished by a solid phase extraction device, in-line size
exclusion chromatography and/or the optional chromatography column
140.
[0106] In one embodiment, the first and/or second
sample-purification device 135 may include a solid phase extraction
(SPE) cartridge. In some embodiments, the SPE cartridge may be in
line directly with the high resolution/high mass accuracy mass
spectrometer 150. In one embodiment, the SPE cartridge may be a
polypropylene tip with a small volume of silica or other sorbent
containing bonded C.sub.4, C.sub.8 or C.sub.18 or other functional
groups immobilized in the cartridge, for example, a StageTip.TM.
cartridge (Thermo Fisher Scientific). In alternative embodiments,
polymeric sorbents or chelating agents may be used. The bed volume
may be as small as 1 .mu.L or less but greater volumes may also be
used. The apparatus and method are well suited to the complex
samples derived from the microbial cells because each SPE cartridge
is used only once, minimizing carryover problems from one sample to
another.
[0107] In one embodiment, a sample-purification device 135 may be
an in-line size-exclusion chromatography column designed to remove
salts, small molecules, and lipids from the sample 110. The
approach can be used to separate medium and large molecular weight
proteins as well. Phases are selected to be compatible with partial
(i.e., less than 100 percent) organic solutions and organic acids.
Phases can accommodate protein size distributions that differ in
molecular weight from 10.sup.3 to 10.sup.8 Da. Flow rates are
adjusted in real time to effect separation of intact proteins from
small molecules with separation flow rates typically much less than
the higher flow rates used to remove small molecules, lipids, and
salts from the system. In this embodiment, a sample-purification
device 135 may also be heated to facilitate faster diffusion rates
for intact proteins, thus significantly shortening run times. The
flow of mobile phase through a sample-purification device 135 may
also be diverted during a portion of the clean-up process to remove
certain impurities from the flow stream and prevent them from
entering the mass spectrometer 150.
[0108] In one embodiment, the optional chromatography column 140
may include a column configured for at least partial
chromatographic separation of the proteins in the sample. The
stationary phase in the chromatography column may be porous or
non-porous silica or agarose particles, or a monolithic material
polymerized or otherwise formed inside the column. The stationary
phase may be coated with an appropriate material such as C.sub.18,
C.sub.8, C.sub.4 or another suitable derivative, or contain cation
exchanger or other material, or the combination of the above to
facilitate the separation of the proteins, and such material may be
chemically bonded to the particles or monolith inside the column.
Particle sizes typically range from about 1.5 .mu.m to 30 .mu.m.
Pore sizes can range from 50 to 300 angstroms. Inside diameters of
columns typically range from about 50 .mu.m to 2.1 mm, and column
length from about 0.5 cm to 25 cm, or other. The mobile phase or
eluent may be a pure solvent, or a mixture of two or more solvents,
and may contain added salts, acids and/or other chemical modifiers.
The proteins are separated on the column based on one or more
physiochemical properties, including size, net charge,
hydrophobicity, affinity, or other physiochemical properties.
Chromatographic separation methods include one or more of ion
exchange, size exclusion, HILIC, hydrophobic interaction, affinity,
normal-phase, or reverse-phase chromatography.
[0109] Additional methods of purifying the samples may include,
without limitation, liquid chromatography, HPLC, UHPLC,
precipitation, solid-phase extraction, liquid-liquid extraction,
dialysis, affinity capture, electrophoresis, filtration,
ultra-filtration or other suitable methods known in the art for
purification.
[0110] Various methods have been described involving the use of
HPLC for sample clean-up prior to mass spectrometry analysis. One
of skill in the art can select HPLC instruments and columns that
are suitable for use in the invention. The chromatographic column
typically includes a medium (i.e., a packing material) to
facilitate separation of chemical moieties in space and time. The
medium may include very small particles, which may have a bonded
surface that interacts with the various chemical moieties to
facilitate separation of the analytes of interest. One suitable
bonded surface is a hydrophobic bonded surface such as an alkyl
bonded surface. Alkyl bonded surfaces may include C.sub.4, C.sub.8,
or C.sub.18 bonded alkyl groups. In addition, monolithic and other
phases known in the state of the art may be used as well. The
chromatographic column includes an inlet port for receiving a
sample and an outlet port for discharging an effluent that includes
the fractionated sample. For example, a test sample may be applied
to the column at the inlet port, eluted with a solvent or solvent
mixture, and discharged at the outlet port. In another example,
more than one column may be used sequentially or as a
two-dimensional (2D) chromatography system wherein a test sample
may be applied to a first column at the inlet port, eluted with a
solvent or solvent mixture onto a second column, and eluted with a
solvent or solvent mixture from the second column to the outlet
port. Different solvent modes may be selected for eluting the
analytes. For example, liquid chromatography may be performed using
a gradient mode, an isocratic mode, or a polytyptic (i.e. mixed)
mode.
[0111] FIG. 2 is a schematic depiction of an exemplary mass
spectrometer 150a which may be employed as the mass spectrometer
150 of FIG. 1. The mass spectrometer illustrated in FIG. 2 is a
hybrid mass spectrometer, comprising more than one type of mass
analyzer. Specifically, the mass spectrometer 150a includes an ion
trap mass analyzer 216 as well as an Orbitrap.TM. analyzer, which
is a type of electrostatic trap mass analyzer. Since, as will be
described below, various analysis methods in accordance with the
present teachings employ multiple mass analysis data acquisitions,
a hybrid mass spectrometer system can be advantageously employed to
improve duty cycles by using two or more analyzers simultaneously.
The Orbitrap.TM. mass analyzer 212 employs image charge detection,
in which ions are detected indirectly by detection of an image
current induced on an electrode by the motion of ions within an ion
trap.
[0112] In operation of the mass spectrometer 150a, an electrospay
ion source 201 provides ions of a sample to be analyzed to an
aperture of a skimmer 202, at which the ions enter into a first
vacuum chamber. After entry, the ions are captured and focused into
a tight beam by a stacked-ring ion guide 204. A first ion optical
transfer component 203a transfers the beam into downstream
high-vacuum regions of the mass spectrometer. Most remaining
neutral molecules and undesirable high-velocity ion clusters, such
as solvated ions, are separated from the ion beam by a curved beam
guide 206. The neutral molecules and ion clusters follow a
straight-line path whereas the ions of interest are caused to bend
around a ninety-degree turn by a drag field, thereby producing the
separation.
[0113] A quadrupole mass filter 208 of the mass spectrometer 150a
is used in its conventional sense as a tunable mass filter so as to
pass ions only within a selected narrow m/z range. A subsequent ion
optical transfer component 203b delivers the filtered ions to a
curved quadrupole ion trap ("C-trap") component 210. The C-trap 210
is able to transfer ions along a pathway between the quadrupole
mass filter 208 and the ion trap mass analyzer 216. The C-trap 210
also has the capability to temporarily collect and store a
population of ions and then deliver the ions, as a pulse or packet,
into the Orbitrap.TM. mass analyzer 212. The transfer of packets of
ions is controlled by the application of electrical potential
differences between the C-trap 210 and a set of injection
electrodes 211 disposed between the C-trap 210 and the Orbitrap.TM.
mass analyzer 212. The curvature of the C-trap is designed such
that the population of ions is spatially focused so as to match the
angular acceptance of an entrance aperture of the Orbitrap.TM. mass
analyzer 212.
[0114] Multipole ion guide 214 and optical transfer component 203b
serve to guide ions between the C-trap 210 and the ion trap mass
analyzer 216. The multipole ion guide 214 provides temporary ion
storage capability such that ions produced in a first processing
step of an analysis method can be later retrieved for processing in
a subsequent step. The multipole ion guide 214 can also serve as a
fragmentation cell. Various gate electrodes along the pathway
between the C-trap 210 and the ion trap mass analyzer 216 are
controllable such that ions may be transferred in either direction,
depending upon the sequence of ion processing steps required in any
particular analysis method.
[0115] The ion trap mass analyzer 216 is a dual-pressure quadrupole
linear ion trap (i.e., a two-dimensional trap) comprising a
high-pressure linear trap cell 217a and a low-pressure linear trap
cell 217b, the two cells being positioned adjacent to one another
separated by a plate lens having a small aperture that permits ion
transfer between the two cells and that presents a pumping
restriction and allows different pressures to be maintained in the
two traps. The environment of the high-pressure cell 217a favors
ion cooling, ion fragmentation by either collision-induced
dissociation or electron transfer dissociation or ion-ion reactions
such as proton-transfer reactions. The environment of the
low-pressure cell 217b favors analytical scanning with high
resolving power and mass accuracy. The low-pressure cell includes a
dual-dynode ion detector 215.
[0116] The use of either a step of electron transfer dissociation
or proton transfer reaction within a mass analysis method requires
the capability of causing controlled ion-ion reaction within a mass
spectrometer. Ion-ion reactions, in turn, require the capabilities
of generating reagent ions and of causing the reagent ions to mix
with sample ions. The mass spectrometer 150a, as depicted in FIG.
2, illustrates two alternative reagent-ion sources, a first
reagent-ion source 299a disposed between the stacked-ring ion guide
204 and the curved beam guide 206 and a second reagent-ion source
299b disposed at the opposite end of the instrument, adjacent to
the low-pressure cell 217b of the linear ion trap mass analyzer
216. Generally, any particular system will only include one reagent
ion source at most. However, two different reagent ion sources are
depicted and discussed here for illustrative purposes. Although the
following discussion is directed to reagent ion sources for PTR,
similar discussion may apply to ETD reagent ion sources.
[0117] A first possible reagent ion source 299a may be located
between the stacked ring ion guide 204 and the curved beam guide
206. The reagent ion source 299a comprises a glow discharge cell
comprising a pair of electrodes (anode and cathode) that are
exposed to a reagent gas conduit 298a that delivers the reagent gas
from a reagent liquid (or solid) reservoir 297a having a heater
that volatilizes the reagent compound. When a high voltage is
applied across the electrodes, glow discharge is initiated which
ionizes the reagent flowing between the electrodes. Reagent anions
from the glow discharge source are introduced into the ion optics
path ahead of the quadrupole mass filter 208 within which they may
be m/z selected. The reagent ions may then be accumulated in the
multipole ion guide 214, and subsequently transferred into the high
pressure cell 217b of the dual-pressure linear ion trap 216 within
which they are made available for the PTR reaction. The reaction
products may be directly transferred to the low pressure cell 217a
or to the Orbitrap.TM. mass analyzer 212 for m/z analysis.
[0118] A possible alternative reagent ion source 299a may be
located adjacent to the low pressure linear trap cell 217b where it
may comprise an additional high-vacuum chamber 292 from which
reagent ions may be directed into the high pressure cell 217b
through an aperture in between chamber 292 and the high-pressure
cell. In operation, gaseous reagent compound is supplied from a
reagent liquid (or solid) reservoir 297b having a heater that
volatilizes the reagent compound and is directed through a reagent
gas conduit 298b that delivers the reagent gas into a partially
confined ion generation volume 296. In operation, thermionic
electrons supplied from an electrically heated filament 294 are
directed into the ion generation volume 296 with a certain
pre-determined energy by application of an electrical potential
between the filament 294 and an accelerator electrode (not shown).
The supplied energetic electrons cause ionization of the reagent
gas so as to generate reagent ions. The reagent ions may then be
guided into the high pressure cell 217b by ion optical transfer
component 203a under the operation of gate electrodes (not
shown).
[0119] Exemplary methods in accordance with the present teachings
are schematically illustrated in the flow diagrams shown in FIGS.
3A-3F. FIG. 3A schematically illustrates a first such exemplary
method, method 300, for monitoring for the presence of and,
optionally, quantifying, certain specific targeted analyte proteins
or peptides in a biological sample. For example, the sample may be
a sample of microorganisms. The initial steps 302, 304 and 306 of
the method 300 are the steps of cell lysis (if the sample is a
sample of microorganisms or other cells) and extraction,
solid-phase clean-up, or size-exclusion chromatography and
chromatographic separation, respectively, as described above. Step
302 may only be applicable if the sample comprises a tissue sample,
a bacterial cell sample, a cell sample of another microorganism, or
another form of cell sample. In some experimental situations, the
extracted sample may be directly infused into a mass spectrometer
in the subsequent sample introduction step 308; thus, the steps 304
and 306 are shown by dashed lines as being optional. Samples may
also be prepared using offline approaches including dialysis, or
other techniques known in the state of the art. However, in many
other experimental situations, the steps 304 and 306 are useful so
as to at least partially purify the sample prior to mass-spectral
analysis.
[0120] When an analysis must be completed according to time
constraints, as in some clinical applications, the required time
for the analysis may be shortened by employing either a SPE step
304, a time-compressed chromatography step as described in U.S.
Pat. No. 5,175,430 to inventor Enke, or the method of "Fast Partial
Chromatographic Separation" (FPCS) in the chromatography step 306
as described in international (PCT) patent application publication
WO 2013/166169 A1. Generally, in performing FPCS, a crude extract
of microbial cells containing a complex mixture of various organic
and inorganic analytes (small organic molecules, proteins and their
naturally occurring fragments, lipids, nucleic acids,
polysaccharides, lipoproteins, etc.) is loaded on a chromatographic
column and subjected to chromatography. However, instead of
allowing a gradient to elute each analyte separately (ideally, one
analyte per chromatographic peak), the gradient is intentionally
accelerated to the extent that substantially no chromatographic
peaks obtained for example approximately eight minutes or less, and
preferably five minutes or less instead of a much longer run time
that would be required to obtain a baseline separation. In the FPCS
separation, many analytes are intentionally co-eluted from the
column at any given time according to their properties and the type
of chromatography (reverse phase, HILIC, etc.) used. Partial or
incomplete separation may be also accomplished by other methods
known to one skilled in the art, including but not limited to the
use of mobile phase solvents and/or modifiers that reduce retention
of compounds on the column, selection of stationary phase media
that reduce retention of compounds on the column (including
particle size, pore size, etc.), operation of the chromatographic
system at higher flow rate, operation of the chromatographic system
at an elevated temperature, or selection of a different
chromatographic separation mode (i.e., reversed-phase, size
exclusion, etc.). The FPCS technique yields few or, possibly, no
resolved chromatographic peaks across the whole gradient. Thus,
substantially the only relevant information derived from a
chromatogram is the time of elution from the column. Each mass
spectrum that is recorded represents a "subset" of co-eluting
analytes that is then ionized, separated in the mass analyzer and
detected.
[0121] In step 308 (FIG. 3A), the sample is introduced into a mass
spectrometer. The sample may be provided as the eluate material
that emerges from an SPE cartridge, a chromatography apparatus or,
alternatively, by direct infusion of the eluate solution. Upon
being provided to the mass spectrometer, the sample compounds are
ionized (step 308) by an electrospray ionization source of the mass
spectrometer. These electrospray-generated ions are herein referred
to as "first-generation" ions. At this juncture, a full or
segmented MS.sup.1 scan may optionally be performed (step 309) in
order to identify the protein-rich regions in m/z space. (Note that
in this document, the term "scan" may be taken to generally refer
to a mass spectrum when used as a noun or, alternatively, to the
acquisition of a mass spectrum, when used as a verb). In a
preferred embodiment, the MS.sup.1 scan can be obtained over the
full mass range of the mass spectrometer instrument in order to be
able to subsequently choose, in data-dependent or independent
fashion, an information-rich portion of the spectrum for isolation
(step 310). However, in the case of a targeted analysis, the
MS.sup.1 scan may be unnecessary and execution of the method 300
may proceed directly to step 310, in which a subset of the ions is
then isolated for further reaction and analysis. When targeted
analysis is employed, the isolation performed in step 310 may be
such that ions within a certain pre-determined m/z range or
possibly multiple pre-determined m/z ranges are retained for the
subsequent reaction and analysis whereas ions outside the
pre-determined m/z range or ranges are discarded. The
pre-determined m/z range or ranges are chosen so as to correspond
to preferably known m/z ratios of targeted analyte proteins or
peptides whose presence or quantity is detected or monitored in the
execution of the method.
[0122] Generally, the isolation of step 310 may be performed, in
known fashion, by introducing the ions from the ion source into an
ion trap--such as a three-dimensional ion trap, a curved ion trap
(sometimes referred to as a "C-Trap") a single segment linear ion
trap, multiple segmented linear ion trap, multipole ion guide or
quadrupole mass filter--and then resonantly ejecting the ions whose
m/z ratios are outside of the desired range by applying a
supplemental AC voltage across pairs of electrodes of the ion trap
or applying the appropriate RF/DC voltage ratios to isolate the ion
population of interest. In some embodiments, the frequency of the
supplemental voltage may be swept through various frequencies such
that the ions are ejected in sequence according to their m/z
ratios. In such cases, the ions may be detected as they are ejected
so as to generate a mass spectrum of the original set of ions.
However, since a mass spectrum may not be required at this stage,
the supplemental AC voltage may be alternatively applied as a
combination of superimposed frequencies that are chosen so as to
cause essentially simultaneous ejection of the ions whose whose m/z
ratios are outside of the desired range. In some embodiments, the
combination of superimposed frequencies may be provided with
multiple segments of missing frequencies (i.e., "notches") such
that ions comprising two or more non-contiguous m/z ratio ranges
are simultaneously isolated within the trap. Each one of the
non-contiguous m/z ratio ranges may correspond to a preferably
known m/z ratio of a respective unique targeted analyte protein or
peptide. The applied RF/DC voltage ratios of a quadrupole mass
filter may also be used to isolate the defined or targeted mass
ranges of interest. Particular m/z ranges of the first-generation
ions are selected by a single or series of fixed RF/DC voltage
ratios in order to select the appropriate mass isolation windows.
The instrumental configuration employed in this case may be a
hybrid mass spectrometer instrument comprising a quadrupole, a
C-trap, an Orbitrap.TM. mass analyzer, and a high energy collision
cell (HCD) where the isolated ion population can be stored in
either the C-trap or HCD cell for PTR experiments. The isolated
population or populations of the first-generation ions are herein
referred to as "precursor" ions, because these ions will be
subjected to subsequent ion-ion reactions or to fragmentation.
[0123] In a preferred embodiment, the isolation of the precursor
ion population may be performed in a first segment of a segmented
linear ion trap. After isolation of the desired ion population, the
multiply-charged protein ion population may be advantageously moved
to another segment of the linear ion trap. These steps can be
repeated multiple times for isolated defined ranges of precursor
ions prior to the PTR process.
[0124] Next, anions are generated using either a rhenium-based
filament with chemical ionization or glow discharge ionization
source from a suitable high electron affinity based gaseous
reagent. Ionization can be performed using nitrogen, methane,
isobutane, or other known gases in the state of the art. The anion
reagent may be a gas at room temperature or may be a liquid with
sufficient vapor pressure to produce an excess of anions which will
drive the PTR process under pseudo-first order reaction conditions.
The anions are then transferred from the source region to the
segmented linear trap whereby the specific anion reagent is mass
isolated using supplemental AC voltages as described above. The
anion source can be in-line with the electrospray source or mounted
on the opposite end of the segmented linear ion trap.
Alternatively, a quadrupole mass filter can perform the anion
isolation as well with the subsequent PTR process occurring in the
C-trap or HCD cell of the instrument.
[0125] In step 312 of the method 300 (FIG. 3A), the ions which were
mass-isolated in step 310 (i.e., "precursor" ions) are subjected to
a proton transfer reaction in which a reagent anion species is
reacted for a specified time period with the sample precursor ions
in the ion trap so as to extract protons from the precursor
cations. In one embodiment, the multiply-charged precursor ion
population and the singly-charged anion population are reacted by
adjusting the DC voltage offsets of the segmented linear ion trap
so as to store both the multiply-charged positive ions with the
singly charged anions to facilitate the PTR process. The reagent
anions are chosen such that, in this instance, the reagent anions
behave as a Bronsted-Lowry base and such that the precursor ions
behave as one or more Bronsted-Lowry acids. The reagent anions are
formed by separate ionization of a suitable reagent gas/liquid with
sufficient vapor pressure, that includes but is not limited to
sulfur hexafluoride, perfluoro-1,3-dimethyl cyclohexane,
perfluorodecalin, and perfluoroperhydrophenanthrene. After allowing
the reaction to proceed for a specified time, a supplementary AC
voltage is applied across electrodes of the ion trap so as to eject
the reagent anions, thereby leaving product ions and, possibly,
some residual precursor ions within the ion trap.
[0126] In the opposite polarity experiment, multiply-charged anions
derived from proteins or other biomolecules can also be reacted
with singly-charged cations. A variety of sources can be employed
to generate singly-charged cations including electron, chemical,
and electrospray ionization processes. These reactions follow the
same reaction kinetics described previously. Typical reagent
cations have included pyridine, benzo(f)quinolone, and the noble
gases argon and xenon. In addition, multiply-charged proteins of
opposite polarity have also been reacted as well as the
multiply-charged anions from nucleic acids with the
multiply-charged cations of proteins.
[0127] In step 314 of the method 300 (FIG. 3A), a mass spectrum is
obtained of the product ions from the PTR process retained in the
ion trap over a full range of m/z ratios of interest. The mass
spectrum may be obtained, in known fashion, by detecting ions that
are sequentially ejected from the 3D or linear ion trap in order of
their m/z ratios. Alternatively, the ions may be directed to a
different mass analyzer of the mass spectrometer, such as a
Time-of-Flight (TOF) mass analyzer or an Orbitrap.TM.-type of
electrostatic trap mass analyzer, to be analyzed with greater
accuracy or mass resolution then may be available by sequential
scanning of the ion trap. Further, by directing the product ions to
a separate analyzer, the ion trap may be re-filled with a new
sample of precursor ions while the mass analysis is being
performed. If the accurate mass analyzer is of a type--such as an
FT-ICR mass analyzer or an Orbitrap.TM. mass analyzer--that detects
image currents produced by cyclic ion motion within an ion trap,
then the PTR reaction steps may advantageously reduce collision
cross sections of targeted protein or polypeptide molecules such
that these molecules remain stable in the trap for a sufficient
length of time to generate high-quality mass spectra. Also, the PTR
product ions will have less kinetic energy when leaving the high
pressure C-trap region upon their transfer to the Orbitrap.TM. mass
analyzer. Due to the PTR process, the resulting product ion
population will be fully desolvated which will improve the quality
of the resulting mass spectrum.
[0128] In step 316 of the method 300, the mass spectrum generated
by the mass analysis performed in step 314 is automatically
examined so as to recognize one or more individual series of
related m/z ratios, wherein each m/z ratio of a series represents a
respective different charge state--that is, a different degree of
protonation--of a single intact protein or polypeptide molecule.
For example, see FIG. 7C which depicts two different series of
lines, represented by the envelope 905 and the envelope 906,
respectively. After ionization as well as subsequent to the PTR
reaction, each protein or polypeptide molecule, M, of mass m.sub.p,
is represented as at least one (and likely several different)
protein or polypeptide cation species. Each such cation species of
a related series formed from the particular molecule, M, may be
represented by the chemical formula (M+zH).sup.z+, where the
integer, z, is the number of protons adducted to the original
molecule or is the number of protons remaining on the protein after
the PTR step. In this example, considering only monoisotopic ions,
the mass-to-charge ratio, (m/z).sub.ion, is thus given by:
(m/z).sub.ion.apprxeq.(m.sub.p+z.times.1.007)/z.apprxeq.(m.sub.p+z)/z.ap-
prxeq.m.sub.p/z (Eq. 1)
where the final approximation results from the fact that
m.sub.p>>z. Accordingly, such series of ion species
representing only different states of protonation may be readily
recognized by using automated software in real time to determine
the monoisotopic ions. Once such series have been recognized, the
molecular mass, m.sub.p, of the parent protein or polypeptide
molecule may be discerned in real time. Similar approaches can be
applied to larger molecular weight molecules using average or
monoisotopic mass as well. The automatic examination of the mass
spectral data and recognition of one or more individual series of
related m/z ratios may be performed by any one of many known mass
spectral data analysis programs or software packages designed
specifically for this purpose. However, for use in clinical
applications or other time-critical applications, this automatic
examination is preferably performed by an optimized computational
method such as the computational methods that are described in
detail in the appendix to this document.
[0129] The m/z values generated by the PTR process or,
alternatively, the molecular weights obtained from the PTR product
ions can then be searched against a database containing tabulated
values of m/z values or molecular weights of proteins or
polypeptides (step 402 of FIG. 3A) so as to recognize the presence
of such analytes in the sample. If the sample is derived from a
microorganism, then the database may relate to individual pathogen
standards that contain the observed m/z values or molecular weights
from known reference standards/patient samples. In such cases, by
matching these m/z values or molecular weights from a database
containing individual referenced pathogens, a small subset of
possible pathogen identifications is obtained. The subset can be
limited by determining a particular mass accuracy, weighting the
intensities of the individual peak, and/or by weighting the
molecular weight values by mass in a given scoring system.
[0130] In certain cases of microorganism studies, the m/z or
molecular weight matches may provide a direct match to a particular
pathogen identification which may be determined automatically (e.g,
step 404 of FIG. 3A.). However, in all probability, the m/z
molecular weight information will reduce substantially the number
of possible pathogen identifications that can be unequivocally
identified using tandem mass spectrometry. This process was
originally described for use in conjunction with the steps 302,
304, 306, and 308-310 in international (PCT) patent application
publication WO 2013/166169 A1. Additionally, Bayesian, logistic
regression, or decision tree based methods can be employed to
further refine the identification of the pathogen. In a preferred
embodiment, this m/z or molecular weight search is performed in
real time during data acquisition (i.e., as the sample is being
analyzed). Alternatively, the search may be performed
post-acquisition (i.e., after the sample has been analyzed) as
well. The comparison of a small number of m/z values or molecular
weights (3-10) of proteins to a reference database will generally
be sufficient to significantly reduce the candidate number of
pathogen identifications to five or less.
[0131] Optionally, execution of the method 300 may return back to
any of steps 302, 308 or 310 after execution of step 402 as
indicated by dashed arrows in FIG. 3A. This same option is also
applicable to method 370 illustrated in FIG. 3B, the method 380
illustrated in FIG. 3C, the method 390 illustrated in FIGS. 3D-3E
and the method 395 illustrated in FIG. 3F. Returning to step 302
corresponds to repeating the entirety of the method 300 in the
analysis of a different sample. Returning to step 308 corresponds
to introducing a different portion of a same sample into the mass
spectrometer system and repeating the mass spectral analysis on the
different portion. In some cases, the different portion of the same
sample may comprise a different chemical fraction of the same
sample (that is, it may comprise a different composition from the
prior analyzed portion), if the sample is being chemically
fractionated, e.g., by chromatography (step 306) or by some other
chemical fractionation technique. In some cases, the different
portion of the sample may comprise the same composition as the
prior analyzed portion (or may be considered to comprise
essentially the same composition) as the prior analyzed portion if
there is no chemical fractionation step or if the rate of change of
chemical composition caused by the fractionation is much slower
than the rate at which the mass spectrometer system can repeat
steps 312-402.
[0132] Returning to step 310 from step 402 corresponds to mass
isolating a second, different predetermined m/z range or ranges of
ion species in step 310 (as compared to the m/z range or ranges of
ion species isolated in the prior execution of step 310) and then
repeating steps 312-402 using the newly isolated ion species and
their reaction products. This procedure of repeating steps 310-402
is particularly useful if it may be assumed that the sample
composition has not changed between successive iterations of these
steps. Under these circumstances, the repetition of steps 310-402
may provide additional information from the same sample
composition. The sample may often be assumed to remain constant or
negligibly different if there is no chemical fractionation prior to
sample introduction into the mass spectrometer or if the rate of
change of chemical composition caused by the fractionation is much
slower than the rate at which the mass spectrometer system can
repeat the steps 312-402.
[0133] FIG. 3B schematically illustrates a flow diagram of a second
exemplary method, method 370, in accordance with the present
teachings. The steps 302-314 of the method 370 (FIG. 3B) are
identical to the similarly numbered steps of the method 300 (FIG.
3A) and thus the description of these steps is not repeated here.
The method 370 differs from the method 300 only with regard to the
steps following the generation of a mass spectrum in step 314.
According to the earlier-described method 300, the mass spectrum of
PTR product ions is assumed to be sufficient to detect or quantify
proteins and polypeptides of interest. However, in many cases, it
may be necessary to perform tandem mass spectrometry (sometimes
referred to as MS/MS or MS.sup.n) after the generation of PTR
reaction products in order to resolve remaining ambiguities in the
recognition of specific protein or polypeptide molecules. In other
cases, it may be necessary to perform a second stage of PTR as
discussed further below. In cases in which fragmentation is
required, the PTR reaction products may be considered to comprise a
first generation of reaction products which are then fragmented to
form a second generation of product ions. The combination of a
specific m/z ratio of a first-generation reaction product with one
or more specific m/z ratios of fragment ions may, in many cases,
allow identification of a specific protein or polypeptide molecule
associated with a given pathogen. In many instances the protein
identified with a specific pathogen may also be found in other
similar pathogens. In order to correctly identify a single
pathogen, method 370 (specifically tandem mass spectrometry) may
need to be performed on as many proteins that are present in a
given PTR fraction, or multiple PTR fractions of the same
sample.
[0134] In step 316 of the method 370, a computational method is
performed so as to automatically analyze the mass spectral data of
PTR reaction products obtained in step 314. The computational
method attempts to identify charge-state sequences of proteins or
polypeptides. The results of the real-time automatic computational
analysis obtained in step 316 of the method 370 may be later used
as a basis for making an m/z selection in the subsequent step 318,
in which a subset of the PTR product ions, comprising a restricted
range of m/z ratios, are selected and isolated so as to be later
fragmented in step 320. Preferably, the automatic identification of
charge-state sequences (step 316) is carried out by a fast
computational method, such as the computational methods that are
described in detail in the appendix to this document, that is
optimized for such real-time data analysis.
[0135] Accordingly, steps 318-322 of method 370 (FIG. 3B) represent
the application of the techniques of tandem mass spectrometry or
selected reaction monitoring (SRM) as applied to the ions formed by
PTR. If the particular employed mass spectrometry system permits, a
portion of the PTR product ions may have already been stored
(immediately after step 312) in an ion storage apparatus of the
mass spectrometer system. In such cases, the branching step 315
causes execution of step 317a, in which the previously stored ions
are retrieved for further processing. Otherwise, if the prior batch
of PTR product ions was exhausted by the mass analysis step (step
314), then, in accordance with the alternative step 317b, the steps
308-312 may need to be re-executed in order to generate a new batch
of such PTR product ions.
[0136] In step 318 of the method 370, certain of the PTR
reaction-product ions (i.e., the first-generation product ions)
within a particular m/z range or particular m/z ranges are mass
isolated by ejecting ions whose m/z ratios are not within the range
or ranges of interest. The isolated ions are subsequently
fragmented in step 320. The particular chosen range or ranges will
generally be responsive to the details of a particular identified
charge-state sequence identified an immediately prior execution of
step 316 and the choice will generally be made automatically by
computer. Thus, the choice of a particular m/z range or ranges for
isolation and fragmentation is an example of so-called
"data-dependent analysis" (or "data-dependent acquisition",
etc.).
[0137] In most conventional MS/MS analyses, involving low-mass
molecules of a few hundred to a few thousand Daltons,
data-dependent fragmentation comprises choosing the "top P number
of the most abundant precursors" for tandem mass analysis based on
the information of a preceding MS.sup.1 data acquisition, where the
number P is either a constant or perhaps a variable input by a
user. It has been found that this conventional form of
data-dependent analysis does not perform well when used in the
analysis of multicomponent samples of biopolymer analytes. For
example, FIG. 7C illustrates two charge state distributions,
denoted by the envelope 905 and the envelope 906, respectively. In
this example, each envelope corresponds to a different respective
analyte molecule species. Thus, the sets of lines encompassed by
envelopes 905 and 906 may be referred to as
"molecular-species-correlative charge-state distributions".
Considering the lines (individual m/z values) in FIG. 7C to
represent precursor ions, then if P=10, the conventional
data-dependent fragmentation technique would choose the ten
leftmost solid vertical lines under the envelope 906 for
fragmentation. Using the conventional technique, none of the dotted
lines corresponding to envelope 905 would be chosen. The
conventional procedure would thus yield redundant information
relating to the molecule species corresponding to envelope 906 and
no information relating to the molecule species corresponding to
envelope 905.
[0138] To overcome the shortcomings of conventional data-dependent
fragmentation when applied to high-molecular-weight molecules, the
inventors have developed the herein-used novel "top P unique
analyte-specific clusters" data-dependent technique so as to
replace, for application to high-molecular-weight molecules, the
previous "top P number of the most abundant precursors" logic. Each
molecular-species-correlative charge-state distribution is a set of
related mass spectral lines (m/z values) which are interpreted,
according to the novel "top P unique analyte-specific clusters"
logic, to all be generated from a single unique molecule. Each
molecular-species-correlative charge-state distribution groups
together various charge states and isotopic clusters that are
indicated to have been generated from a single molecule, prior to
ionization. However, the molecular-species-correlative distribution
excludes adducts, which are removed prior to data analysis.
According to the novel method, fragmentation is performed only on
one (or possibly more) selected representatives of a given
molecular-species-correlative charge state distribution envelope
thereby avoiding the redundancy noted above associated with the
conventional data-dependent fragmentation method. According to the
novel "top P unique analyte-specific clusters" logic, after a
representative m/z ratio (or ratios) has been chosen for a first
molecular-species-correlative charge-state distribution, any
further fragmentation is directed to a representative m/z ratio of
the next determined molecular-species-correlative charge-state
distribution, and so on.
[0139] As previously described, the isolation performed in step 318
of the method 370 may be accomplished by applying a supplemental AC
voltage across pairs of electrodes of an ion trap such that ions
having m/z ratios that are not within the range or ranges of
interest are ejected from the trap while those ions having m/z
ratios that are within the range or ranges are retained within the
trap. In some instances, the ion trap used for mass isolation may
be identical to the mass analyzer used to conduct the full-scan
mass analysis in step 314.
[0140] The supplemental AC voltage applied to the ion trap used for
mass isolation may comprise a summation of superimposed frequencies
such that ions within two or more non-contiguous m/z ranges are
simultaneously isolated. In the subsequent step 320, the
mass-isolated first-generation product ions are fragmented by a
suitable ion fragmentation technique, such as collision induced
dissociation (CID). The fragmentation may be accomplished by
transferring the first-generation product ions (product ions formed
by PTR of original precursor ions), in known fashion, to a
dedicated fragmentation cell within which the transferred ions are
fragmented so as to generate fragment ions, these fragment ions
comprising a second generation of reaction products. Optionally, a
portion of the fragment product ions may be stored for possible
future additional fragmentation in optional step 321.
[0141] In step 322 of the method 370 (FIG. 3B), the fragments
generated in step 320 are mass analyzed by a mass analyzer of the
mass spectrometer. If the second-generation product ions are
produced within a fragmentation cell that is specifically dedicated
for the purpose of fragmentation, the ions must be first
transferred to the mass analyzer prior to the execution of step
322. An ion trap mass analyzer may be employed to analyze the
second-generation product ions in step 322, in which case the mass
analyzer employed for step 322 may be identical to the mass
analyzer employed to conduct the full-scan mass analysis of step
314. Alternatively, an accurate-mass analyzer capable of measuring
mass-to-charge ratios to an accuracy of 10 ppm or better--such as
an FT-ICR mass analyzer, a time-of-flight (TOF) mass analyzer or an
Orbitrap.TM.-type of electrostatic trap mass analyzer--may be
employed for step 322.
[0142] As is known, the correlation between the m/z value of a
certain selected ion species subjected to fragmentation and the m/z
value (or values) of one or more fragment ion species produced by
the fragmentation may be sufficient to automatically determine (in
step 402b) the chemical identity of the selected ion species. In
this case, the selected ion species is a PTR reaction-product
species generated in step 312 that is mass-isolated in step 318.
The identification of a small number (i.e., 3-10) of such proteins
will generally be sufficient to uniquely identify a microorganism
species (optional step 404b). However, a single stage of
fragmentation may be insufficient for performing a chemical species
identification. In such instances, the second generation product
ions may be further fragmented so as to form a next generation of
product ions, indicated by the optional repeat (indicated with
dashed lines) from step 322 back to step 318 in which a selected
subset of the fragment product ions are isolated, according to
their m/z values, and the so-isolated fragment ions are further
fragmented. More generally, a subset of the n.sup.th generation of
product ions may be selected for further fragmentation by any
suitable ion fragmentation method such as, but not limited to,
collision-induced fragmentation, higher-energy collisional
dissociation, electron transfer dissociation, electron capture
dissociation, negative electron transfer dissociation,
electron-detachment dissociation, surface-induced dissociation, or
photodissociation, whereby an (n+1).sup.th generation of product
ions is formed. The results of the mass analysis step 322 may form
the basis of an automated decision as to whether or not each
additional fragmentation is required and, if so, which m/z values
correspond to the ion species to be fragmented.
[0143] In the above discussion, the optional repeat from step 322
back to step 318 of the method 370 was described as for the purpose
of further fragmenting previously-generated fragment ions. However,
in some embodiments, the second or subsequent execution of step 318
may be for the purpose of choosing a second, different ion species
of the PTR reaction products (generated and possibly stored in step
312) for fragmentation, based on the automatic identification of
charge state sequences previously performed in step 316. The
possible need for a second PTR step may be understood with
reference now to FIG. 12C. As an example, a first execution of the
mass isolation step (step 318 of method 370) may isolate an ion
species corresponding to a mass spectral line belonging to charge
state envelope A208, whereas a second execution of step 318 may
isolate an ion species corresponding to one of the mass spectral
lines belonging to charge state envelope A206. As described in the
appendix to this document, each such set of mass spectral lines
(the set belonging to envelope A208 or the set belonging to
envelope A206). The novel "Top P Unique Analyte-Specific Clusters"
workflow described in the appendix is specifically adapted to
recognize such clusters corresponding to different respective
potential analyte molecules. According to such a workflow
procedure, the second execution of the isolation step (step 318)
and the fragmentation step (step 320) of the method 370 are
performed so as to exclude isolation and fragmentation of the ion
species corresponding to the envelope A208 (assuming one such ion
species was isolated and fragmented during an earlier execution of
these steps), even though they may be of greater intensity than the
ion species corresponding to envelope A206. In this way, fragment
information about different potential analytes is obtained during
each iteration of the optional loop comprising steps 318-322.
[0144] The method 300 diagramed in FIG. 3A, which was discussed
above, provides a relatively simple and straightforward method of
sample analysis that may be applicable for samples of relatively
low complexity as, for example, when highly-resolved
chromatographic separation (step 306) has been performed prior to
introduction of a chromatographic fraction into a mass spectrometer
(step 308). However, the simple method 300 may not be appropriate
for more complex samples and the analysis of such samples may
present a number of challenges. Firstly, the proteins present in a
complex mixture have a wide range of molecular weights. Secondly,
the large number of charge states that result from the presence of
a large number of lysine, arginine, histidine residues may result
in multiple overlapping sets of peaks, each set of peak
corresponding to a different chemical species. Thirdly, if the mass
analysis (step 314) is of sufficiently high resolution, the
presence of resolved peaks of an isotopic distribution for any
given charge state can confound most data processing algorithms.
Finally, the distribution of available ions among multiple charge
states and, possibly, among multiple isotopic states necessarily
reduces the signal intensity of any resolved peak in the mass
analysis.
[0145] In order to address the above-noted challenges in the
analysis of complex samples, the method 380, for which a schematic
flow diagram is illustrated in FIG. 3C, provides the opportunity
for conducting multiple PTR stages. Under the earlier-described
method 300, it is assumed that the mass spectrum obtained (in step
314) of the first-generation PTR reaction products (generated in
step 312) exhibits sufficient improvement in signal-to-noise ratio
and sufficient reduction in isobaric interferences such that
charge-state sequences may be recognized and that proteins or
polypeptides may be identified. If such improvement in mass
spectral quality remains inadequate for such purposes after a first
PTR reaction event, then the additional refinement steps 327-330 of
the method 380 (FIG. 3C) may be performed. Further, one or more of
the PTR stages may utilize the known technique of "ion parking" in
order to simplify the charge state distribution, as noted in the
previous paragraph. Ion parking is a technique whereby specific
selected ion/ion reactions within an ion trap are inhibited. In
practice, a resonance excitation waveform is applied across
electrode pairs of an ion trap, ion guide or other ion storage
device in an amplitude that is insufficient to cause ion ejection
but sufficient to increase the velocities of ions having selected
m/z values. This excitation process increases the relative velocity
between the excited ions (cations, for purposes of the present
discussion) and reagent anions and it is believed that this
relative velocity increase causes a reduction in the rates of
reaction between the excited cations and reagent anions.
[0146] During the PTR process, the rate of reaction between cations
and reagent anions varies as the square of the charge number of the
various cations with the anion charge on the reagent ions equal to
-1. Thus, in the absence of ion parking, the PTR process leads to a
rapid reduction in the number of highly charged cations. Over the
course of the reaction, the distribution of charge states of
cations derived from a single molecular species, M (a protein or
polypeptide molecule having mass m.sub.p), shifts towards lower
charge states. The population of each ion species having an
intermediate charge state will first increase as the
more-highly-charged precursor ions lose protons and then decrease
as each respective species loses more protons then it gains from
the diminishing quantity of more-highly-charged cations. The
ultimate result, if the PTR reaction is allowed to proceed to
completion, is complete neutralization of all such cations and
total loss of all mass spectrometric signal.
[0147] When the ion parking technique is applied during the PTR
reaction, then the charge reduction process is essentially stopped
at the charge state, z.sub.1, corresponding to the particular
mass-to-charge ratio (for example, m.sub.p/z.sub.1) of the ions
which are resonantly excited by the applied AC waveform. Those
precursor cations derived from the molecular species, M, with
initial charge states, z, such that z>z.sub.1 will lose protons
until their charge states are reduced to z.sub.1, after which
further reaction and proton loss will be inhibitied. Those
precursor cations derived from the molecular species, M, with
initial charge states, z, such that z<z.sub.1 will be completely
neutralized. Accordingly, after PTR reaction with ion parking, a
significant portion of the original protonated molecular ions
(i.e., precursor ions) of molecule M will be represented, in a mass
spectrum, by the single ionic species having charge state, z.sub.1.
This "concentration" of the molecule species, M, into a single
charge state can advantageously amplify the mass-spectrometric
signal associated with that species, thereby improving
signal-to-noise ratio and reducing the lower limit of detection
and, optionally, the lower limit of quantification of the species.
Further, many isotopic variants of ions generated from molecule
species, M, will have ink values outside of the range of values
corresponding to the applied AC resonant excitation waveform. Such
isotopic variants will be neutralized so as to not interfere with
the mass spectrometric identification of ions of interest. Other
isotopic variants comprise ink values that are within the range of
values corresponding to the applied AC resonant excitation
waveform. The isotopic distribution pattern of such isotopically
variant ions will be greatly simplified relative to the isotopic
distribution observed in the original precursor ions because they
will mostly relate to the single charge state, z.sub.1 of ions
generated from molecule, M.
[0148] Returning to the discussion of the method 380 outlined in
FIG. 3C, it is to be noted that the steps 302-310 of the method 380
are identical to the similarly numbered steps of the method 300
(FIG. 3A) and are not re-described here. Subsequently, in step 328,
precursor ions are subjected to PTR, optionally as modified by the
ion parking technique. As previously noted, step 328 is executed by
applying a supplemental AC excitation waveform across a pair of
electrodes of an ion trap within which sample-derived cations are
reacted with reagent anions for a predetermined time period. As
described above, the employment of this "ion parking" procedure
will concentrate the distribution of ions derived from any
particular protein or polypeptide into a particular restricted
range of m/z values. This will generally restrict the ions derived
from any particular protein or polypeptide into a particular charge
state, thereby simplifying a resulting mass spectrum and increasing
the intensity of any mass spectral peaks corresponding to the
particular protein or polypeptide. The particular range of m/z
values into which the ions are restricted may comprise ions of
different respective charge states derived from different
respective molecular species. In some embodiments, the applied AC
waveform used to effect the ion parking may comprise a summation of
waveforms of different respective frequencies such that the summed
waveform causes the PTR reaction to yield a final population of PTR
product ions corresponding to two or more non-contiguous m/z
ranges.
[0149] In the subsequent step 330, the population of PTR product
ions produced in step 328 is mass analyzed by a mass analyzer and,
in step 331, an automatic computation may be performed on the data
produced in the mass analysis so as to automatically identify any
charge-state sequences that may be represented in the data, where
each such charge state sequence corresponds to a different
potential protein or polypeptide analyte. Prior to the mass
analysis of step 330, a portion of the PTR product ions may be
stored (step 329) in preparation for possible subsequent PTR
reaction. Depending upon the results of the automatic
identification of charge state sequences (step 331), an automatic
decision may be made to subject the PTR product ions to such
further PTR reaction, as indicated by the dashed line optional
pathways shown in FIG. 3C. The decision may also be made, based on
the results of the automatic identification of charge state
sequences, to only subject a selected subset of the PTR product
ions to subsequent PTR reaction. In such cases, step 327 is
executed. Thus, according to some embodiments, the steps 327-331
may comprise an iterated loop wherein, at each iteration of the
loop, a different respective ion species, corresponding to a
different respective protein or polypeptide is selected and
isolated for further purification by the PTR process. The ion
species that are selected in this fashion may be determined in step
331 from in accordance with the novel "Top P Unique
Analyte-Specific Clusters" workflow described in the appendix to
this document.
[0150] If the mass analyzer employed in step 330 is of a type that
detects image currents produced by cyclic ion motion within an ion
trap or other ion storage device--such as an FT-ICR mass analyzer
or an Orbitrap.TM. mass analyzer--then the PTR reaction steps may
advantageously reduce collision profiles of targeted protein or
polypeptide molecules such that these molecules remain stable in
the trap for a sufficient length of time to generate high-quality
mass spectra. After a sufficient number of PTR reaction steps, the
chemical identity of the protein or polypeptide may then be rapidly
discerned (in step 402c) by matching to databases of known
molecular masses. The identification of a small number of (3-10) of
proteins will generally be sufficient to uniquely identify a
microorganism species (optional step 404c). Identification can also
be accomplished via the use of classifiers applied to the PTR data
as discussed previously that includes but is not limited to
Bayesian, logistic regression or decision tree based
approaches.
[0151] FIGS. 3D-3E illustrate, in flow diagram form, another
method, method 390, in accordance with the present teachings. The
steps 302-331 of the method 390 are shown in FIG. 3D and are
identical to the previously-discussed similarly-numbered steps of
the method 380 (FIG. 3C); thus, these steps are not re-described
here. Instead of proceeding to the identification step 402d
directly from step 330 (as in the method 380 of FIG. 3C), execution
of the method 390 (FIGS. 3D-3E) proceeds from step 330 to a mass
selection and isolation step 332. In step 332, a subset of the PTR
product ions--generated by one or more applications of the PTR
procedure--are isolated according to selected m/z ratios. Decisions
regarding the specific m/z ratios to be isolated during this step
may be automatically performed based on the mass spectrometric
results obtained in step 330 or, with respect to an optional
subsequent mass isolation and fragmentation (see optional repeat
branch of FIG. 3E), based on the results of a mass analysis of the
fragment ions themselves (step 338). The steps 332-338 illustrated
in FIG. 3E represent an ion fragmentation procedure which may be
iterated (see optional repeat branch) so as to produce multiple
generations of fragmentation product ions. These steps 332-338 are
similar to the steps 318-322 of the method 370 illustrated in FIG.
3B and are thus not discussed in detail.
[0152] After execution of the fragmentation and mass analysis
steps, the peptide identification step 402d of the method 390 (FIG.
3E) is executed. Whereas the identification step 402a of the method
300 (FIG. 3A) makes use only of the m/z ratios (or molecular
weights) of ion species comprising protonated or
multiply-protonated analyte molecules, the identification step 402d
of the method 390 also takes into account the m/z ratios of the
fragments--possibly of multiple generations--of these ion species.
Thus, in the case of complex mixtures of proteins or polypeptides,
a greater confidence may be associated with the results of the
identifications made using the method 390. Control of the
experiments may be performed in real time according to some
embodiments by making use of real-time data deconvolution as noted
above. The identification of a small number of (3-10) of proteins
species in step 402d will generally be sufficient to uniquely
identify a microorganism species in step 404d.
[0153] FIG. 3F diagrammatically illustrates, in flow diagram form,
another method, method 395, in accordance with the present
teachings. Most of the steps in the method 395 (FIG. 3F) are
similar to similarly numbered steps in the method 370 (FIG. 3B) and
these steps are not re-described in detail. Similarly to the method
370, the method 395 includes a step (step 312) of subjecting
original precursor ions to PTR charge reduction followed by steps
(steps 318 and 320) of isolating selected PTR product ion species
and subjecting the isolated ion species to fragmentation so as to
form fragment product ion species. The method 395 differs from
method 370 through the provision of an additional step, step 340,
of subjecting the fragment ions to PTR charge reduction. Since the
various PTR product ion species generated from the original
precursor ions may be multiply-charged and may be distributed among
species with various degrees of protonation, the fragment ions
formed from them may themselves be distributed among multiple
protonation states. The PTR charge reduction of the fragment ion
species in step 340 can simplify the charge state distributions of
the fragment ions prior to their mass analysis in step 341.
Optionally, any of the PTR steps (step 312 and step 340) may employ
ion parking. An optional repeat from step 341 back to step 318 so
as to repeat the steps 318-341 may be performed for the purpose of
choosing a second, different ion species of the PTR reaction
products (generated and possibly stored in step 312) for
fragmentation, based on the automatic identification of charge
state sequences previously performed in step 316. As previously
discussed with respect to the method 370 (FIG. 3B), the second,
different ion species may belong to a set of lines of a second
charge state envelope that is different from the charge state
envelope to which a prior isolated and fragmented ion species
belongs (see also FIG. 12C). The novel "Top P Unique
Analyte-Specific Clusters" workflow described in the appendix is
specifically adapted to recognize such clusters corresponding to
different respective potential analyte molecules. In this way,
fragment information about different potential analytes is obtained
during each iteration of the optional loop comprising steps 318-341
of the method 395.
EXAMPLE A
[0154] FIGS. 4A and 4B provide an example of mass spectroscopic
signal enhancement provided by a single PTR reaction step (e.g., as
in the method 300 shown in FIG. 3A). In a first application (FIGS.
4A, 4B), an extract from the pathogen E. coli was analyzed via
direct infusion; the mass spectrum of the first-generation
electrospray-generated ions is shown in FIG. 4A. As expected, there
are many proteins present that overlap at various m/z values
leading to the presence of a broad spectral region between
approximately m/z=780 and m/z=1420 within which many ions are
detected but with very little usable information in terms of
discernible protein charge state distributions. Next, an m/z
"window" of the first-generation ions of width 2 Th and centered at
m/z=750 was isolated and the resulting isolated ion population was
subjected to PTR reaction. The m/z position 412a shown in FIG. 4A
indicates the center position of the isolation window.
[0155] FIG. 4B shows a mass spectrum of the PTR reaction products
of precursor ions of the E. coli extract. The PTR reactions were
carried out with reagent anions derived from 3 ppm of sulfur
hexafluoride (SF.sub.6) in a nitrogen gas stream delivered to a
glow discharge reagent ion source contained within the ion optics
of a mass spectrometer of the same general configuration as
illustrated in FIG. 2. As with most PTR product-ion spectra, the
mass spectrum shown in FIG. 4B exhibits a relatively intense
isolated peak at the position (indicated as position 412b) of the
original first-generation-ion isolation window. Such peaks at the
position of the isolation window generally indicate the presence of
residual singly-charged first-generation ions--generally not of
interest--that fortuitously occur at the position of the isolation.
Other peaks in the spectrum of FIG. 4B represent product ions
generated from the PTR reaction. These product ions generally
comprise overlapping sets of related ions, each set corresponding
to ions comprising a distribution of charge states from an original
multiply-charged precursor ion within the original isolation
window. One such potential charge-state distribution pattern is
approximately indicated by the envelope 413. The results shown in
FIGS. 4A and 4B show that the PTR reaction process generally
significantly simplifies the spectrum and reduces background
interference. Nonetheless, since many protein-derived or
peptide-derived precursor ions may be present in the original
isolation window, the charge-state distribution patterns may
overlap. Mathematical decomposition (sometimes referred to as
"deconvolution") may be required to recognize the individual
patterns.
EXAMPLE B
[0156] FIGS. 5A and 5B illustrate an example of analysis of an E.
Coli extract that is performed by a procedure that includes two
stages of PTR reaction (for example, see steps 327, 328, 329 and
330 of method 380 in FIG. 3C). FIG. 5A illustrates a PTR product
ion spectrum generated isolated first-generation precursor ions
from within a 5 Th mass window centered at m/z=1200, indicated by
position 711 in FIG. 5A. In this instance, the initial PTR spectrum
does not include peaks that are sufficiently well resolved to
enable identification of any proteins in the sample. Therefore, a
subset of the first-generation PTR product ions were isolated for a
second stage of PTR from within a 5 Th mass window centered at
m/z=1320, indicated by position 712a in FIG. 5A and position 712b
in FIG. 5B. The second-generation PTR product ions, which occur at
m/z ratios greater than 1320 in FIG. 5B show clear charge-state
distribution patterns that may be successfully used for
identification of proteins in the sample.
[0157] FIGS. 6A-6G illustrate an example of analysis of an E. coli
extract that is performed by a procedure that includes a first
stage of product ion formation by PTR reaction followed by
subsequent stages of CID of the PTR reaction product ions (for
example, see steps 312 through 322 method 370 in FIG. 3B). FIG. 6A
illustrates a PTR product ion spectrum generated isolated
first-generation precursor ions from within a 5 Th mass window
centered at m/z=640, indicated by position 811 in FIG. 6A. The PTR
product ions occur at m/z ratios greater than that indicated by
position 811 in FIG. 6A. The three most intense PTR product ions,
located at m/z ratios of 833 , 926 and 917 and indicated by mass
spectral peaks 813, 814 and 815, respectively, in FIG. 6A, were
then individually isolated and separately subjected to
collision-induced dissociation so as to produce three sets of
second-generation product ions. FIGS. 6B and 6C respectively depict
the isolated PTR product ion at m/z=833 and the second generation
product ions (fragment ions) generated by CID of the isolated PTR
product ion Likewise, FIGS. 6D and 6E respectively depict the
isolated PTR product ion at m/z=926 and the second generation
product ions generated by CID of the isolated PTR product ion at
m/z=926. Likewise, FIGS. 6F and 6G respectively depict the isolated
PTR product ion at m/z=917 and the second generation product ions
generated by CID of the isolated PTR product ion at m/z=917.
EXAMPLE C
[0158] As should be evident from the previous discussions, positive
ion electrospray ionization of any protein or polypeptide molecule
will produce a plurality of ions comprising different respective
charge states (i.e., number of charges) as a result of different
degrees of protonation of the original molecule. Charge states of
+50 or more or possible and each charge state will be represented
by multiple mass spectral lines representing different degrees of
natural isotopic substitution. A further complication arises from
the fact that for most natural biological samples, numerous
different proteins of polypeptide molecules may be represented in a
mass spectrum. A yet further complication arises from the fact that
many other molecules--not necessarily of interest--may be present
in a sample.
[0159] In many basic-research-oriented studies, the above-noted
complicating factors of multiple analytes and multiple interfering
species may be partially or wholly resolved by performing chromatic
separation prior to introducing each separated compound
individually into a mass spectrometer. However, clinical analyses
may often be performed under tight time constraints that do not
allow for traditional time-consuming chromatographic separation.
The clinical time constraints may only allow for an incomplete or
partial separation using either solid-phase extraction (SPE),
size-exclusion chromatography, or the method of Fast Partial
Chromatographic Separation (FPCS) described above. Thus, when such
partial separation procedures are employed, the mass spectral
signature of any particular protein or polypeptide may be spread
out over a wide mass-to-charge ratio and may be complexly
overlapped with the mass spectral signatures of other compounds.
Since the available charge, as provided by an electrospray
apparatus, will be spread out over many different types of ions,
most of the observed mass spectral lines will coexist with and
possibly be hidden within a general densely populated and
low-intensity or ill-defined spectral "background" indicated
schematically by spectral envelope 902 in FIGS. 7A-7B.
[0160] The inventors have realized that the mass spectral signature
of any particular protein, polypeptide or other biologically
relevant high-molecular-weight analyte may be hypothetically
amplified by simultaneously isolating multiple charge states of the
same original molecule and then reacting the assemblage of multiple
charge states with PTR reagent ions so as to simultaneously reduce
the assemblage to a small number of charge states distributed over
a few charge-state values, these charge-state values being reduced
relative to the original charge states. This concept is illustrated
by the vertical boxes 904a-904g shown overlaid over the general
charge-state envelope 902 in FIG. 7A. Each such vertical box
represents a particular precursor ion species and represents a
small range of m/z values chosen to correspond to a particular
charge state (and possibly including a few isotopic variants) of a
particular analyte. Hypothetically, if all ions outside of the
ranges corresponding to the vertical boxes could be excluded and
only the ions from within the indicated ranges mixed together, then
subsequent PTR would essentially provide a summation of the signals
from the various original plurality of charge states. The use of
such multi-species isolation of a plurality of precursor ion
species can increase the sensitivity of the analysis up to N-fold,
where N is the number of m/z ranges selected and simultaneously
isolated.
[0161] Such multiple-species isolation is fairly easy to achieve
when isolation is performed in a linear ion trap (such as the
low-pressure linear trap cell 217b illustrated in FIG. 2), because
resonance-excitation waveforms, which are used to eject unwanted
ions, may be constructed with multiple notches. Each such notch
corresponds to a different respective m/z window within which ions
will not be ejected (and thus isolated). Thus, the co-isolating of
a plurality of electrospray-generated (first-generation) precursor
ion species may be performed, in some embodiments, by
simultaneously isolating all of the plurality of precursor ion
species. One way of doing this is by applying a broadband resonance
ejection frequency waveform to an ion trap into which ions received
from an electrospray source have been introduced, wherein the
waveform comprises multiple summed sinusoidal frequency components,
wherein included frequency components corresponding to the m/z
ranges of ions that one desires to eject from the trap and excluded
frequency components correspond to the m/z range of ions that one
desires to retain within the trap. In this procedure, the omitted
frequencies define one or more frequency notches in the ejection
frequency waveform. The frequency components may be calculated by
first choosing a desired multi-notch waveform and then calculating
an inverse Fourier Transform of the desired waveform.
[0162] Alternatively, the co-isolating of the plurality of
precursor ion species may be performed by isolating individual
precursor ion species in a conventional sense, one ion species at a
time using a respective single-notch waveform applied to an ion
trap. The individually isolated precursor ion species may be
transferred, one at a time, to an ion storage component (such as
the multipole ion guide 214 illustrated in FIG. 2) in which the
various selected and isolated ion species are accumulated over
time. As a yet-further alternative, the co-isolating of the
plurality of precursor ion species may be performed by passing a
plurality of ions received from an electrospray source through a
quadrupole mass filter while the bandpass of the quadrupole mass
filter is sequentially tuned to preferentially transmit, in turn,
each m/z range corresponding to a particular precursor ion species.
The filtered ions that pass through the quadrupole mass filter are
then passed into an ion storage component that accumulates the ions
from all the preferentially transmitted m/z ranges. For example, in
the mass spectrometer 150a illustrated in FIG. 2, the quadrupole
mass filter 208 may perform the sequence of filtering steps and the
ions of each transmitted m/z range may be transmitted into and
accumulated within the multipole ion guide 214. The accumulated
precursor ion species may then be transferred back to the
low-pressure cell 217b for PTR reaction.
[0163] The above-described procedure employing simultaneous
multi-species isolation assumes that appropriate isolation ranges
904a-904g a priori known. Such knowledge about the correct
isolation ranges to employ may be available in certain instances of
targeted analysis, when the identity of (and other information
pertaining to) an analyte that is to be searched for is already
known and the purpose of the analysis is to determine the presence
or absence of the analyte or to determine the quantity or
concentration of the analyte. However, the above assumption may be
invalid in the case of survey analyses, in which the identities of
analytes may not be known in advance. In such latter cases, an
initial random survey may be performed by isolating a random mass
range 903 of the first-generation ions, as schematically depicted
in FIG. 7B, and then reacting the isolated ions with a PTR reagent
anion. As previously illustrated in FIGS. 4A and 4B, such a
procedure can provide resolved, interpretable mass spectral lines
relating to charge state distributions of one or more analytes. In
many instances, a set of related lines may be recognized with by
the mutual consistency of their m/z values with Eq. 1 for a certain
sequence of consecutive integers, z. The degree of consistency of
the line positions may be performed automatically, by computer
analysis, such that overlapping sets of such related lines may be
mathematically decomposed and recognized.
[0164] As an example of the above type of analysis, mathematical
decomposition of the PTR product ion lines generated by isolation
and reaction of precursor ions within m/z range 903 may lead to
recognition of two overlapping sets of lines, depicted by envelope
905 and envelope 906, as illustrated in FIG. 7C. With the
information provided by this initial survey procedure, an
appropriate and consistent set of m/z values may be chosen, which
may be employed in a subsequent simultaneous multi-species
isolation and reaction procedure. For example, the m/z values of
certain resolved instances of the lines under envelope 905 may be
chosen, perhaps automatically. Subsequent multi-species isolation
and PTR reaction of precursor ions corresponding to these chosen
m/z values will then provide an amplified spectrum that may be
employed to determine a quantity or concentration of the particular
molecule represented by the envelope 905. This procedure may later
be repeated using the associated with envelope 906 so as to
determine a quantity or concentration of another molecule. The
determined quantities or concentrations may not be accurate, in an
absolute sense, but the ratios of the determined quantities or
concentrations may provide useful information relating to relative
quantities or concentrations. This entire procedure outlined above
may be repeated multiple times using different randomly chosen m/z
ranges 903, thereby providing determinations of relative quantities
or concentrations of several compounds. As stated previously,
control of such experiments can be accomplished in a data-dependent
fashion utilizing the results of real-time spectral
deconvolution.
[0165] FIG. 8 provides a general flow diagram of an exemplary
method, method 397, of survey analysis using the above-outlined PTR
signal amplification by reaction of PTR reagent ions with
first-generation ions from multiple non-contiguous m/z ranges.
Steps 302, 304, 306, 308, 309, 312, 314, 316, 402 and 404 of the
method 397 are identical to the similarly numbered steps of the
method 300 illustrated in FIG. 3A and are thus not re-described
here. Also, the new step 311 is similar to the previously described
step 310 of method 300, except that step 311 refers only to mass
isolation of a random m/z range (such as the range 903 depicted in
FIG. 7C) of first-generation ions, instead of to a "random or
predetermined m/z range or ranges" as described for the prior
method 300. After the initial survey PTR reaction (step 312) and
identification of charge-state sequences (step 316), the latter of
which is preferably performed by the computational methods
described in the appendix to this document, the step 323 is
executed, in which multiple non-contiguous m/z ranges of the
first-generation ions are isolated and accumulated, wherein the
non-contiguous m/z ranges correspond to an identified charge state
sequence. The first-generation ions may be obtained from a
previously stored batch of such ions (prior step 319a) or,
alternatively (prior step 319b), the sample introduction and
electrospray ion generation step may need to be repeated.
[0166] After the isolation and accumulation of multiple
non-contiguous m/z ranges of the first-generation ions (step 323),
the accumulated ions are reacted with PTR reagent ions (step 324).
The resulting amplified spectra will generally be of high quality
thereby facilitating the derivation (step 325) of, for example, an
accurate molecular weight of the molecule corresponding the
multiple non-contiguous m/z ranges or an accurate quantity,
concentration, or relative abundance of such molecule. If an
immediately prior execution of step 316 identified more than one
set of related m/z ratios, then step 319a or 319b and steps 323-325
may be executed again (following the leftmost "Y" branch of step
326) using a new set of non-contiguous m/z ranges that correspond
to a different identified charge state sequence. If a search for
possible additional analytes is to be continued, then execution may
return to step 311 (following the rightmost "Y" branch of step 326)
at which a different random m/z range is chosen.
EXAMPLE D
[0167] According to another method for reduction of sample
complexity utilizing proton transfer reactions in accordance with
the present teachings, mass spectrometric analysis employing PTR
can be coupled directly with chromatography in order to simplify
and detect additional proteins that would otherwise be missed. In
this embodiment, a full scan mass spectrum is taken and the protein
molecular weights are calculated using a real-time deconvolution
program. Next, an isolation window is chosen of a defined width and
the subset of m/z values in the window are subjected to PTR
reactions.
[0168] For example, FIG. 9A shows a full scan mass spectrum of
first-generation ions generated from eluate at a retention time of
10 min. and 30 s. during the course of a ten-minute gradient
reverse-phase liquid chromatography separation of an E. coli
extract. As indicated by the braces in FIG. 9A, this full-scan mass
spectrum exhibits the distinct spectral signatures of two proteins
having approximate molecular weights of 35.1 and 31.1 kDa
respectively. For the next step, a population of ions having m/z
values within an m/z isolation window 510 of 10 Th width and
centered at 750 Th were isolated. The isolated ion population was
then subjected to PTR reactions with the anionic reagent sulfur
hexafluoride for 10 ms. The resulting product ion mass spectrum,
shown in FIG. 9B, exhibits the mass spectral signatures of two
additional proteins not seen in the full-scan mass spectrum having
molecular weights of 11220.07 Da and 24599.56 Da. In addition, the
35.1 kDa protein component previously observed in the full-scan
mass spectrum also exhibits a spectral signature in the PTR product
ion spectrum which includes a line, outlined in box 520,
corresponding to a +47 charge state at a nominal m/z value of 749.
The line at 749 Th represents charge reduction of
even-more-highly-charged states of the 35.1 kDa protein. The
proteins observed at 11.2 and 24.6 kDa would not otherwise be
identified in the absence of the PTR step in this example of a
reverse-phase chromatographic run as a result of complex spectral
overlap and interfering noise from an abundance of singly-charged
background ions.
[0169] FIGS. 10A and 10B show the results of a similar
chromatography/MS experiment obtained from eluate at a retention
time of 42 min. and 30 s. from a sixty-minute gradient elution run.
As shown in FIG. 10A, a high background at this elution time causes
difficulty in identifying analyte peaks in the full-scan spectrum.
However, the PTR product ion spectrum plotted in FIG. 10B is much
more amenable to interpretation and mass spectral deconvolution.
The PTR product ion spectrum exhibits the mass spectral signatures
of three distinct proteins--specifically having molecular weights
11165.92 Da, 13480.28 Da and 18727.23 Da--that would not otherwise
be observed. In this instance, the PTR product ions were generated
from isolated precursor ions generated from the mass spectral
window, indicated by box 610 in FIG. 10A, of 10 Th width centered
at m/z 750. By performing this type of analysis upon eluates that
elute at various different retention times during the course of a
single experiment, a sufficient number of sample peptides may be
recognized so as to enable identification of a microorganism to the
species, subspecies, or strain level. As also indicated by the
results shown in FIGS. 9A-9B, if there is m/z overlap of protein
ions from the full mass spectrum within the isolation window, then
the protein will also be seen in the PTR product ion mass
spectrum.
[0170] Interestingly, the full scan mass spectrum and PTR
product-ion mass spectrum can provide complementary information, as
illustrated in FIGS. 11A and 11B which represent mass spectral
results obtained from eluate eluting at a retention time of 18 min.
and 9 s. over the course of a thirty-minute chromatographic
separation. In this example, the full-scan mass spectrum (FIG. 11A)
exhibits a strong mass spectral signature of essentially a single
protein having a molecular weight of 9534.3 Da, However, when a PTR
product ion spectrum is generated from ions isolated within a 10 Th
wide window centered around m/z 750 Th (box 530), the mass spectral
signature comprises a strong signal from a protein having a
molecular weight of 14965.5 Da (best represented by the peak 535 of
the +12 charge state at approximately 1247 Th) along with five
other minor proteins having molecular weights of 12669.8 Da,
14150.0 Da, 14236.1 Da, 14965.5 Da, and 15117.5 Da. FIG. 11C is a
full-scan mass spectrum obtained from eluate eluting during the
same chromatographic separation at a retention time of 22 min. and
27 s. The spectrum includes peaks indicating the presence of a
protein having a molecular weight of 24961.3 Da. Upon PTR reaction
of ions isolated within the isolation window 540, the PTR product
ion spectrum shown in FIG. 11D was obtained. The mass spectral
signature in the PTR product ion spectrum includes a relatively
strong signal from a protein having a molecular weight of 28461.5
Da (best represented by the peak 545 of the +22 charge state at
approximately 1294 Th) as well as two other proteins having
molecular weights of 18590.5 Da and 20168.0 Da. Thus, from just the
data at these two retention times, it is possible to detect the
presence and the molecular weights of eleven different
proteins.
ADDITIONAL EXAMPLES
[0171] The following paragraphs list additional specific examples
of various specific embodiments in accordance with the present
teachings.
Example 1
[0172] A method for identifying the presence or absence of a
protein or polypeptide analyte compound within a liquid sample
comprising a mixture of compounds that includes a plurality of
protein compounds or a plurality of polypeptide compounds or
pluralities of both protein and polypeptide compounds, the method
comprising: [0173] (a) introducing a portion of the liquid sample
into an electrospray ionization source of a mass spectrometer;
[0174] (b) forming positively charged ions of the mixture of
compounds of the portion of the liquid sample by electrospray
ionization, the positively charged ions comprising a plurality of
ion species; [0175] (c) isolating a first subset of the ion species
comprising a first mass-to-charge (m/z) ratio range that includes
an m/z ratio of a particular predetermined multiply-protonated
molecular species of the analyte compound; [0176] (d) generating a
plurality of first-generation product ion species from the isolated
first subset of ion species by causing the isolated first subset of
ion species to be reacted, for a predetermined time duration, with
reagent anions that, upon reaction, extract protons from each of
one or more ion species that comprises a protonated molecular
species of a protein or polypeptide compound; [0177] (e) generating
a mass spectrum, using a mass analyzer, of either the
first-generation product ion species or of second-generation
product ion species generated from the first-generation product ion
species; [0178] (f) conducting a search of the mass spectrum of
either the first-generation or the second-generation product ion
species for a set of one or more m/z ratios that are diagnostic of
the protein or polypeptide analyte compound; and [0179] (g)
identifying the presence of the analyte compound within the sample
if the set of one or more m/z ratios is identified in the mass
spectrum.
Example 2
[0180] A method as recited in Example 1, further comprising
repeating the steps (a) through (e) a second time, wherein the
steps (f) and (g) are performed during or prior to the second
performing of the steps (a) through (e).
Example 3
[0181] A method as recited in Example 1, further comprising
repeatedly performing steps (a) through (g) a plurality of times,
wherein each repetition of step (a) comprises introducing, into the
electrospray ionization source, an eluate from a chromatographic
column corresponding to a respective retention time.
Example 4
[0182] A method as recited in Example 1, wherein the step (f)
comprises conducting a search of the mass spectrum of the
first-generation product ion species for a series of m/z ratios
that correspond to a sequence of multiply-protonated ion species of
the analyte compound that are progressively charge-reduced with
respect to the charge state of the particular predetermined
multiply-protonated molecular species.
Example 5
[0183] A method as recited in Example 1, wherein: [0184] the step
(c) comprises further isolating a second subset of the ion species
comprising a second m/z ratio range that includes an m/z ratio of a
particular predetermined multiply-protonated molecular species of a
second protein or polypeptide analyte compound; [0185] the step (f)
comprises conducting an additional search of the mass spectrum of
either the first-generation or the second-generation product ion
species for a second set of one or more m/z ratios that are
diagnostic of the second protein or polypeptide analyte compound;
and [0186] the step (g) comprises identifying the presence of the
second analyte compound within the sample if the second set of m/z
ratios is identified in the mass spectrum.
Example 6
[0187] A method as recited in Example 5, wherein the first m/z
ratio range is identical to the second m/z ratio range.
Example 7
[0188] A method as recited in Example 5, wherein the step (c)
comprises simultaneously isolating the first subset of the ion
species comprising the first m/z ratio and the second subset of the
ion species comprising the second m/z ratio range such that the
first and second m/z ratio ranges are non-contiguous.
Example 8
[0189] A method as recited in Example 1, wherein the step (d) of
generating a plurality of first-generation product ion species
comprises causing the isolated first subset of ion species and
reagent anions to be reacted for a time duration that causes the
product ion species to be stable against decomposition during the
subsequent generation of the mass spectrum in step (e).
Example 9
[0190] A method as recited in Example 8, wherein the step (e)
comprises generating a mass spectrum of the first-generation
product ion species using a mass analyzer that generates the mass
spectrum by detecting image currents caused by motions of the ions
of the product ion species within an ion trap.
Example 10
[0191] A method as recited in Example 1, wherein the step (d) of
generating a plurality of first-generation product ion species
includes applying a supplemental AC voltage across electrodes of an
ion trap within which the isolated first subset of ion species are
reacted with reagent anions, wherein a frequency of the
supplemental AC voltage is such that ion-ion reaction between the
reagent anions and selected first-generation product ion species is
inhibited.
Example 11
[0192] A method as recited in Example 10, wherein the frequency of
the supplemental AC voltage is such that, subsequent to the
execution of step (d), product ions formed from the analyte
compound exist substantially as a single ion species having a
particular charge state.
Example 12
[0193] A method as recited in Example 11, wherein: [0194] the step
(e) comprises generating a mass spectrum of the first-generation
product ion species; and [0195] wherein the mass of the single ion
species is greater than 20,000 Da and the charge state of the
single ion species is sufficiently great such that ions of the
single ion species may be detected, during the generation of the
mass spectrum, by either a quadrupole mass analyzer, a Fourier
transform ion cyclotron resonance mass spectrometer or an
electrostatic trap mass analyzer.
Example 13
[0196] A method as recited in Example 1, wherein the step (e) of
generating a mass spectrum comprises generating a mass spectrum of
second-generation product ion species, wherein the
second-generation product ion species are generated by the steps
of: [0197] isolating a subset of the first-generation product ion
species comprising a particular product-ion m/z ratio range; and
[0198] fragmenting the isolated subset of the first-generation
product ion species so as to form fragment ion species, wherein the
fragment ion species comprise the second-generation product ion
species.
Example 14
[0199] A method as recited in Example 1, wherein the step (e) of
generating a mass spectrum comprises generating a mass spectrum of
second-generation product ion species, wherein the
second-generation product ion species are generated by: [0200]
causing the first-generation product ion species to be reacted, for
a second predetermined time duration, with the reagent anions,
wherein products of reaction between the first-generation product
ion species and the reagent anions comprise the second-generation
product ion species.
Example 15
[0201] A method as recited in Example 14, wherein a supplemental AC
voltage is applied across electrodes of an ion trap within which
the first-generation product ion species are reacted with the
reagent anions, wherein a frequency of the supplemental AC voltage
is such that ion-ion reaction between the reagent anions and
selected product ion species is inhibited.
Example 16
[0202] A method as recited in any one of Examples 1-15, further
comprising generating the liquid sample comprising the mixture of
compounds by a procedure comprising: [0203] (i) culturing
microorganisms or cells; [0204] (ii) lysing the cultured
microorganisms or cells; and [0205] (iii) extracting proteins from
the lysate of cultured microorganisms or cells.
Example 17
[0206] A method as recited in Example 16, wherein the step (iii) of
extracting the liquid sample from the lysate includes passing the
lysate through a solid-phase-extraction apparatus.
Example 18
[0207] A method of identifying the presence or absence of a
microorganism type in a sample, comprising: [0208] (i) identifying
a list of analyte compounds whose simultaneous presence in the
sample is diagnostic of the presence of the microorganism type in
the sample, said list of analyte compounds comprising protein
compounds, polypeptide compounds or both protein and polypeptide
compounds; [0209] (ii) extracting, from the sample, a liquid
solution comprising a mixture of sample-derived proteins and
polypeptides; [0210] (iii) for each respective analyte compound in
the list, performing the steps of: [0211] (a) introducing a portion
of the liquid solution into an electrospray ionization source of a
mass spectrometer; [0212] (b) forming positively charged ions of
the mixture of compounds of the portion of the liquid solution by
electrospray ionization, the positively charged ions comprising a
plurality of ion species; [0213] (c) isolating a first subset of
the ion species comprising a first mass-to-charge (m/z) ratio range
that includes an m/z ratio of a particular predetermined
multiply-protonated molecular species of the respective analyte
compound; [0214] (d) generating a plurality of first-generation
product ion species from the isolated first subset of ion species
by causing the isolated first subset of ion species to be reacted,
for a predetermined time duration, with reagent anions that, upon
reaction, extract protons from each of one or more ion species that
comprises a protonated molecular species of a protein or
polypeptide compound; [0215] (e) generating a mass spectrum, using
a mass analyzer, of either the first-generation product ion species
or of second-generation product ion species generated from the
first-generation product ion species; [0216] (f) conducting a
search of the mass spectrum of either the first-generation or the
second-generation product ion species for a set of one or more m/z
ratios that are diagnostic of the respective analyte compound; and
[0217] (g) identifying the presence of the respective analyte
compound within the liquid solution if the set of one or more m/z
ratios is identified in the mass spectrum; and [0218] (iv)
identifying the presence of the microorganism type within the
sample if the presence of each and every analyte compound of the
list of analyte compounds is identified within the liquid
solution.
Example 19
[0219] A method of identifying the presence or absence of a
microorganism type in a sample, comprising: [0220] (i) identifying
a list of analyte compounds whose simultaneous presence in the
sample is diagnostic of the presence of the microorganism type in
the sample, said list of analyte compounds comprising protein
compounds, polypeptide compounds or both protein and polypeptide
compounds; [0221] (ii) extracting, from the sample, a liquid
solution comprising a mixture of sample-derived proteins and
polypeptides; [0222] (iii) introducing at least a first portion of
the liquid solution into an ionization source of a mass
spectrometer; [0223] (iv) generating, from the at least first
portion of the liquid solution at the ionization source, positively
charged ions of the mixture of compounds, the positively charged
ions comprising a plurality of ion species; [0224] (v) isolating at
least a first subset of the plurality of ion species, each isolated
subset of the at least a first isolated subset comprising a
respective mass-to-charge (m/z) ratio range; [0225] (vi) generating
a plurality of first-generation product ion species from each
isolated subset of ion species by causing each said isolated subset
of ion species to be reacted, for a predetermined time duration,
with reagent anions that, upon reaction, extract protons from each
of one or more ion species of said isolated subset of ion species
that comprises a protonated molecular species of a protein or
polypeptide compound; [0226] (vii) generating at least one mass
spectrum, using a mass analyzer of the mass spectrometer, of either
first-generation product ion species or second-generation product
ion species generated by further reaction of the first-generation
product ion species; [0227] (viii) for each respective analyte
compound in the list, performing the steps of: [0228] (a)
conducting a search of the at least one mass spectrum of either the
first-generation or the second-generation product ion species for a
set of one or more m/z ratios that are diagnostic of the respective
analyte compound; and [0229] (b) identifying the presence of the
respective analyte compound within the liquid solution if the set
of one or more m/z ratios is identified in the mass spectrum; and
[0230] (ix) identifying the presence of the microorganism type
within the sample if the presence of each and every analyte
compound of the list of analyte compounds is identified within the
liquid solution.
Example 20
[0231] A method as recited in Example 19, wherein a performing of
the steps (a) and (b) is performed concurrently with the performing
of one or more of the steps (iii) through (vii).
Example 21
[0232] A method as recited in Example 19, wherein the microorganism
type is defined as a particular genus of bacteria and the list of
analyte compounds includes a sufficient number of analyte compounds
that are diagnostic of the particular genus of bacteria to enable
identification of the presence or absence of the particular genus
of bacteria in the sample.
Example 22
[0233] A method as recited in Example 19, wherein the microorganism
type is defined as a particular species of bacteria and the list of
analyte compounds includes a sufficient number of analyte compounds
that are diagnostic of the particular species of bacteria to enable
identification of the presence or absence of the particular species
of bacteria in the sample.
Example 23
[0234] A method as recited in Example 19, wherein the microorganism
type is defined as a particular sub-species of bacteria and the
list of analyte compounds includes a sufficient number of analyte
compounds that are diagnostic of the particular sub-species of
bacteria to enable identification of the presence or absence of the
particular sub-species of bacteria in the sample.
Example 24
[0235] A method as recited in Example 19, wherein the microorganism
type is defined as a particular strain of virus and the list of
analyte compounds includes a sufficient number of analyte compounds
that are diagnostic of the particular viral strain to enable
identification of the presence or absence of the particular viral
strain in the sample.
Example 25
[0236] A method as recited in Example 19, wherein the microorganism
type is defined as a particular strain of virus and the list of
analyte compounds includes a sufficient number of analyte compounds
that are diagnostic of the particular viral strain to enable
identification of the presence or absence of the particular viral
strain in the sample.
Example 26
[0237] A method for identifying the presence or absence of a
protein or polypeptide analyte compound within a sample comprising
a mixture of compounds that includes a plurality of protein
compounds or a plurality of polypeptide compounds or pluralities of
both protein and polypeptide compounds, the method comprising:
[0238] (a) introducing a portion of the liquid sample into an
electrospray ionization source of a mass spectrometer; [0239] (b)
forming positively charged ions of the mixture of compounds of the
portion of the liquid sample by electrospray ionization, the
positively charged ions comprising a plurality of first-generation
ion species; [0240] (c) isolating a plurality of subsets of the
first-generation ion species comprising respective mass-to-charge
(m/z) ratio ranges, wherein each m/z ratio range includes an m/z
ratio of an ion species comprising a respective protonation state
of the analyte compound; [0241] (d) generating a plurality of
first-generation product ion species from the isolated plurality of
subsets of the first-generation ion species by causing the isolated
plurality of subsets of the first-generation ion species to be
reacted, for a predetermined time duration, with reagent anions
that, upon reaction, extract protons from each ion species that
comprises a respective protonation state of the analyte compound;
[0242] (e) generating a mass spectrum of the first-generation
product ion species; and [0243] (f) identifying either the presence
of the analyte compound within the sample if the mass spectrum
comprises one or more lines at respective predetermined ink ratios
that comprise respective intensities above a predetermined
threshold or the absence of the analyte compound within the sample
otherwise.
Example 27
[0244] A method as recited in Example 26, further comprising
repeatedly performing steps (a) through (f) a plurality of times,
wherein each repetition of step (a) comprises introducing, into the
electrospray ionization source, an eluate from a chromatographic
column corresponding to a respective retention time.
Example 28
[0245] A method as recited in Example 26, wherein the step (f)
further comprises determining, if the mass spectrum comprises one
or more lines at respective predetermined ink ratios that comprise
respective intensities above a predetermined threshold, a quantity
or concentration of the analyte compound within the sample based on
the one or more intensities.
Example 29
[0246] A method as recited in Example 26, further comprising, after
the step (b) of forming positively charged ions and prior to the
step (c) of isolating a plurality of subsets of the
first-generation ion species, the steps of: [0247] (b1) isolating a
subset of the first-generation ion species comprising a
randomly-selected mass-to-charge (m/z) ratio range; [0248] (b2)
generating a plurality of product ion species from the isolated
subsets of the first-generation ion species by causing the isolated
subset of the first-generation ion species to be reacted with
reagent anions that, upon reaction, extract protons from each ion
species that comprises a respective protonation state of the
analyte compound or a respective protonation state of another
protein or polypeptide compound; [0249] (b3) generating a mass
spectrum of the product ion species; and [0250] (b4) automatically
determining the m/z ratio ranges to be used in the subsequent step
(c), based on the mass spectrum of the product ions.
Example 30
[0251] A method as recited in Example 28, wherein the step (b4)
comprises automatically determining, from the mass spectrum, a set
of m/z ratios corresponding to multiply-protonated ion species of
the other protein or polypeptide compound.
Example 31
[0252] A method of identifying the presence of absence of a
microorganism in a sample, comprising: [0253] making an extract of
the sample; [0254] repeatedly executing the method recited in
Example 26 so as to, at each execution, identify the presence or
absence of a different respective protein or polypeptide analyte
compound within the sample extract; and [0255] identifying the
presence of the microorganism within the sample if the presence of
each respective protein or polypeptide analyte compound within the
sample extract or the absence of the microorganism within the
sample otherwise.
CONCLUSIONS
[0256] The use of PTR-type of ion-ion reactions as taught in this
document has several advantages for analysis of complex mixtures of
protein or polypeptide ions. A first significant advantage is
provided by the greatly improved signal-to-noise ratio as may be
readily observed by comparing FIG. 3 with FIG. 4. Even though some
charge is lost (i.e., complete neutralization) as a result of the
PTR process, a significant signal-to-noise ratio is gained as a
result of the reaction of multiply-charged proteins with singly
charged anions. The rate of such a reaction is proportional to the
square of the product of the charges. Thus, the originally
highly-charged analyte ions are converted into less-charged PTR
product ions whose mass spectral signatures appear at significantly
greater mass-to-charge ratios. By contrast, low-charge-state
chemical background ions are less significantly affected by the PTR
process during a typical experimental reaction period because of
the low rates of reaction of such ions. This process essentially
removes the mass spectral signatures of the proteins and
polypeptides from the low-mass, low-charge-state chemical
background "noise". For example, as shown in FIG. 4, the background
ions are represented by the large singly-charged peak that is "left
behind" at m/z.apprxeq.642. It is also believed that adducts or
water molecules still adhered to large proteins are removed as a
result of the exothermic heat of reaction (at least 125 kcal/mol)
deposited by the PTR reaction. The transformation of such ions into
simple protonated molecules may further enhance signal-to-noise
characteristics. Potentially, the number of protein identifications
obtained via this approach could exceed current complex top-down
methods utilizing some form of separation technology.
[0257] A second important advantage associated with methods in
accordance with the present teachings is provided by greatly
improved charge state assignment. For example, the inventors have
experimentally determined that approximately 75% of the charge
state assignments for individual charge states may be correctly
assigned by employing methods in accordance with the present
teachings. This improved ability to recognize charge states results
from the significantly improved signal-to-noise ratio. In turn,
this provides more accurate determination of the molecular weight
of the protein or polypeptide. This comparison applies to the
current Patterson-FFT charge state algorithm that is frequently
used for real-time charge state determination. Another important
advantage associated with methods in accordance with the present
teachings is provided by the ability to perform rapid throughput
analyses. When combined with the Fast Partial Chromatographic
Separation technique applied above, these methods allow for
analyses of samples in a high throughput fashion on a time scale of
one minute or less.
[0258] The discussion included in this application is intended to
serve as a basic description. Although the invention has been
described in accordance with the various embodiments shown and
described, one of ordinary skill in the art will readily recognize
that there could be variations to the embodiments and those
variations would be within the spirit and scope of the present
invention. Thus, the reader should be aware that the specific
discussion may not explicitly describe all embodiments possible;
many alternatives are implicit. Accordingly, many modifications may
be made by one of ordinary skill in the art without departing from
the scope of the invention as described by the claims. Neither the
description nor the terminology is intended to limit the scope of
the invention. Any patents, patent applications, patent application
publications or other literature mentioned herein are hereby
incorporated by reference herein in their respective entirety as if
fully set forth herein.
APPENDIX--MATHEMATICAL COMPUTATIONAL METHODS
1. Introduction
[0259] Structural elucidation of ionized molecules of complex
structure, such as proteins, is often carried out using a tandem
mass spectrometer that is coupled to a liquid chromatograph. The
general technique of conducting mass spectrometry (MS) analysis of
ions generated from compounds separated by liquid chromatography
(LC) may be referred to as "LC-MS". If the mass spectrometry
analysis is conducted as tandem mass spectrometry (MS/MS), then the
above-described procedure may be referred to as "LC-MS/MS". In
conventional LC-MS/MS experiments a sample is initially analyzed by
mass spectrometry to determine mass-to-charge ratios (m/z)
corresponding to the peaks of interest. The sample is then analyzed
further by performing product ion MS/MS scans on the selected
peak(s). Specifically, in a first stage of analysis, frequently
referred to as "MS.sup.1", a full-scan mass spectrum, comprising an
initial survey scan, is obtained. This full-scan spectrum is the
followed by the selection (from the results obtained) of one or
more precursor ion species. The precursor ions of the selected
species are subjected to reaction, generally fragmentation such as
may be accomplished employing a collision cell or employing another
form of fragmentation cell such as those employing surface-induced
dissociation, electron-transfer dissociation or photon
dissociation. In a second stage, the resulting fragment (product)
ions are detected for further analysis (frequently referred to as
either "MS/MS" or "MS.sup.2") using either the same or a second
mass analyzer. A resulting product spectrum exhibits a set of
fragmentation peaks (a fragment set) which, in many instances, may
be used as a means to derive structural information relating to the
precursor peptide or protein or other biochemical oligomer. It
should be noted that, using the fragment ions as a starting
population, the process of ion selection and subsequent
fragmentation may be repeated yet again, thereby yielding an
"MS.sup.3" spectrum. In the general case, a mass spectrum obtained
after (n-1) iterated stages of selection and fragmentation may be
referred to as an "MS.sup.n" spectrum. This is a time-consuming
process because the sample needs to be analyzed at least twice and
the MS/MS data is only recorded for a limited number of
components.
[0260] Most presently available mass spectrometers capable of
tandem analysis are equipped with an automatic data-dependent
function whereby, when selecting the precursor ion for MS.sup.2
analysis from the ion peaks in MS.sup.1, the ion precursors are
selected in decreasing intensities. In a simple data-dependent
experiment shown in FIG. 12A, a detector continuously measures
total current attributable to ions entering a mass spectrometer
detector. A threshold intensity level A8 of the total ion current
is set below which only MS.sup.1 data is acquired. As a first
component--detected as peak A10--elutes, the total ion current
intensity crosses the threshold A8 at time t1. When this occurs, an
on-board processor or other controller of the mass spectrometer
determines the most intense ion in the MS.sup.1 spectra and
immediately initiates an MS/MS scan with regard to the most intense
ion. Subsequently, the leading edge of another elution peak A12 is
detected. When the total ion current once again breaches the
threshold intensity A8 at time t3, an MS/MS scan is initiated with
regard to the most intense ion detected after time t3. Generally,
the peak A12 will correspond to the elution of a different chemical
component and, thus, the most abundant ion detected after time t3
will be different from the ion for which MS/MS analysis was
conducted during the elution peak A10. In this way, both MS and
MS/MS spectra are acquired on each component as it elutes.
[0261] The simple data dependent experiment described above works
well with chromatographically resolved or partially resolved
components, as are illustrated in FIG. 12A. However, in a very
complex mixture there may be components whose elution peaks
completely overlap, as illustrated in the graph of ion current
intensity versus retention time in FIG. 12B. In this example
elution peak A11 represents the ion current attributable to ion
m11, and elution peak A13 represents the ion current attributable
to ion m13, the masses of these ions being schematically
illustrated in the mass spectrum representation in inset box A16.
In the hypothetical situation shown in FIG. 12B, there is almost
perfect overlap of the elution of the compounds that give rise to
ions m11 and m13, with the mass spectral intensity of ion m11
always being greater than that of ion m13 during the course of the
elution. Under these conditions, the simple data-dependent
technique discussed above with reference to FIG. 12A will fail to
ever initiate MS/MS analysis of ion m13 (and possibly other
important ions), since only the most intense component (mu) will be
selected for MS/MS.
[0262] The hypothetical two-ion situation illustrated in FIG. 12B
is a simplified example. Most modern mass spectrometer instruments
are capable of performing a series of MS/MS analyses with regard to
each respective one of several abundant ions detected in an
MS.sup.1 analysis. Typically, instead of choosing just a single
most-abundant precursor, modern instruments will select the "top P
number of the most abundant precursors" for tandem mass analysis
based on the information of a preceding MS.sup.1 data acquisition,
where the number P is either a constant or perhaps a variable input
by a user. Nonetheless, the basic issue demonstrated by FIG. 12B
remains, especially for multicomponent samples of biopolymer
analytes which may give rise to tens to hundreds of mass spectral
peaks in a single mass spectrum. Regardless of how such a sample is
introduced into a mass spectrometer (for example, by
chromatographic separation, flow injection, or capillary
electrophoresis; as a chemical separate delivered from a
lab-on-a-chip device, by infusion or other method), more than one
analyte may be represented in a single mass spectrum from a single
time point, and each such analyte may give rise to many ions, as
illustrated in hypothetical mass spectrum illustrated in FIG. 12C.
In FIG. 12C, solid vertical lines outlined by envelope A208
represent centroids of a first set of mass spectral peaks generated
from a first analyte compound and dotted vertical lines outlined by
envelope A206 represent centroids of a second set of mass spectral
peaks generated from a second co-eluting analyte compound. It is
evident that, even if the number, P, of most-abundant peaks to be
analyzed is equal to 10, for example, than only the ions of only
one of the analyte compounds will be selected for MS/MS analysis
using the traditional data dependent methods described above.
Information relating to the second analyte will be lost. Further,
the data so obtained will comprise redundant information on the
same component.
[0263] To more successfully address the complexities of mass
spectral analysis of co-eluting compounds, many mass spectral
instruments also employ the so-called "Dynamic Exclusion" principle
by which a mass-to-charge ratio is temporarily put into an
exclusion list after its MS.sup.n spectrum is acquired. The
excluded mass-to-charge ratio is not analyzed by MS.sup.n again
until a certain time duration has elapsed after the prior MS.sup.n
spectrum acquisition. This technique minimizes a chance of
fragmenting the same precursor ion in several subsequent scans, and
allows a mass spectrometer to collect MS.sup.n spectra on other
components having less intense peaks which would otherwise not be
examined. After a selected period of time the excluded ion will be
removed from the list so that any other compounds with the same
mass-to-charge ratio can be analyzed. This time duration during
which the ion species is on the exclusion list is generally
estimated based on an average or estimated chromatographic peak
width. Thus, use of the Dynamic Exclusion principle allows more
data to be obtained on more components in complex mixtures.
[0264] Unfortunately, existing dynamic exclusion techniques may
perform poorly for analyzing mass spectra of mixtures of complex
biomolecules. For example, consider once again the hypothetical
situation illustrated in FIG. 12C. If the ions depicted in FIG. 12C
are analyzed using the dynamic exclusion principle, then at least
10 ion species derived from a single analyte (outlined by envelope
A208) will be analyzed, in decreasing order of their intensities in
the illustrated MS.sup.1 spectrum, by MS.sup.n analysis prior to
any peaks from the less abundant analyte (outlined by envelope
A206) being considered. This sequence will occur regardless of the
fact that each precursor each ions species is placed onto an
exclusion list after its respective analysis. The amount of time
consumed performing ten unnecessarily redundant MS.sup.n analyses
may then lead to expiration of the exclusion time of the most
abundant ion (or may lead to exhaustion of the time available to
fully analyze a small number of most abundant ions), after which
the entire sequence may of MS.sup.n analyses may be repeated.
[0265] A further complicating factor in the application of the
dynamic exclusion principle to mass analysis of mixtures of complex
biomolecules derives from the fact that the elution profiles of the
various compounds are highly variable and difficult to predict.
Different biopolymer compounds may exhibit different elution
profiles as a result of complex interactions between a
chromatographic stationary phase and a biopolymer with multiple
molecular interaction sites. Moreover, the time profiles of various
ions generated from even a single such compound may fail to
correlate with the elution profile of the un-ionized compound or
with the profiles of one another as a result of ionization
suppression within an ionization source of a mass spectrometer.
[0266] As an example of the elution profile variability that may be
encountered, FIG. 13 illustrates a set of chromatograms collected
from a single liquid chromatography-mass spectrometry experimental
run of an E.Coli extract. Total ion current is shown in the topmost
chromatogram (curve A40) and various extracted ion chromatograms,
illustrating the ion current that is contributed by respective
m/z-ratio ranges are shown in the lowermost five plots (curves A50,
A60, A70, A80 and A90). Curve A50 represents the m/z range
660.0-660.5 Da. Similarly, curves A60, A70, A80 and A90 represent
m/z ranges 700.5-701.5 Da, 1114.5-1114.5 Da, 942.5-943.5 Da and
540.5-540.5 Da. Peaks A1, A2 and A3 are examples of peaks with
broad chromatographic profiles. Peaks A4 and A5 are examples of
narrow profiles. Peak A6 shows an extremely broad peak. The peak
widths span over an order of magnitude, therefore severely limiting
the applicability of an exclusion list having a pre-defined
exclusion time duration. To address the above computational
difficulties, the following describes an improved optimized
computational method for making charge state assignments and for
real-time recognition of multiplexed charge state distributions,
this method referred to as the method of "Top P Unique
Analyte-Specific Clusters".
2. Key Features of Self Consistent Map Charge Assignment
Algorithm
[0267] 2.1. Use of centroids exclusively. Standard mass spectral
charge assignment algorithms (e.g., Senko et al., 1995) use full
profile data of the lines in a mass spectrum. By contrast, the
novel approach which is employed in the present methods uses
centroids. The key advantage of using centroids over line profiles
is data reduction. Typically the number of profile data points is
about an order of magnitude larger than that of the centroids. Any
algorithm that uses centroids will gain a significant advantage in
computational efficiency over that standard assignment method. For
applications that demand real-time charge assignment, it is
preferable to design an algorithm that only requires centroid data.
The main disadvantage to using centroids is imprecision of the m/z
values. Factors such as mass accuracy, resolution and peak picking
efficiency all tend to compromise the quality of the centroid data.
But these concerns can be mostly mitigated by factoring in the m/z
imprecision into the algorithm which employs centroid data.
[0268] 2.2. Intensity is binary. Another key departure from most
existing algorithms is the encoding of intensities as binary (or
Boolean) variables (true/false or present/absent) according to the
present methods. The present methods only take into consideration
whether a centroid intensity is above a threshold or not. If the
intensity value meets a user-settable criterion based on signal
intensity or signal-to-noise ratio or both, then that intensity
value assumes a Boolean "True" value, otherwise a value of "False"
is assigned, regardless of the actual numerical value of the
intensity. Again the encoding of a numerical value as a simple
binary value results in a significant data reduction. In many
programming languages, a double-precision value uses eight bytes of
memory storage whereas a binary (or Boolean) value uses just a
single byte. Also, comparing Booleans is intrinsically much faster
than comparing double-precision variables. A well-known
disadvantage of using a Boolean value is the loss of information.
However, if one has an abundance of data points to work with--for
example, thousands of centroids in a typical high resolution
spectrum, the loss of intensity information is more than
compensated for by the sheer number of Boolean variables.
Accordingly, the inventors' approach and, consequentially, the
algorithms taught herein, exploit this data abundance to achieve
both efficiency and accuracy.
[0269] Nonetheless, additional accuracy without significant
computational speed loss can be realized by using approximate
intensity values rather than just a Boolean true/false variable.
For example, one can envision the situation where only peaks of
similar heights are compared to each other. One can easily
accommodate the added information by discretizing the intensity
values into a small number of low-resolution bins (e.g., "low",
"medium", "high" and "very high"). Such binning can achieve a good
balance of having "height information" without sacrificing the
computational simplicity of a very simplified representation of
intensities.
[0270] 2.3. Mass-to-charge values are transformed and assembled
into low-resolution bins and relative charge state intervals are
pre-computed once and cached for efficiency. Another innovation of
the approach taught in the present disclosure is in transformation
of m/z values of mass spectral lines from their normal linear scale
in Daltons into a more natural dimensionless logarithmic
representation. As may be seen from the detailed discussion
following, this transformation greatly simplifies the computation
of m/z values for any peaks that belong to the same protein, for
example, but represent potentially different charge states. This
transformation involves no compromise in precision. When performing
calculations with the transformed variables, one can take advantage
of cached relative m/z values to improve the computational
efficiency.
[0271] 2.4. Simple counting-based scoring and statistical selection
criterion. Combining the encoding of centroid intensities as
Boolean values, and the transformation of m/z values, the present
approach encodes the whole content of any mass spectrum in question
into a single Boolean-valued array. The scoring of charge states
reduces to just a simple counting of yes or no (true or false) of
the Boolean variables at transformed m/z positions appropriate to
the charge states being queried. Again, this approach bypasses
computationally expensive operations involving double-precision
variables. Once the scores are compiled for a range of potential
charge states, the optimal value can easily be picked out by a
simple statistical procedure. Using a statistical criterion is more
rigorous and reliable than using an arbitrary score cutoff or just
picking the highest scoring charge state.
[0272] 2.5. Iterative process to achieve optimality and defined by
complete self consistency of charge assignment. The final key
feature of the present novel approach is the use of an appropriate
optimality condition that leads the charge-assignment towards a
solution. The optimal condition is simply defined to be most
consistent assignment of charges of all centroids of the spectra.
Underlying this condition is the reasoning that the charge state
assigned to each centroid should be consistent with those assigned
to other centroids in the spectrum. The present algorithm
implements an iterative procedure to generate the charge state
assignments as guided by the above optimality condition. This
procedure conforms to accepted norms of an optimization procedure.
That is, an appropriate optimality condition is first defined and
then an algorithm is designed to meet this condition and, finally,
one can then judge the effectiveness of the algorithm by how well
it satisfies the optimality condition. Most existing approaches
lack this logical framework, and their theoretical merits are
therefore difficult to assess objectively.
3. Details of Decomposition Algorithm
[0273] The inventors have developed methods that, inter alia, are
capable of assigning self-consistent charge states to mass spectral
lines and decomposing complex mass spectra comprising overlapping
information pertaining to several analytes into multiple sets of
lines, wherein each set of lines corresponds to a respective
analyte. FIG. 14 is an overview flowchart of a general set of steps
in accordance with the present teachings for accomplishing these
results. Several operations listed in FIG. 14 are illustrated in
greater detail in other flow diagrams of the accompanying set of
drawings.
[0274] 3.1. High-level methods. As shown, FIG. 14 depicts at least
two general execution or workflow pathways. According to a first
general execution pathway or workflow--here termed
"File-Deconvolution Workflow" only for purposes of reference--the
methods of the present teachings are employed for the purposes of
analyzing and possibly interpreting previously collected and stored
mass spectral data. According to a second general execution pathway
or workflow--here termed "Data-Dependent-Acquisition Workflow" only
for purposes of reference--the methods of the present teachings are
employed in a "real-time" or "online" fashion at the time that mass
spectral data is being acquired and at least some aspects of the
course of data acquisition are determined or controlled based on
the results of computations or algorithms in accordance with the
invention. Some steps illustrated in FIG. 14 are common to both of
the above-defined execution pathways and are denoted in FIG. 14 by
boxes defined by double lines. Other steps are exclusive to the
Data-Dependent-Acquisition Workflow pathway and are denoted by
boxes defined by dashed lines. At least one step--step A312--is
exclusive to the File-Deconvolution Workflow pathway and is denoted
by a box defined by a dotted line. Finally, steps A920 and A925,
which are depicted by boxes with single solid lines, are optional
with regard to the Data-Dependent-Acquisition Workflow but will
generally be performed in conjunction with the File-Deconvolution
Workflow. The File-Deconvolution Workflow will typically follow the
general pathway indicated by dotted arrows at the lower portion of
FIG. 14.
[0275] Still with reference to FIG. 14, the File-Deconvolution
Workflow commences at step A312, in which previously acquired and
stored mass spectral data in the form of at least one mass spectrum
is input from an electronic storage device and made available for
use in subsequent analysis. The mass spectrum may be an MS.sup.1
spectrum, an MS.sup.2 spectrum or, generally, any form of MS.sup.n
spectrum. By contrast, the Data-Dependent-Acquisition Workflow
begins at step A310 in which a sample is introduced into a mass
spectrometer and is subsequently ionized in step A315. The sample
introduction may be from a chromatograph, by means of injection or
by other means. An MS.sup.1 spectrum of the ions is generated in
step A320. It is assumed that steps similar to steps A310, A315 and
A320 would have been performed in the generation of the data that
is input in the alternative pathway that includes step A312.
[0276] In step A325, new peak centroids (i.e., centroids not
previously identified during the experiment in question or in a
prior MS.sup.1 spectrum of the input data); are identified and
added to a list of centroids. In the next step A400, the m/z values
of the centroids are transformed and the intensity data is
converted to a Boolean-valued data array in which bins are assigned
over the transformed m/z scale. The step A400 comprises a first
substep A420 of constructing and populating a Boolean occupancy
array and a second substep A460 of constructing and populating a
relative separation matrix (see FIG. 15). The details of these
substeps are described in greater detail in a subsequent section of
this disclosure.
[0277] In step A510, which only applies to the
Data-Dependent-Acquisition Workflow, centroids of analytes for
which MS.sup.n analysis has been completed are removed from a
"selection list" and may be added to an "exclusion list", if mass
analysis is being performed on a sample whose composition is time
varying, such as upon an effluent from a chromatographic column.
The selection list includes one or more mass-to-charge (m/z) values
or value ranges which are to be analyzed or which are being
analyzed by the mass spectrometer by tandem mass analysis (MS/MS
analysis) or possibly by MS.sup.n analysis, each such m/z value or
range corresponding to a chemical component of the sample as
identified by the methods of the present teachings. The exclusion
list includes one or more mass-to-charge (m/z) values or value
ranges which are to be excluded from future analysis either for the
duration of an experiment or for a temporary time period during the
experiment. The temporary time period, if employed, may be
determined according to methods of the present teachings, as
described in a subsequent portion of this disclosure. Alternatively
for direct infusion or flow injection analysis, the one or more
mass-to-charge values or value ranges which are to be excluded from
future analysis can be performed on signal rank basis. Centroids
depicting low-intensity mass spectral lines are removed from the
exclusion and selection lists in step A515. The removed m/z values
or ranges may be later added to the selection list if the
corresponding mass spectral signal intensities subsequently
increase during an experimental run.
[0278] In step A600 tentative charge states assignments are made as
outlined in FIG. 17 and further discussed below with reference to
that figure. Then, in step A700, the tentatively assigned charge
states are adjusted and final charge state assignments are made
using requirements for self-consistency. The details of this
process are outlined in FIG. 18 and further discussed below with
reference to that figure. Once the final charge state assignments
have been made, the experimentally observed centroids are
decomposed into analyte-specific clusters in step A800 using
information derived from the spacing of isotopic clusters. The
details of step A800 are illustrated in FIG. 19 and described
further with reference to that figure.
[0279] The execution of the method A300 may branch at step A910
along one of two possible execution paths indicated by solid-line
arrows and dotted-line arrows, respectively. If real-time tandem
mass spectrometry is being controlled by the results of the prior
data analysis, then the method execution may follow the "N" branch
(denoted by solid lines) from step A910 directly to step A915,
thereby skipping steps A920 and A925. Alternatively, if more data
analysis operations are to be conducted upon MS.sup.1 data measured
in step A320 or if data was previously input in step A312, then the
"Y" branch of step A910 is followed whereafter molecular weights
may be calculated or analyte species identified (step A920) and the
results of the calculations may be reported or stored (step A925).
As determined at step A915, if tandem mass spectrometry is to be
performed, as will generally be true if the
Data-Dependent-Acquisition Workflow execution path is being
followed, then the method branches along the "Y" branch to step
A930. Otherwise, execution proceeds, along the "N" branch to step
A960.
[0280] Considering, now, the "online" execution path illustrated on
the right-hand side of FIG. 14, a determination is made in step
A930 if centroids attributable to known adducts are present in the
considered set of centroids. Is so (the "Y" branch of step A930)
then the centroids corresponding to adduct species or to
otherwise-modified species (for instance, species generated from
loss of a neutral molecule) are added to the exclusion list in step
A935. Otherwise, step A935 is bypassed. Step A940 is the
commencement of top-down analysis in which a representative peak is
selected for fragmentation from each of top P analyte-specific
clusters determined in step A800. The following steps A945, A950
and A955 are conventional steps of, respectively, isolating ions of
the m/z ratios corresponding to the selected centroids, fragmenting
the isolated ions and performing a mass analysis (MS.sup.2) of the
product ions.
[0281] Execution of the method A300 may end after step A960, if
either the mass spectral experimentation or the data analysis is
complete. Otherwise, execution passes back to either step A310 at
which the next portion of sample is introduced to the mass
spectrometer or to step A312 at which the next portion of mass
spectral data is input.
[0282] 3.2. Building a Boolean-valued occupancy array. FIG. 16
shows the details of the step A420 of building an occupancy array,
[O.sub.k]. The values of the array are Boolean variables and the
indices of the array correspond to the discretized transformed
mass/charge values. The step A420 takes, as input, a collection of
centroids, C.sub.i (1.ltoreq.i.ltoreq.L) where L is an observed
number of mass spectral lines. Each C.sub.i is characterized by its
mass/charge (m/z).sub.i, its intensity I.sub.i, its signal-to-noise
ratio (S/N).sub.i and its resolution R.sub.i. Next, a filtering of
the centroids is performed (step A422) by collecting the subset {}
of centroids which pass a user settable criterion of intensity and
signal to noise thresholds. Next, in step A424, a mass/charge
transformation is performed on each C.sub.i in {} by taking the
natural log of the mass/charge value minus that of the mass of a
proton, M.sub.proton as in Eq. 1.
T(m/z).sub.i=In((m/z).sub.i-M.sub.proton) Eq. (1)
After this transformation, each centroid, C.sub.i in the subset {}
is characterized by T(m/z).sub.i, I.sub.i, (S/N).sub.i and R.sub.i.
The greatest, T(m/z).sub.High, and the smallest, T(m/z).sub.low,
values of the T(m/z) values from subset {} are noted in step A426.
This information is then used to create the array [O.sub.k] of
values, where each element of the array is a Boolean-valued
"occupancy" which maintains a record of whether or not a "signal"
is deemed to occur at the respective transformed mass-to-charge
value, T(m/z).sub.k, associated with the array element. Upon
creation, each element, O.sub.k, of the array is initialized to the
Boolean value "FALSE". The number of discrete elements in the
array, or "length" of the array [O.sub.k] is denoted as L.sub.occs,
which is determined as
L occs = ( T ( m / z ) high - T ( m / z ) low ) D Eq . ( 2 )
##EQU00001##
where D is the width of each bin in the array and is D=MA/10.sup.6,
where MA, typically 10, denotes a user settable parameter of the
mass accuracy of the spectrum of interest.
[0283] After creation and initialization, the array [O.sub.k] must
be populated (performed in step A436) with meaningful values. The
elements of the occupancy array [O.sub.k] are indexed by the
variable, k(1.ltoreq.k.ltoreq.L.sub.occs) whereas the elements of
the filtered centroid subset {} are indexed by the variable, i. The
latter indices are converted into corresponding k-values in step
A430, in which, for each centroid, C.sub.i, in the subset {}, the
corresponding index, k.sub.i, is determined as follows:
k i = ( T ( m / z ) i - T ( m / z ) low ) D Eq . ( 3 )
##EQU00002##
and is rounded to the nearest integer (the rounding operation is
indicated by the operator "ROUND[ ]" in FIG. 16. If the resolution,
R.sub.i, of the centroid C.sub.i is available (some spectra such as
those collected in the centroid mode, may not have this defined),
then the "Y" branch of the decision step A432 is followed, in which
the additional indices k.sub.i.sup.Lo and k.sub.i.sup.Hi are
calculated in step A434a as follows
k i Lo = ( T ( m / z ) i - 0.5 ( R i ) ) D Eq . ( 4 a )
##EQU00003##
k i Hi = ( T ( m / z ) i - 0.5 ( R i ) ) D Eq . ( 4 b )
##EQU00004##
with values rounded to the nearest integer. In cases in which
R.sub.i is not available, these indices are instead set to
k.sub.i-1 and k.sub.i+1, respectively, in step A434b. Finally, in
step A436, array values are all set to the Boolean value "TRUE" for
indices ranging from k.sub.i.sup.Lo to k.sub.i.sup.Hi, namely
O.sub.k:=TRUE; k.sub.i.sup.Lo.ltoreq.k.ltoreq.k.sub.i.sup.Hi Eq.
(5)
[0284] 3.3. Building a relative separation matrix (RSM). As shown
in FIG. 15, step A460 is the step of constructing a relative
separation matrix and is the second sub-step of the general step
A400. The creation of a relative separation matrix is motivated by
observation that, given two centroids C.sub.1 and C.sub.2, then, if
they belong to the same protein isotopic peak but differ just in
charge states, then their mass/charge values are related as
|z.sub.1|.times.((m/z).sub.1-M.sub.proton)=|z.sub.2|.times.((m/z).sub.2--
M.sub.proton) Eq. (6)
in which z.sub.1 and z.sub.2 are the charge state of the centroids
C.sub.1 and C.sub.2 respectively, and M.sub.proton is the mass of a
proton. The charge state values, z.sub.1 and z.sub.2, will
generally be either all positive or all negative depending on the
mode of ionization used in the mass spectrometer instrument
conducting the analyses. Performing the transformation as described
in Eq. (1) yields the relationship that
T(m/z).sub.1=T(m/z).sub.2+ln|z.sub.2/z.sub.1| Eq. (7)
The important property of Eq. (7) is that the transformed
T(m/z).sub.i values at different charge states are related by an
additive factor that is independent of the transformed values. Thus
one can pre-compute and cache the quantities ln(z.sub.2/z.sub.1) as
a matrix that can be reused in subsequent calculations by simple
look-ups by pre-computing the RSM. The absolute values of the
charge states will generally range between unity and some maximum
value, |Z.sub.max| or, more specifically, 1.ltoreq.z.sub.1,
z.sub.2.ltoreq.|Z.sub.max|. The last step is to discretize the
ln|z.sub.2/z.sub.1| matrix by dividing by D as in Eq. (4):
RSM z 1 , z 2 = ln | z 2 / z 1 | D Eq . ( 8 ) ##EQU00005##
The limits of the matrix, determined by Z.sub.max, may be set by a
user anticipating the maximum and minimum charge states that will
be encountered in a set of spectra. Alternatively, Z.sub.max may be
a pre-determined or pre-calculated value. Typically, the absolute
values of the charge states range from 1 to 50 for a top down
experiment. So in such a case, RSM will be a 50.times.50
anti-symmetric matrix.
[0285] 3.4. Building a scoring distribution for each centroid and
using it to assign tentative charge states. Before a
self-consistent set of charge assignments may be determined by
iteration (in step A700, FIG. 18), a reasonable initial set of
tentative charge assignments must be formulated. The step A600, the
details of which are shown in FIGS. 17A and 17B, generates this
initial set of by assigning a likely charge state to various of the
centroids of subset {}. Steps A601-A615 consider each such
centroid, in turn, and, for each considered centroid, step through
various putative values of putative charge state, z, from a minimum
charge state value, Z.sub.min up to a maximum charge state value,
Z.sub.max. For example, putative charge states from z=1 through
z=50 might be considered for each centroid. For each combination of
a centroid, C.sub.i (as selected in step A601 or step A615) and a
putative charge state z.sub.1, (as set in either step A603 of
A609), a set of "probe indices" k.sub.p(C.sub.i,z.sub.i) is
calculated in step A605. The probe indices are a set of k-values
that reference bins of the occupancy array, [O.sub.k], for purposes
of testing for "TRUE" values at each of these indices. The
k.sub.p(C.sub.i,z.sub.i) matrix includes a first row having the
indices corresponding to the discretized T(m/z).sub.i values of the
(+/-m) theoretical isotopic peaks of the selected centroid C.sub.i.
For example, if m=5, the probe indices corresponding to the (+/-5)
theoretical isotopic peaks are the transformed values of:
( m / z ) i - ( 5 ) ( 1.003 ) z , ( m / z ) i - ( 4 ) ( 1.003 ) z ,
, ( m / z ) i + ( 5 ) ( 1.003 ) z ##EQU00006##
The k.sub.p(C.sub.i,z.sub.i) matrix also includes two additional
rows, the elements of which are calculated by generating, for each
of the 2m probe indices in the row described above, an additional
probe index corresponding to expected location of the z-1 peak and
another additional probe index corresponding to the expected
location of the z+1 peaks. Specifically, the indices
[k.sub.p(C.sub.i,z.sub.i)+RSM(z.sub.i-1, z.sub.i)] and
[k.sub.p(C.sub.i,z.sub.i)+RSM(z.sub.i+1, z.sub.i)] are generated,
where RSM is the pre-computed and cached relative separation matrix
described above. Note that the k.sub.i index of the centroid
C.sub.i, itself, is excluded from the probe indices matrix because,
at this stage of execution of the algorithm, it is given that the
occupancy array contains a value of "TRUE" at such index.
Similarly, one can also increase the probe matrix in include more
charge states of (z-m, z-m+1, . . . , z+m-1, z+m) instead of just
(z-1, z, z+1) as described above.
[0286] In step A607, a score value is calculated for each tested z
value and each centroid C.sub.i. The set of scores is used to
generate a scoring distribution for each z value. Each score S(z)
is calculated by summing, for each possible value of z.sub.1, the
experimentally-derived occupancy values. Specifically, the score
for each value of z is determined by
S(z)=.SIGMA.O.sub.k/C Eq. (9)
where the sum is over k of k.sub.p(C.sub.i,z.sub.i) such that
(1.ltoreq.k.ltoreq.L.sub.occs) and C is just the number of such
k's. In other words, the score at z is just the fraction of
k.sub.p(C.sub.i,z.sub.i) indices that are "occupied" by a measured
above-threshold mass spectral signal (i.e., a value of "TRUE") as
coded in occupancy array constructed in step A420 (FIG. 15). Thus,
the calculation in step A605 is a form of streamlined approximate
"inner product" calculation, with the greatest possible score of
any single calculation being unity. The score distribution is
formed by summing the scores for each value of z from the lowest to
the highest user settable limits. Using our example of 1 and 50 as
the low and high limits, we will end up with a distribution of 50
scores for each centroid.
[0287] Decision step A611 determines, for each centroid, if the
maximum value of z has been considered. If not then execution
returns to step A605 for calculation of probe indices with a new
value of z (as set in step A609). Otherwise, execution branches to
decision step A613 which determines if the last centroid in the
subset {} has been considered. If not, then execution proceeds to
step A615 in which the next centroid is selected and then to step
A603 in which the z-value is reset to its initial state. Otherwise,
execution proceeds to step A617 (FIG. 17B) at which the process of
formulating tentative charge assignments is begun.
[0288] Steps A617-A635 shown in FIG. 17B illustrate the process of
making tentative charge assignments using the scoring distributions
previously generated in multiple iterations of step A607 (FIG.
17A). In step A617, the first centroid is selected; later the
choice of centroid being considered is updated in step A635. After
either of these two steps, the mean, .mu., and standard deviation,
.sigma., of the respective scoring distribution is computed in step
A620. Thus, repeated iteration of steps A620-A635 causes these
statistical measures to be computed for the scoring distribution
associated with each centroid. In step A625, if there are any
scores larger than mean .mu.+3.sigma., then the z-value with the
largest score is assigned to the centroid as the initial
charge-state assignment. If there are no scores larger than
.mu.+3.sigma., then a null value as provided as the initial
assignment for the centroid in question.
[0289] 3.5. Achieving optimality of completely self consistent
charge assignment by iteration. After the tentative charge-state
assignments have been made in step A600, execution of the method
A300 (FIG. 14) proceeds to step A700 in which the tentative charge
state assignments are adjusted. Details of the step A700 are shown
in FIG. 18. The optimal condition is simply defined to be most
consistent assignment of charges of all centroids of the spectra.
Underlying this condition is the reasoning that the charge state
assigned to each centroid should be consistent with those assigned
to other centroids in the spectrum.
[0290] The details of the step A700 shown in FIG. 18 implement an
iterative procedure to generate the charge state assignments as
guided by the above optimality condition. Each centroid with a
non-null assignment (as assigned in step A625 of FIG. 17B) is
considered, in turn. Each of these may be associated with a set of
probe indices as indicated in step A605 of FIG. 17A. This process
is repeated for all centroids with a non-null assignment, and a new
charge state distribution is determined at each probe index.
Specifically, in step A702, the first or next centroid having a
non-null tentatively assigned charge state, z.sub.t, is selected.
In step A704, the probe indices for the centroid in question are
generated, as previously described with respect to step A605 of
FIG. 17A, if necessary. Then, in step A706, a charge state is
calculated at each of the probe indices corresponding to the
centroid in question, assuming that the charge state of the
selected centroid is z.sub.t. For each probe index, a record is
kept of how many times each charge state is calculated for that
probe index. Before beginning each loop through steps A702-A710,
these records are cleared (re-set zero) in step A701. Thereafter,
during each loop, each time that a charge state is calculated for a
probe index in step A706, the number of times that the charge state
has been so calculated at that probe index is incremented. If, at
step A710, there are additional centroids with a non-null
assignment, then execution returns to step A702 and the next such
centroid is selected.
[0291] After the last centroid has been considered, execution
branches to step A712. In step A712, the number of occurrences of
each charge state (as calculated in step A706) are tabulated at
each probe index, thereby generating a charge state distribution
for each probe index. Using the new charge-state distributions, a
"charge assignment by majority" (CAM) is obtained in step A714 by
adjusting tentative charge state at each probe index so at to equal
the charge state with the highest number of tabulated at the
respective index. The set of all such CAM charge assignments forms
an array of values--the charge assignment by majority array.
[0292] The charge assignments are considered to be inconsistent if,
at step A716, the values of the CAM array differ from the
charge-state values used in the generation of the CAM array. By
contrast, a completely self consistent charge assignment is defined
as the assignment of charge at each index such that it is in
complete concordance with that from the CAM array resulting from
it. Thus, at step A716, the adjusted tentative charge states are
compared to their prior values. If there has been a change that is
greater than a certain tolerable limit, then the charge assignments
are not self-consistent. In this case, the "N" branch of step A716
is followed and execution returns to step A701 whereby a new set of
calculations are performed so as to achieve self consistency. Thus,
a set of repetitions of the CAM array determination are performed
by using the charges from each CAM to generate a subsequent CAM.
Optimality is achieved when convergence is achieved--that is, the
CAM generates the same CAM.
[0293] In practice, one might not achieve exact convergence by this
procedure. However, the inventors' experience shows that, after a
few iterations, the incidence of non-concordance becomes negligibly
small and thus one can stop the iteration at a very good
charge-state assignment. Accordingly, in step A716, convergence is
considered to be operationally achieved when the difference in
successive CAM arrays is within a certain tolerable limit (i.e.,
within a certain tolerance). In this case, execution branches to
step A718 at which the final self-consistent charge state and each
centroid is set to be equal to the tentative charge state at which
the operational convergence occurred.
4. Determination of Analyte-Specific Clusters
[0294] The clustering approach starts with the clustering criterion
defined by Eq. (10), in which the number of C.sup.13
non-monoisotopic peaks, .DELTA.N.sup.C13, that are reasonably
expected to occur within a restricted m/z range is given by
Number of C 13 Peaks = [ ( z 1 ( m / z ) 1 ) - ( z 2 ( m / z ) 2 )
] - ( z 1 - z 2 ) M proton M C 13 Eq . ( 10 ) ##EQU00007##
in which z.sub.1 and z.sub.2 are the charge states assigned to mass
spectral lines, (m/z).sub.1 and (m/z).sub.2 are the experimentally
measured mass to charge values, M.sub.C13 is the mass difference
between the isotopes of carbon, C.sup.13 and C.sup.12, and
M.sub.proton is the mass of a proton. The error (.delta.) or
standard deviation associated with the calculation is computed from
a user-supplied value of accuracy, .alpha., which is defined in
ppm, as well as the resolutions R.sub.1 and R.sub.2 of the
centroids under consideration as described in Eq. (11)
.delta. = 1 M C 13 { ( .alpha. 2 + 1 / 2 R 1 2 ) ( z 1 ( m / z ) 1
) 2 + ( .alpha. 2 + 1 / 2 R 2 2 ) ( z 2 ( m / z ) 2 ) 2 } Eq . ( 11
) ##EQU00008##
To determine if any two centroids (peaks) belong to the same
analyte-specific cluster (associated with a particular bio-molecule
such as a protein), the theoretical .DELTA.N.sup.C13 value is
calculated using Eq. (10). If the calculated .DELTA.N.sup.C13 value
is an integer within the measurement error, as computed as in Eq.
(11), then the two centroids are considered to belong to the same
analyte-specific cluster, provided that the number of C.sup.13
peaks does not exceed a user defined limit(typically 10 to 15). Of
course, one skilled in the art can easily use a multitude of other
similar statistical tests such as the z-test, or t-test to
determine whether the two peaks differ by an integral number of
C.sup.13, given the uncertainties of their m/z's as encoded in
.alpha. and the resolution R's.
[0295] The step A800 of decomposing the mass spectral lines into
analyte-specific clusters shown in FIG. 19 makes use of the above
reasoning. The step A800 considers centroids for which charge
assignments have been made, as previously described. Step A805
begins with the charge-assigned centroid that has the greatest
experimentally-observed intensity. The so-selected centroid is then
uses as a "seed" for the first cluster. Then, proceeding in order
of decreasing intensity (steps A810 through A830), a check is made
to determine if the next centroid in the list clusters with the
seed centroid of this cluster. This check is performed by first
calculating .DELTA.N.sup.C13 and its error, .delta., using Eq. 10
and Eq. 11, respectively (step A815). If it is noted, in the
decision step A820, that the presently-calculated value of
.DELTA.N.sup.C13 is an integer, within the calculated error, then
execution follows along the "Y" branch to step A825 in which the
centroid under consideration is grouped together with the seed
centroid as belonging to a single cluster. If not, then the "N"
branch is followed such that, in step A830, if there are remaining
non-seed centroids, execution returns to step A810 in which the
next-intense non-seed centroid is selected for cluster checking.
If, at step A830, the list of non-seed centroids is exhausted (that
is, there are no remaining non-seed centroids having intensities
less than the presently considered centroid) but there are
remaining non-clustered centroids (determined in step A835), then
execution returns to step A805 in which a new cluster is started
with using the most-intense non-seed centroid as the new seed.
Subsequent iterations check against all cluster seeds created and
create new clusters if the new centroid does not cluster with any
preceding clusters.
[0296] Finally, in step A840, a simple heuristic is employed to
determine if any cluster created by the clustering algorithm is
"healthy". In our initial implementation, we use the simple rule
that a "healthy" cluster must have at least four distinct charge
states or at least N (user settable, but defaulting to 15) member
centroids. We filter out clusters that are not "healthy" according
to these criteria. After the removal of "unhealthy" clusters, the
remaining are the final analyte-specific clusters, each
representing a different bio-polymer or other high-mass
compound.
5. Protein Molecular Weight Calculations
[0297] One of the more common ways of calculating the mono-isotopic
molecular weight, M.sub.mono, of a protein from an experimental
high-resolution spectrum is to use the so-called "Averagine" method
(Senko, M. W, Beu, S. C. and McLafferty, F. W., 1995, Determination
of monoisotopic masses and ion populations for large biomolecules
from resolved isotopic distributions. J. Am. Soc. Mass Spectrom.,
6: 229-233), which itself is an extension of an earlier method for
low-resolution data (Zubarev, R. A. and Bonddarenko, P. V., 1991,
An a-priori relationship between the average and monoisotopic
masses of peptides and oligonucleotides. Rapid Commun. Mass
Spectrom., 5: 276-277). Briefly, the Averagine method first models
an experimental isotopic cluster by a hypothetical model
molecule--the "Averagine" molecule. By optimizing the fit between
the experimental and the theoretical isotopic distribution, one can
arrive at an estimate of the mono-isotopic mass desired.
[0298] The Averagine technique is used within various mass
spectrometry peak decomposition and analysis algorithms that are
commercially available from Thermo Fisher Scientific of Waltham
Mass. USA. Although the Averagine method has been highly
successful, the present inventors are motivated to develop a
different approach based on the following considerations: (1)
Calculation speed. Averagine fitting may be time consuming, a not
insignificant consideration for real-time applications, such as
those described herein in which decisions are automatically made,
in real time, regarding which of several observed ions to fragment.
It should be noted, however, that, in situations where a large
number of spectral fits are not required, calculation speed may not
pose any concern; and (2) Mass accuracy. For a larger molecular
weight protein whose signature appears in a crowded spectrum, the
corresponding isotopic cluster tends to be noisy and incomplete
(missing isotopes--especially the edges, missing charge states
etc). The use of an Averagine fit may not be appropriate in such
instances.
[0299] The present inventors therefore here teach an approach that
promises to produce a robust estimate of the mono-isotopic mass
that is very easy to calculate and more resistant to noise and
artifacts. The main goal is robustness and precision, accepting the
compromise that the estimate might be biased. In short, the
estimate might not be the "true" mono-isotopic mass (but
nonetheless very close to it), but it should be robust/stable in
face of experimental imperfections. The error should deviate from
the true mono-isotopic mass by either 0 or +/-1 dalton (1 Da)
precisely, after taking mass accuracy into consideration. The
inventors here point out that robustness, in many cases, is more
important than accuracy. For example, if one were to build a
molecular weight database based on experimental data, the ability
to produce the same answer both while building the database and
while testing the database by new data is generally desired, even
if the estimates are potentially off by 1 Da from the true
molecular weight but nonetheless are identical from experiment to
experiment.
[0300] The approach starts with three simple observations: (1) the
isotopic patterns for most proteins are due to the
C.sup.12/C.sup.13 binomial distribution and all the other isotopes
are of too low an abundance to warrant consideration; (2) the mode
(i.e., the peak having the greatest intensity) of a binomial
distribution is a very robust feature of the binomial distribution
compared to either the average, the standard deviation, or the
exact boundaries of the distribution, and (3) for the binomial
distribution, the mode is located less than 1 Da to the left of the
average (see Table A1, which is presented in FIGS. 20A-20D). This
means that the mode is a very usable replacement for the average,
which itself is more difficult to estimate for more noisy data. For
example, a distribution truncated at the edges will give rise to an
unreliable average estimate while the mode, unless the distribution
is highly distorted, is very stable against such truncations.
[0301] The starting point for the calculation is defined by M, the
observed mode of an isotopic cluster. Zubarev's approach to
calculate the first approximation of the monoisotopic mass is then
employed where:
M.sub.1=M.times.0.999316 Eq. (12)
The second approximation of the monoisotopic mass is then defined
by:
M.sub.2=M-n.times.1.003 Eq. (13)
where n is the smallest integer such that M.sub.2.gtoreq.M.sub.1.
Finally, in the calculation of the monoisotopic mass, M.sub.mono,
if there is an experimental peak of the cluster which is within 1
Dalton greater than M.sub.2 then:
M.sub.mono=M.sub.2+1.003 Eq. (14a)
otherwise,
M.sub.mono=M.sub.2 Eq. (14b)
[0302] This method of calculating the mono-isotopic mass has been
incorporated in the results illustrated herein. The inventors'
results show that the predictions compare very favorably to those
predicted by the Averagine method. For large proteins, testing on
standard proteins indicates that the mono-isotopic mass estimate is
stable. In addition, a cluster molecular weight is also calculated
for closely related peaks or proteoforms. We term the result of
such a calculation as the "Cluster Molecular Weight". After all the
proteoforms have been discovered in a batch, a cluster analysis of
all the proteoforms is performed using the more discriminatory
error function:
Error=min|w.sub.1-w.sub.2-N.times.1.003| Eq. (15)
over -3.ltoreq.N.ltoreq.3. If Error<0.5
(w.sub.1+w.sub.2).times.10 ppm , then w.sub.1 and w.sub.2 should be
considered equivalent. Each proteoform will then be mapped into
clusters of equivalent proteoforms represented by a consensus
monoisotopic mass. This mass is termed and stored as "consensus
MW".
6. Program Input and Output
[0303] FIG. 21A shows the starting page (i.e., a visual display
screen capture) of a post-data-acquisition version of a computer
program that employs the data dependent methods described herein.
On the left hand side of the display illustrated in FIG. 21A, the
"Raw File" box serves as the input line for the mass spectrometry
data file to be processed. The "Batch Mode" check box can be
enabled, thereby allowing a user to process multiple data files,
while the "Auto Scan Increment" check box is used to enable
processing of consecutive spectra. Results from the
post-data-acquisition version of the program can be plotted in a
display by the user enabling the "Plot Deconv" check box. The
minimum and maximum spectrum (scan) number to process is set by the
"Scan buttons" which directly default to the file length (in scans)
or which can be set by the user.
[0304] Output can be controlled as seen in the lower left hand side
of FIG. 21A, by causing results to be output to a peak list and by
the user specifying the output as either MS1 or MS2 type data (in
csv file format). The mass tolerance (Mass Tol) defaults to 3;
however this too can be set by the user. Output can also be
produced in a .puf file format for input into the ProSight.TM. PC
protein identification program. Details of the spectral
decomposition results (also referred to herein as "deconvolution"
results) can also be stored in a .csv file format for further data
analysis. The deconvolution summary in the "Results" tab lists the
data file(s) and scan(s) analyzed to produce the report. Moving
down the tab are the total number of centroids detected along with
the number filtered as part of the program. The percentage of peaks
successfully receiving charge-state assignments is found in the
"Zscape" box along with a comparison to results as calculated by
one of the leading existing deconvolution programs currently used
by those skilled in the state-of-the-art. The "both assigned" and
"concordance" boxes measure the agreement between the two programs.
Moving to the bottom of the "Results" tab, the percentage of
cluster assigned and the total number of unique proteins
deconvoluted are shown. An expanded view of this tab is shown in
FIG. 21D.
[0305] Two of the tabs located on the right hand side of the
display shown in FIG. 21A provide for choosing the assignment and
clustering parameters associated with the deconvolution process. In
FIG. 21B, the "Assignment Parameters" tab includes the mass
accuracy in parts per million (ppm), the minimum peak intensity
threshold, the minimum signal-to-noise ratio (s/n) needed, and the
lowest and highest charge state expected for the deconvolution
process. These parameters are further divided into two columns one
each for MS.sup.1 and MS.sup.2 analysis.
[0306] The "Clustering Parameters" tab shown in FIG. 21C is also
divided into two columns relating to MS.sup.1 and MS.sup.2 analysis
respectively. Provision is made for user input of the minimum
number of contiguous charge states and isotopes for the clustering
convergence calculation described above. The "Sufficient Contiguous
Charge States", "Sufficient Contiguous Isotopes" and "Mass
Separation" parameter input displays are also present on this input
tab.
7. Examples
[0307] FIG. 22A shows the deconvolution result from a five
component protein mixture consisting of cytochrome c, lysozyme,
myoglobin, trypsin inhibitor, and carbonic anhydrase. A top display
panel A1203 of the display shows the acquired data from the mass
spectrometry represented as centroids. A centrally located main
display panel A1201 illustrates each peak as a respective symbol.
The horizontally disposed mass-to-charge (m/z) scale A1207 for both
the top panel A1203 and central panel A1201 is shown below the
central panel. The computer display may also include (not
specifically shown in FIG. 22A) the settings for mass accuracy
(expressed in ppm), the peaks/isotope cluster setting, the minimum
intensity threshold and signal-to-noise settings, and the minimum
and maximum charge states associated with the calculation. The
panel A1205 on the left hand side of the display shows the
calculated molecular weight(s), in daltons, of protein molecules.
The molecular weight (MW) scale of the side panel A1205 is oriented
vertically on the display, which is perpendicular to the
horizontally oriented m/z scale A1207 that pertains to detected
ions. Each horizontal line in the central panel A1201 indicates the
detection of a protein in this example with the dotted contour
lines corresponding to the ionic charge states, which are displayed
as a direct result of the transformation calculation discussed
previously. In FIG. 22B is shown a display pertaining to the same
data set in which the molecular weight (MW) scale is greatly
expanded with respect to the view shown in FIG. 22A. The expanded
view of FIG. 22B illustrates well-resolved isotopes for a single
protein charge state (lowermost portion of left hand panel A1205)
as well as potential adduct or impurity peaks (two present in the
display). The most intense of these three molecules is that of
trypsin inhibitor protein. A further-expanded view in FIG. 22C
shows the exact detail of the trypsin inhibitor protein at the
isotopic level. The symbol size used to represent the individual
isotopes is scaled according to the intensity of each isotope
peak.
[0308] FIG. 23A shows the data and deconvolution results of a crude
extract from the bacterium E. coli. This sample was directly
infused into the mass spectrometer using only a single stage of
mass spectrometry. The calculated results, obtained using methods
in accordance with the present teachings, indicate the presence of
58 unique discernable proteins in this sample. Many of the proteins
in this example have overlapping charge states which are easily
clustered using the aforementioned algorithm. FIG. 23B illustrates
another display corresponding to the same data set showing an
expanded view of the m/z scale in the vicinity of m/z=700 Da/e (as
well as an expanded view of the MW scale in Daltons) showing three
distinct charge states depicted by differently patterned centroids
in the top panel A1203. The centroids A1301 in the top panel A1203
of the display correspond to a +22 isotopically resolved charge
state of a protein of mass 15,305.76 Da. In this case, this is the
only charge state distribution present, yet the algorithm correctly
identifies the cluster even though the centroid bars A1303 and
A1305 occur within 1 Da of the charge state in question. Many
currently available deconvolution programs cannot correctly assign
charge state to independent distributions (two different proteins)
within a 3 Da window. Also, the centroid bars A1305 represent the
+23 charge state of a protein from E. coli of mass 16,017.57 Da.
Note that the +23 charge state of this protein directly overlaps
with the centroid bars A1303 of a separate +22 charge state protein
of mass 15327.47 Da. Typical deconvolution programs are unable to
correctly assign peaks in spectra having this kind of closely
spaced or overlapping charge states as can be seen by comparison to
FIG. 13C, which shows the same mass spectrum acquired and processed
using a program employing a conventional algorithm. The
conventional approach is unable to make any charge state
assignments in this region of the spectrum, as is indicated by the
"question marks" over the peaks of interest in the figure. FIG. 13D
has the correctly labeled charge states of the original profile
data as assigned by our algorithm employing the novel methods
taught herein for the two overlapping charge states described
above.
[0309] The program employing methods in accordance with the present
teachings can also determine charge states for those peaks that do
not contain individually resolved isotopes. In another example,
illustrated in FIG. 24A, the mass spectrum of an intact antibody is
shown with varying degrees of glycosylation. An example of the
different glycoforms of the antibody are displayed in the inset of
FIG. 24A. FIG. 24B illustrates the deconvoluted molecular weights
of the four deconvoluted glycoforms ranging from 148378 Da to
148763 Da.
[0310] The methods in accordance with the present teachings also
have utility for deconvoluting tandem mass spectrometry data. In
another example, as illustrated in FIGS. 25A and 25B, two charge
states from the protein carbonic anhydrase II were selected for
collisional activated dissociation. In FIG. 25A is shown the MS/MS
spectrum and corresponding deconvolution of the +26 charge state of
carbonic anhydrase II. Here 64% of the centroids were correctly
identified compared to only 9% using the conventional algorithm.
Exactly 50% of the centroids were clustered even in the event where
many MS/MS fragments do not produce multiple charge states of the
same fragment. The total number of fragment ions identified
correctly was 35. FIG. 25B shows the MS/MS fragmentation and
deconvolution of the +21 charge state of carbonic anhydrase II at
m/z 1001. Here 74% of the centroids were clustered and 78% of the
charge states were assigned correctly. A total of 49 fragments ions
were identified using the program.
8. Directing Data Dependent Acquisition to Avoid Redundant
Measurements
[0311] In the traditional approach to setting up a dynamic
exclusion list, m/z values are placed on the list for a specified
time period, which approximates the average peak width of a given
compound/type of compound. When using such an approach with small
molecules or peptides (i.e. tryptic peptides which typically have
the same physiochemical properties), it works well to increase the
dynamic range associated with the compound identification process.
On the contrary, intact proteins (as are measured in top-down
proteomics studies) widely vary in sizes, amino acid compositions,
physiochemical properties, and 3-D structures. This variability
typically leads to many more sites on the protein (than would be
the case for smaller-molecule analytes) interacting with the
stationary phase of a chromatographic column. The result is that
some peaks may be only a few seconds wide while others can persist
on the order of minutes. A typical example of the variability that
can be expected is illustrated in FIG. 13, showing the varying peak
profiles obtained from a single chromatographic run. Therefore, the
standard approach to dynamic exclusion is not an ideal fit for
top-down analysis. To rectify this problem, the present methods
employ a signal intensity ranking system to determine for how long
the charge states associated with a given protein should be placed
on the dynamic exclusion list. In this new approach, the seed
centroid of each cluster is put on the exclusion list. When a new
seed centroid is proposed in subsequent MS.sup.1 scan, a check is
first made to determine if the new centroid clusters with any of
the seed centroids presently on the selection list in step A510
(FIG. 14). If so, a check is made to determine if the intensity of
the new centroid has fallen below a threshold (as a fraction of the
intensity of the original seed centroid). Only when the intensity
does fall below the threshold, will the original seed centroid be
taken off of the exclusion list (step A515).
[0312] Alternatively, all charge states from a given protein can be
placed on the exclusion list, thus eliminating selecting different
charge states from the same protein for tandem MS analysis. While
these charge states are on the dynamic exclusion list, the signal
intensity of the peaks comprising the list are monitored until they
are below a defined minimum intensity or there is an increase in
signal from one of the charge states at a defined mass difference
(ppm), indicating the presence of two components of differing mass
and charge but the same m/z value.
* * * * *